Clinical Study Protocol  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 1 of 160   
  
 
 
 
 
Protocol Title: Role of glare and spectral filtering on contrast sensitivity: A pilot study 
Protocol CR -6501  
Version: 4.0  
 
Date: 02 November 2022  
 
 
Investigational Products: None.  
 
Keywords: Sphere platform, senofilcon A with a new UV/HEV filter (ACUVUE OASYS 
MAX  1-Day),  senofilcon  A without  the new UV/HEV  filter  (ACUVUE  OASYS  1-Day),  daily 
wear, daily disposable, non -dispensing, contrast sensitivity function under photopic and 
mesop ic conditions.  
 
Statement of Compliance to protocol, GCP and applicable regulatory guidelines:  
This clinical  trial will be conducted  in compliance  with ISO 14155:2020  Clinical  investigation 
of medical devices for human subjects - Good clinical practice,1 and the Declaration of 
Helsinki.2 
 
Confidentiality Statement:  
This document contains confidential information, which should not be copied, referred to, 
released  or published  without  written  approval  from  Johnson  & Johnson  Vision  Care,  Inc. The 
information  may not be disclosed  to others  except  to the extent  necessary  to obtain  Institutional 
Review Board/Independent Ethics Committee approval and informed consent, or as required 
by International, Federal and State Laws, as applicable. Persons to whom this information is 
disclosed must be informed that this information i s privileged and confidential and that it 
should not be further disclosed without the written permission of Johnson & Johnson Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprietary to Johnson & Johnson Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this  document.  
Clinical Study Protocol  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 2 of 160   
  
TABLE OF CONTENTS  
PROTOCOL TITLE, NUMBER, VERSION  AND  DATE  ................................ ......................  6 
SPONSOR NAME  AND  ADDRESS  ................................ ................................ .......................  6 
MEDICAL  MONITOR  ................................ ................................ ................................ .............  6 
AUTHORIZED  SIGNATURES  ................................ ................................ ...............................  7 
CHANGE  HISTORY  ................................ ................................ ................................ ................  8 
SYNOPSIS  ................................ ................................ ................................ ................................  9 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF  TERMS  ......................................16  
1. INTRODUCTION  AND  BACKG ROUND  ................................ ................................ .... 17 
1.1. Name and Descriptions of  Investigational  Products  ................................ ...................  25 
1.2. Intended Use of  Investigational  Products  ................................ ................................ ... 25 
1.3. Summary of Findings from  Nonclinical  Studies  ................................ .........................  25 
1.4. Summary of Known Risks and Benefits to  Human  Subjects  ................................ ...... 25 
1.5. Relevant  Literature  References  and Prior  Clinical  Data  Relevant  to Proposed  Clinical 
Study.  ................................ ................................ ................................ ..............  26 
2. STUDY OBJECTIVES, ENDPOINTS  AND  HYPOTHESES  ................................ ....... 27 
2.1. Objectives  ................................ ................................ ................................ ...................  27 
2.2. Endpoints  ................................ ................................ ................................ ....................  27 
2.3. Hypotheses  ................................ ................................ ................................ ..................  27 
3. TARGETED  STUDY  POPULATION  ................................ ................................ ...........  28 
3.1. General  Characteristics  ................................ ................................ ...............................  28 
3.2. Inclusion  Criteria  ................................ ................................ ................................ ........  28 
3.3. Exclusion  Criteria  ................................ ................................ ................................ ....... 28 
3.4. Enrollment  Strategy  ................................ ................................ ................................ .... 29 
4. STUDY DESIGN  AND  RATIONALE  ................................ ................................ ..........  30 
4.1. Descripti on of  Study  Design  ................................ ................................ .......................  30 
4.2. Study  Design  Rationale.  ................................ ................................ ..............................  30 
4.3. Enrollment Target and  Study  Duration  ................................ ................................ ....... 30 
5. TEST ARTICLE ALLOCATION  AND  MASKING  ................................ .....................  30 
5.1. Test Article  Allocation  ................................ ................................ ................................  30 
5.2. Masking. ................................ ................................ ................................ ......................  31 
5.3. Procedures for Maintain ing and Breaking  the Masking  ................................ ..............  32 
6. STUDY  INTERVENTION  ................................ ................................ .............................  32 
6.1. Identity of  Test Articles  ................................ ................................ ..............................  32 
6.2. Ancillar y Supplies/Products.  ................................ ................................ .......................  33 
Clinical Study Protocol  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 3 of 160   
 6.3. Administration of  Test Articles  ................................ ................................ ..................  33 
6.4. Packaging  and Labeling  ................................ ................................ ..............................  33 
6.5. Storage  Conditions  ................................ ................................ ................................ ...... 34 
6.6. Collection and Storage  of Samples  ................................ ................................ .............  34 
6.7. Accountability of  Test Articles  ................................ ................................ ...................  34 
7. STUDY  EVALUATIONS  ................................ ................................ ..............................  35 
7.1. Time and  Event  Schedule  ................................ ................................ ...........................  35 
7.2. Detailed  Study  Procedures  ................................ ................................ ..........................  36 
VISIT  1 ................................ ................................ ................................ ...........................  36 
FINAL  EVALUATION  ................................ ................................ ................................ .. 45 
7.3. Unscheduled  Visits  ................................ ................................ ................................ ..... 45 
7.4. Laboratory  Procedures  ................................ ................................ ................................  47 
8. SUBJECTS  COMPLETION/WITHDRAWAL  ................................ ..............................  47 
8.1. Completion Criteria  ................................ ................................ ................................ .... 47 
8.2. Withdrawal/Discontinuation from  the Study  ................................ ..............................  47 
9. PRE-STUDY AND  CONCOMITANT  INTERVENTION/MEDICATION  .................  48 
9.1. Systemic  Medicati ons ................................ ................................ ................................ . 48 
10. DEVIATIONS FROM  THE PROTOCOL  ................................ ................................ ..... 49 
11. STUDY  TERMINATION  ................................ ................................ ..............................  50 
12. PROCEDURE FOR HANDLING PRODUCT  QUALITY  COMPLAINTS  .................  51 
13. ADVERSE  EVENTS  ................................ ................................ ................................ ...... 52 
13.1. Definitions  and Classifications.  ................................ ................................ ................  52 
13.2. Assessing  Adverse  Events  ................................ ................................ ........................  54 
13.2.1.  Causality  Assessment  ................................ ................................ ....................  55 
13.2.2.  Severity  Assessment  ................................ ................................ ......................  55 
13.3. Documentation and Follow -Up of  Adverse  Events  ................................ .................  55 
13.4. Reporting  Adverse  Events  ................................ ................................ ........................  57 
13.4.1.  Reporting Adverse Events  to Sponsor ................................ ...........................  57 
13.4.2.  Reporting  Adverse  Events  to the Responsible  IEC/IRB  and Health  Authorities  ..............................58 
13.5. Event of Special Interest .......................................................................................... 58  
13.6. Reporting  of Pregnancy  ................................ ................................ ..............................  58 
Johnson & Johnson Vision Care, Inc.  
14. STATISTICAL  METHODS  ................................ ................................ ...........................  59 
14.1. General  Considerations  ................................ ................................ ............................  59 
14.2. Sample  Size Justification  ................................ ................................ ..........................  59 
Clinical Study Protocol  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 4 of 160   
 14.3. Analysis  Populations  ................................ ................................ ................................  59 
14.4. Level of  Statistical  Significance  ................................ ................................ ...............  60 
14.5. Primary  Analysis  ................................ ................................ ................................ ...... 60 
14.6. Secondary  Analyses  ................................ ................................ ................................ . 60 
14.7. Other  Exploratory  Analysis  ................................ ................................ ......................  60 
14.8. Interim  Analysis  ................................ ................................ ................................ ....... 61 
14.9. Procedure for Handling Missing Data  and Drop -Outs  ................................ .............  61 
14.10.  Procedure for Reporting Deviations from  Statistical  Plan ................................ ....... 61 
15. DATA HANDLING AND  RECOR D KEEPING/ARCHIVING  ................................ ... 61 
15.1. Electronic Case Report  Form/Data  Collection  ................................ .........................  61 
15.2. Subject  Record  ................................ ................................ ................................ .........  62 
15.3. Trial Registration  on ClinicalTrials.gov  ................................ ................................ ... 62 
16. DATA  MANAGEMENT  ................................ ................................ ................................  62 
16.1. Access to  Source  Data/Document  ................................ ................................ ............  62 
16.2. Confidentiality  of Information  ................................ ................................ .................  62 
16.3. Data  Quality  Assurance  ................................ ................................ ............................  63 
16.4. Data Monitoring  Committee  (DMC)  ................................ ................................ ........  63 
17. CLINICAL  MONITORING  ................................ ................................ ...........................  63 
18. ETHICAL AND  REGULATORY  ASPECTS  ................................ ................................  64 
18.1. Study -Specific  Design  Considerations  ................................ ................................ ..... 64 
18.2. Investigator  Responsibility  ................................ ................................ .......................  64 
18.3. Independent Ethics Committee or Institutional Review  Board  (IEC/IRB)  ..............  64 
18.4. Informed  Consent  ................................ ................................ ................................ ..... 65 
18.5. Privacy of  Personal  Data  ................................ ................................ ..........................  66 
19. STUDY  RECORD  RETENTION  ................................ ................................ ...................  67 
20. FINANCIAL  CONSIDERATIONS  ................................ ................................ ...............  68 
21. PUBLICATION  ................................ ................................ ................................ ..............  68 
22. REFERENCES  ................................ ................................ ................................ ...............  68 
APPENDIX A: PATIENT REPORTED OUTCOMES  (STUDY  QUESTIONNAIRES)  ..... 70 
APPENDIX B: PATIENT  INSTRUCTION  GUIDE  ................................ .............................  71 
APPENDIX C: PACKAGE INSERT  (APPROVED  PRODUCT)  ................................ .........  72 
APPENDIX  D: ................................ ................................ ................................ ......................  122 
- LENS  FITTING  CHARACTERISTICS  ................................ .............................  123 
- SUBJECT REPORTED  OCULAR  SYMPTOMS  ................................ .............  129 
- DETERMINATION OF  DISTANCE SPHEROCYLINDRICAL REFRACTIONS  
............................................................................................................131  

Clinical Study Protocol  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 5 of 160   
 - BIOMICROSCOPY  SCALE  ................................ ................................ ..............  137 
- DISTANCE AND NEAR SNEL LEN VISUAL  ACUITY  EVALUATION  ...... 143 
APPENDIX  E: - GUIDELINES FOR COVID -19 RISK MITIGATION  .............  148 
PROTOCOL COMPLIANCE INVESTIGATOR(S)  SIGNATURE  PAGE  ........................  160 
 
LIST OF TABL ES 
Table 1:  Test Atiicles  ................................ ................................ ................................ ...............  32 
Table 2:  Ancillaiy  Supplies  ................................ ................................ ................................ ...... 33 
Table 3: Time  and Events  ................................ ................................ ................................ ........  35 
Table 4: Disallowed  systemic  medications  ................................ ................................ ..............  49 
Table 5: Disallowed  systemic antihistamines  ................................ ................................ ..........  49 
Table 6: Examples of major and minor  protocol  deviations  ................................ ....................  50 
 
LIST OF FIGU RES 
Figure 1:  Study  Flowchaii  ................................ ................................ ................................ ........  15 
Figure  2: Binocular  contrast  sensitivity va lues derived  from  Figure  2 ofFernandes  et al. (black 
line and symbols) compai·ed to data from Scheiber et al (red line and symbols: 20 year-old 
observers).  Note the deviation at the lower  frequencies  ................................ .........................  17 
Figure 3 : CSF data from van Nes and Bouman. Note that the peak sensitivity value is near 
around 5 cyc /deg and sensitivity is peaking around 400 -500 (about twice the peak from the 
Metropsis sample shown in Fig 2) . (also note the similai·ity in the cmves across luminance - 
from 90 -900 trolands , analogous to 3 to 300 cd/m2 based on a 2 mm pupil)  ..........................  18 
Figure 4: CSF according to Campbell and  Robson  (1968)  ................................ ......................  19 
Figure 5: Figure from Elliott et al. (2009); data are from older (red) and younger (black) 
subjects  with various  abenations  con ected . In this study  the peak  is around  8 cycles  per degree 
and contrast sensitivity is about  80 ................................ ................................ ..........................  20 
Figure  6: The stimuli  used  in the CSV -1000  test (right  side shows  the glare  condition)  ........  21 
Figure 7:  The glarn source ofthe Metropsis is based on white LEDs mounted  ve1iically  ..... 22 
Figure 8: University of Georgia  CSF Apparatus  ................................ ................................ ...... 23 
Figure 9: University of Georgia  glare  system  ................................ ................................ ..........  25 
Figure 1O:  Packaging  Labels  ................................ ................................ ................................ ... 34 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 6 of160   
  
 
 
 
PROTO COL TITLE , NU MBER, VER SION AND DATE  
Title : Protocol T itle: Role of glare and spectral filtering on contrast sensit ivity: A pilot study 
Protocol Nmnber: C R-6501  
Vers ion: 4.0 
Date: 02 November 2022  
 
 
SPONSOR NAME AND ADDRES S 
Johnson & Johnson Vision Care , Ine. (JNC)  
7500 Cen turion PaJkway  
Jacksonv ille, FL 32256  
 
 
MEDI CAL MONITOR  
The Medical Monitor must be notified by the clinica l institution/site by e -mail or telephone 
within  24 hoursofl  eaming ofa Serious  AdverseEven t. The Medical  Monitor  may be contacted 
during bus iness hours for adverse event ques tions. General study related questions shou ld be 
directed towards your assigned clinical resea rch associa te. 
 
The Medical Monitor ing Plan is maintained  as a separate docume nt and include d in the Trial 
Maste r File. 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 7 of160   
  
AUTHORIZED SIGNATURES  
The signatures  below  const itutes  the approval of this protoco l and the attachments  and provide 
the necessa1y  assurances  that this trial will be conducted  according  to all stipulations  of the 
protocol , including  all statements  regarding confidentia lity, and acco rding to local  legal and 
regulato1y  requ ireme nts and applicab le U.S. federal  regulations ,3 ISO 14155 :2020 ,1 and the 
Declarat ion of Helsinki.2 
 
Autho r / Study 
Responsible 
Clinician  See Electronic Signature  Report     
DATE  
 
 
Co -author 
 
 
 
Co -author 
 
 
Clinica l Opera tions 
Manager  
 
DATE  
 
 
 
DATE  
 
See Electronic Signature  Report     
DATE  
 
 
Biostat istician See Electronic Signature  Report    
DATE  
 
Biostat istical  Review See Electron ic Signature Report     
DATE  
 
 
Data Management  
 
 
Medical Safety 
Officer  See Electron ic Signature  Report     
DATE  
 
See Electronic Signature  Report     
DATE  
 
 
Reviewe r See Electronic Signature  Report     
DATE  

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 8 of160   
  
 
Approver  
 
DATE  
 
 
 
 
 
CHAN GE IDSTORY  
 
 
Version Orig inator  Descript ion of Change(s)  Justification  Date  
 and Sectio n 
Affected  Number(s)  for Change  
I.O  
 
 
 Original Protocol  N/A 21 September 2022  
2.0 Updated Section 5.1 Test 
Alticle Allocation to 
clarify that there will be 
only one lens assignment 
for the two light sources  
(i.e., without g lare and 
with olare  er sub·  ect To align the 
random ization 
plan with 
study 
procedures  04 October 2022  
3.0 
 
 1. Section 7.2 - VI Step  
1.21, 1.22, 1.24 and  1.25, 
changed spatial frequency  1. Accuracy  24 October 2022  
 2.3 to 3.2 to match lens   
 fitting schedule .   
  
2. Section 1.5 - changed  
"to believe that" to "for 2. Per Legal 
TeamReview   
 why" / changed    
 "obtainab le" to "of 
interest''    
4.0 
 
 
 
 
 Section 7.2 Steps 1.21 , 
1.22, 1.24 and 1.25, 
updated area under the 
contrast sensitivity curve 
range from 100 to 5.00  Accuracy  02 November 2022  

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 9 of 160   
  
SYNOPSIS  
 
Protocol Title  Protocol Title: Role of glare and spectral filtering on contrast 
sensitivity: A pilot study  
Sponsor  JJVC, 7500 Centurion Parkway, Jacksonville, FL  32256  
Clinical Phase  Clinical trial phase: Feasibility 
Design control phase: Phase 3  
Trial Registration  This study will be registered on ClinicalTrials.gov by the 
Sponsor  
Test Article(s)  Investigational Products: None. 
Approved Products:  
1. senofilcon A with a new UV/HEV filter (ACUVUE 
OASYS MAX  1-Day).  
2. senofilcon  A without  a new UV/HEV  filter  (ACUVUE 
OASYS  1-Day).  
Wear and Replacement 
Schedules  Wear Schedule:  daily wear 
Replacement Schedule: daily  disposable  
Objectives  The purpose of this study is to evaluate the role of a test lens 
on contrast sensitivity with and without glare.  
Primary Objectives: The primary objective is to evaluate the 
visual performance characteristics of a new UV/HEV filter 
under conditions of an H EV-rich ecologically -valid light 
source.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 10 of 160   
  
 
Study Endpoints  Primary Endpoint(s)  
• Area under the curve of photopic contrast sensitivity 
function under bright light conditions (approx. 120 
cd/m2) with a broadband glare  source.  
Secondary Endpoint(s)  
• Area under the curve of mesopic contrast sensitivity 
under dim light conditions (approx. 3  cd/m2) with a 
broadband glare  source.  
Other Observations:  
• Area under the curve of photopic contrast sensitivity 
function under bright light conditions (approx. 120 
cd/m2) without a broadband glare  source.  
• Area under the curve of mesopic contrast sensitivi ty 
under dim light conditions (approx. 3 cd/m2) without 
a broadband glare  source.  
Study Design  This is a split -plot design with two parallel arms consisting  of 
randomized photopic and mesopic conditions where subjects 
are also randomized contralaterally to the Test and Control 
lenses within each arm. This study will be non -dispensing, 
controlled, and double -masked. Subjects will be assigned 
randomly to the pho topic or the mesopic condition arm. Each 
subject  will be fitted  with a Test lens on one eye and a Control 
lens on the other eye within each condition arm. The 
randomization will be stratified by age with a 1:1 ratio for  the 
two age ranges (18 -40 years; 41 -65 years).  
There will be a total of 1 visit:  
• Visit 1: Screening, baseline evaluation and lens fit #1 
and #2. Evaluation of lens 1 and 2. Final  evaluation.  
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedu res of main 
observations (Figure 1).  
Sample Size  Approximately 44 subjects will be enrolled with the intent to 
complete approximately 20 in each group (photopic and 
mesopic).  
Study Duration  This study  is non-dispensing  and is completed  in a single  visit. 
The enrollment period is approximately 2  months.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 11 of 160   
  
 
Anticipated Study 
Population  Subjects  must  be habitual  wearers  of silicone  hydrogel  contact 
lenses worn on a daily wear basis. Subjects can be of any 
gender, race, and ethnicity that meet the eligibility  criteria.  
Eligibility Criteria - 
Inclusion  Potential subjects must satisfy all of the following criteria to 
be enrolled in the study:  
Inclusion Criteria following Screening 
The subject must:  
1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the  form.  
2. Appear able and willing to adhere to the instructions 
set forth in this clinical  protocol.  
3. Be between 18 and 65 (inclusive) years of age at the 
time of  screening.  
4. By self -report, habitually wear spherical silicone 
hydrogel soft contact lenses in both eyes in a daily 
reusable or daily disposable wear modality (i.e. not 
extended wear modality). Habitual wear is defined as 
a minimum  of 6 hours  of wear  per day, for a minimum 
of 5 days per week during the past 30  days.  
5. Possess a wearable pair of spectacles that provide 
correction for distance  vision.  
Inclusion Criteria at Baseline Evaluation  
6. The spherical equivalent of the subject's vertex 
corrected distance refraction must be between -1.00 D 
and -6.00 D (inclusive) in each  eye. 
7. The magnitude of the cylindrical component of the 
subject's vertex -corrected distance refraction must be 
between 0.0 0 D and 1.00 D (inclusive) in each  eye. 
8. The best corrected, monocular, distance visual acuity 
must be 20/25 or better in each  eye. 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 12 of 160   
  
 
Eligibility Criteria - 
Exclusion  Potential subjects who meet any of the following criteria will 
be excluded from participating in the study:  
Exclusion Criteria following Screening 
The subject must not:  
1. Be currently pregnant or  lactating.  
2. Be currently  using  any ocular  medications  or have  any 
ocular infection of any  type.  
3. By self -report, have any ocular or systemic disease, 
allergies, infection, or use of medication the 
investigator believes might contraindicate or interfere 
with contact lens wear, or otherwise compromis e 
study endpoints, including infectious disease (e.g., 
hepatitis,  tuberculosis),  contagious 
immunosuppressive disease (e.g., Human 
Immunodeficiency  Virus  [HIV]),  autoimmune  disease 
(e.g. rheumatoid arthritis, Sjogren's syndrome), or 
history of serious ment al illness or seizures. See 
section 9.1 for additional details regarding excluded 
systemic  medications.  
4. Have habitually worn rigid gas permeable (RGP) 
lenses, orthokeratology lenses, or hybrid lenses (e.g. 
SynergEyes, SoftPerm) within the past 6  months.  
5. Be currently wearing monovision or multifocal 
contact  lenses.  
6. Be currently wearing lenses in an extended wear 
modality.  
7. Have  participated  in a contact  lens or lens care product 
clinical trial within 30 days prior to study  enrollment.  
8. Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate family member of an 
employee (including partner, child, parent, 
grandparent, grandchild or sibling of the employee or 
their spouse) of the clinical  site. 
Exclusion Criteria at Baseli ne Evaluation 
The subject must not:  
9. Have clinically significant (grade 3 or higher on the 
FDA grading scale) slit lamp findings (e.g., corneal 
edema, neovascularization or staining, tarsal 
abnormalities or bulbar injection) or other corneal or 
ocular disea se or abnormalities that the investigator 
believes  might  contraindicate  contact  lens wear  or may 
otherwise compromise study endpoints  (including  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 13 of 160   
  
 
 entropion, ectropion, chalazia, recurrent styes, 
glaucoma, history of recurrent corneal erosions, 
aphakia, moderate or above corneal distortion, 
herpetic keratitis).  
10. Have a history of strabismus or  amblyopia.  
11. Have  fluctuations  in vision  due to clinically  significant 
dry eye or other ocular  conditions.  
12. Have  had any ocular  or intraocular  surgery  (e.g.,  radial 
keratotomy, PRK, LASIK, iridotomy, retinal laser 
photocoagulation,  etc.).  
13. Have signs of a contact lens -related corneal 
inflammatory event (e .g., past peripheral ulcer or 
round peripheral  scar).  
14. Have a history of eyelid injury, surgery or procedure 
that resulted  in abnormal  eyelid  position  or movement.  
Disallowed 
Medications/Interventions  Subjects taking and ocular medications will not be allowed to 
participate.  
See section 9.1 for details regarding disallowed systemic 
medications.  
Measurements and 
Procedures  All measurements will be taken with and without an 
ecologically -valid glare source. Approximately half of the 
subjects  will be tested  under  photopic  conditions  and the other 
half under mesopic  conditions.  
Microbiology or Other 
Laboratory Testing  None.  
Study Termination  The occurrence of an Unanticipated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in 
stopping further dispensing investigational product. In t he 
event of a UADE or SAE, the Sponsor Medical Monitor may 
unmask the treatment regimen of subject(s) and may discuss 
this with the Principal  Investigator  before  any further  subjects 
are enrolled.  
Ancillary Supplies/ Study - 
Specific Materials  An ecologica lly-valid broadband glare source that emulates 
natural  sunlight  in spectral  content  across  the visible  spectrum 
will be used. RevitaLens will be used to return any 
problematic lenses to the  Sponsor.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 14 of 160   
  
 
Principal Investigator(s) 
and Study 
Institution(s)/Site(s)  A full list of Principal Investigators, clinical sites, and 
institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.  
Clinical Study  Protocol  
P ag e 15 of 160  
 Lens Removal and Ocular Physiology  
► T he lenses  will be removed  and ocular  physiology  assess oo. I 
l I John son & John son Vision Care, Ine.  
 
Figure 1: Study F lowchart  
 
 
 
 
 
 
l 
 
 
 
 
 
 
 
 
 
I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Photopic  CSF 
- 20 subjects  
► Phot opic contrastsensit ivity with and 
withouta broadband glare source  l 
Mesopic  CSF 
- 20 subjects  
► Mesop ic contrast sensi tivity: with and 
without a broadband g lare source  l  
40-44 Subj ects 
 
Available powers : -1.00 to -6.00 in 0.25 Dsteps  
Habitual  wearers  of spherica l silicone  hydrogel  soficontact  lenses  wom  as daily wear 
Excludeswearers  of toric,  monovision,  multifocal,  extended  wear  
Age 18-65 
 
lnformed Consent 
EIigibility Criteria 
Baseline  lnformation  
► H abitual lens type, moda lity 
► Subject ive refraction 
► Eye dominancy  
► Ocular physio logy 
Trial Lens Fitting  
 
► Subjects  will berandom ly assigned  a test lenson one eye and a control lens on the other eye 
► Modify  lens powe rs to obtain 0.00 D spherica l over-refraction  
10-Minute Evaluation  
► S ymptoms  
► Fittin g charact eristics, VA 
► F or release, the lensesmust  provide:  
► Apprcp riate frtti ngcharacter istics on both eyes  
► 20/30or better vision in both e-;es 
► ln vesitgator approva l 
 
Clinical Study  Protocol  
P ag e 16 of 160  
 C    R    -6    501, v     4.0 -  
 
 
 
JJ VC C O NFIDENTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 17 of 160   
  
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS  
ADE  Adverse Device  Effect  
ADHD  Attention Deficit Hyperactivity  Disorder  
AE Adverse Event/Adverse Experience  
BSCVA  Best Spectacle Corrected Visual  Acuity  
CFR  Code of Federal  Regulations  
CLUE  Contact Lens User  Experience  
COM  Clinical Operations  Manager  
CRA  Clinical Research  Associate  
CRF  Case Report  Form  
CRO  Contract Research  Organization  
 
D Diopter  
DMC  Data Monitoring  Committee  
eCRF  Electronic Case Report  Form  
EDC  Electronic Data  Capture  
FDA  Food and Drug  Administration  
GCP  Good Clinical  Practice  
HIPAA  Health Insurance Portability and Accountability Act 
HIV Human Immunodeficiency  Virus  
IB Investigator's  Brochure  
ICH The International Council for  Harmonization  
IEC Independent Ethics  Committee  
IRB Institutional Review  Board  
ISO International Organiza tion for  Standardization  
ITT Intent -to-Treat  
JJVC  Johnson & Johnson Vision Care, Inc.  
LASIK  Laser -Assisted in Situ  Keratomileusis  
OD Right  Eye 
OS Left Eye 
OU Both  Eyes  
PIG Patient Instruction  Guide  
PQC  Product Quality Complaint  
PRK  Photorefractive  Keratectomy  
PRO  Patient Reported  Outcome  
QA Quality  Assurance  
SAE  Serious Adverse Event/Serious Adverse  Experience  
SAP Statistical Analysis  Plan 
SAS Statistical Analysis  System  
SD Standard  Deviation  
UADE  Unanticipated Adverse Device  Effect  
USADE  Unanticipated Serious Adverse Device  Effect  
VA Visual  Acuity  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 18 of 160   
  
1. INTRODUCTION AND  BACKGROUND  
Contrast sensitivity functions (CSF) have wide scientific and clinical use (NRC, 1985). Their 
value, however, depends critically on their reliability and their ecological validity. In most 
vision  experiments,  CSFs  are measured  with a CRT  oscilloscope  or computer  monitor  (or even 
less precisely,  with wall charts  like the Peli-Robson  or the CSV -1000),  which  allows  relatively 
simple electronic control of both spatial frequency and contrast. A common method, for 
example,  of measuring  CSF is employed  by the Metropsis  system  (Cambridge  Research).  This 
system presents a series of sine -waves (as Gabor patches) on a highly  calibrated monitor with 
computer control over presentations and refined psychophysical procedures (the modern 
version of the original method used on a CRT screen by Campbell and Robson, 1968). The 
Metropsis system has been used to evaluate spatial vision issues in a variety of patient 
populations (e.g. to assess the effects of brain injury, smoking or toxic exposures; Nguyen et 
al,.2017; Costa et al., 2012; Fernandes et al.,  2017).  
 
Fernandes et al. (2019) evaluated the Metropsis method on 55 normal subjec ts. The curves 
provided  by Fernandes  were  unusually  flat (e.g.,  between  about  0.2-8.8 cycles/degrees;  shown 
in Figure 2) with intraclass correlations of around 0.71 when testing 20 subjects (the authors 
note that this is considerably higher than intraclass  correlations generated by the CSV -1000 
(0.19), Pelli -Robson (0.18), Vistech FDT (0.36) or Miller=Nadler (0.36) CSF  tests.  
 
Figure  2: Binocular  contrast  sensitivity  values  derived  from  Figure  2 of Fernandes  et al. (black 
line and symbols) compared to data from Scheiber et al (red line and symbols: 20 year -old 
observers). Note the deviation at the lower  frequencies.  
 
 
 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 19 of 160   
  
Reliability  is, of course,  critical  in a prognostic  device.  As originally  expressed  by the National 
Research Council (1985), "The value of the contrast sensitivity function in predicting 
performance on complex visual tasks and in discriminating among individuals in their ability 
on these tasks needs to be further explored."  If the amoun t of variance explained (r2) is   
only 50% (meaning a measure predicts half of the variance in that same measure taken at a 
different time), then its ability to predict other variables is, perforce, less than 50%. It would 
be optimal to have a system for m easuring CSF that has better  reliability.  
 
The other major issue with CSF curves measured using monitors is their inconsistency across 
studies (convergent validity). A classic curve in the CSF literature, for example, comes from 
van Nes and Bouman (1967) s hown below (Figure 3).  
 
Figure 3: CSF data from van Nes and Bouman. Note that the peak sensitivity value is near 
around 5 cyc/deg and sensitivity is peaking around 400 -500 (about twice the peak from the 
Metropsis sample shown in Fig 2). (also note the simi larity in the curves across luminance - 
from 90 -900 trolands, analogous to 3 to 300 cd/m2 based on a 2 mm pupil).  
 
 
 
The shape  of the curve  is similar  to the classic  curve  reported  by Campbell  and Robson  (1968). 
The peak is quite different (3 cycles/degree , contrast sensitivity = 700). Shown in Figure  4. 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 20 of 160   
  
Figure 4: CSF according to Campbell and Robson (1968).  
 
 
 
Contrast  these  peaks  with others  often  reported  in the literature.  Here,  for example,  is a sample 
of young and older subjects from Elliott et al. 2009 (Figure  5). 

Clinical Study Protocol  
Page 21 of 160   
 - 
- - Johnson & Johnson Vision Care, Ine.  
 
Figure 5: Figure from Elliott et al. (2009); data are from older (red) and younger (black) 
subjects  with various  abe1rntions  co1Tected.  In this study  the peak  is around  8 cycles  per degree 
and contra.st sensitivity is about  80. 
 
 
 
 
 
Z' 
;? 
.ii> 
C 
Q) 
(/) 
(/) 
 
 
oC 
o 
 
 
 
 
0.1 1 10 10C 
Spatial frequencv (c/deQ} 
 
If one does  a wide  survey  of nonnal CSF curves  in the literature , you can find wide  divergence 
in the shape of CSF curves and in peak sensitivity (a range by at least a factor of ten). One 
reason isa lack of standardizing many of the variables that drive the curves (size, illuminance , 
etc), although even when this is done, convergent validity seems to be poor (Buhren et al. , 
2006).  Another  reason  is that the modulation  depth  of the stimuli  are ra.rely  directly  calibra.ted 
(on monitors, the  actual  values  are derived  not actually  measured  in place) . This is a particular 
issue with CRTs (Garcia -Perez and Peli, 2001). The quality of the stimulus display ranges 
from paper wall charts (e.g., Peli-Robson) to cathode -ra.y tubes to various types of monitor 
designs (e.g., Metropsis). The range of procedures also varies from deriving tlu·esholds from 
relatively  long psychometric  functions  (like  in Metropsis) to ve1y  rough  approximations  (e.g., 
CSV -1000) , see Figure  6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1O 
1   ..  .  _..  _. : 
Clinical Study Protocol  
Page 22 of 160   
 CR-6501,  v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 23 of 160   
  
Figure 6: The stimuli used in the CSV -1000 test (right side shows the glare condition).  
 
 
This lack of standardization is likely why CSF methods often have poor predictability and 
ecological validity. This was originally tested by Owsley and Sloane (1987) : 
 
"A major assumption underlying the use of contrast sensitivity testing is that it predicts 
whether a patient has difficulty seeing objects encountered in everyday life. However, there 
has been  no large -scale  attempt  to evaluate  whether  this putative  relationship  actually  exists."  
 
Owsley and Sloane measured Snellen acuity and the CSF of 93 subjects (aged 20 -77 yrs.). 
These measures were then compared with target images (faces, road signs, and other objects) 
that were  placed  on back -illuminate d slides.  These  slides  were  placed  in an optical  system  that 
allowed  the contrast  within  the object  to be varied.  These  authors  found  that Snellen  acuity  did 
not predict threshold identification of these "real -world targets." CSF did predict real -world 
performance but explained only 25 -40% of the variance. This supports the potential utility of 
CSF as a measure of vision in everyday life while also highligh ting a potential opportunity to 
develop new methods of measuring CSF to improve its ability to predict vision in everyday 
life. 
 
Fortunately,  high quality  sine-wave  transparencies  are available  from  Applied  Image,  who can 
custom make the sine -waves and cal ibrate them precisely. These targets have low harmonic 
distortions (2% or less) and are available cemented between large (100 x100 in) squares of 
glass. They are nearly spectrally flat. These were originally used in a study by Hammond et 
al. (2012) and Fle tcher et al. (2014). These foundational studies showed that CSF can be 
measured using real optics and carefully controlled and calibrated  conditions.  
 
Another  challenge  when  measuring  CSF is to introduce  the kind of stressors  that actually  affect 
spatial vision in the real world. One such stressor is glare. The primary source of glare in  the 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 24 of 160   
  
real world is the sun (Mitra, 2014, Sun et al., 2018). A major issue with many of the existing 
glare systems (see Figure 5) is that the glare source that is used does not resemble actual 
sunlight (Tungsten -Halogen is a common source, the Metropsis uses whi te LEDs). In our 
study we will use white light with xenon as the source and filtered to precisely match specific 
phases  of sunlight.  Another  important  consideration  is the angle.  Often  glare  sources  are made 
to surround the entire display. For example, the  CSV -1000 mounts the glare source on the 
sides, Metropsis mounts the glare source vertically as shown in Figure  7. 
 
Figure 7: The glare source of the Metropsis is based on white LEDs mounted vertically.  
 
 
In the real world, the glare source (say the sun) and the visual target (say a stop sign) are 
relatively far away. In some instances, this distance homogenizes the light scatter interfering 
with perception of the stimulus. In a clinic, the stimulus and gla re source are only a few feet 
away making the glare less uniform (it is more intense as it gets closer to the source). To 
optimally emulate real world visual conditions, the veiling light should be relatively 
homogenous.  
 
Issues revealed by our previous pi lot study:  
In our previous  pilot study,  we measured  CSF (photopic  and mesopic)  under  regular  and glare 
conditions. This was done to assess whether CSF with our HEV -absorbing test lens differed 
from  a clear  control.  Although  preliminary  testing  demonstrated  a significant  reduction  in CSF 
with glare, in a second cohort, we found that our glare condition did not reduce CSF (i.e. the 
CSF curves  were  the same  in the glare  and non-glare  condition).  Hence,  the HEV  test lens did 
not have a reduction to correct. Why did our glare condition not  work?  
 
In our previous  discussion  we argued  that the measures  of CSF provided  by the Metropsis  were 
highly variable, likely reducing our ability to discriminate small differences between the two 
test conditions. Another possible methodological limitation might have been the positioning 
of the glare source. One possible reason why the glare condition did not reduce the CSF  was 

Clinical Study Protocol  
Page 25 of 160   
 Johnson & Johnson Vision Care, Ine.  
 
that it was insufficiently homogeneous and too far from the line of sight. Like in real life, 
people will reflexively try to see around glare ( dive1t their eyes to the least glaring portion of 
the image) and this may have been possible with our glare ring a1Tan gement (the preliminruy 
testing was sho1t and composed of subjects that were highly compliant). In order to really test 
the effects  of glru·e,  the glare  source needs  to be perfectly  homogeneous  and made  such that it 
cannot be avoided. Our current study is designed to address both the reliability issues with 
Metropsis and the homogeneity of the glare  source.  
 
University of Georgia contrast sensitivity testing apparatus:  
The simplified design of this system was based on many of the satne principles that were 
worked  out on the much  more  elaborate  optical  systems  used  in Hammond  et al. (2012)  and 
Fletcher et al. (2014). A custom -built apparatus was used to measure contrast sensitivity 
functions  at 1.6, 3.2, 8, 16 and 24 cycles /degree  (See the schematic  in Figure  8). 
 
Figure 8: University of Georgia CSF Apparatus  
 
 
 
 
 
 
The system  uses two green  (520  nm) lasers  (Ll and L2) that are spatially  diffused  using  two 
six-inch circulru·  integrating  spheres  (aluminum  hemispheres  painted  on the interior  with highly 
diffusing,  98%  reflecting,  non-luminescent , white  paint , Labsphere,  N01th  Sutton,  NH).  To 
measure contrast sensitivity , the intensity of the light source (Ll and L2) is independently 
adjusted using circular neutral density wedges (Wl and W2). The two spheres pass the 
homogeneous green light through two exit poris (~3.5 deg circular). The green laser light 
source  is positioned  with respect  to the surface of  the integrat ing sphere  in such  a way as to 
create a completely homogeneous light at the plane of the retina , essentially a Lambertian  
 
 

Clinical Study Protocol  
Page 26 of 160   
 CR-6501,  v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 27 of 160   
  
emitter. This creates a visual stimulus with luminance that is relatively independent of exact 
eye position.  
 
Light  from  Sphere  1 passes  through  a 2-inch diameter  sine wave  grating  (1.6, 3.2, 8, 16, or 24 
cyc/deg based on a distance of 36 inches to the plane of the eye). These gratings are placed in 
a mount that can be rotated to the left or right (15 degree cant) in order to provide a forced 
choice procedure. A thin optomechanical shutter (Thor Labs) by  L1 allows the intermittent 
exposure ( -1 second exposures) of the grating stimulus. Light from Sphere 2 combines with 
Sphere 1 and wedge adjustment allows for constant variation in the modulation of the sine 
waves. A dedicated photodetector (Graseby Optron ics United Detection Technology (UDT) 
with a photometric  lens Orlando,  FL) is used to constantly  monitor  the luminance  output  (half 
of the combined  beam  going  to the detector  and half going  to the eye of the subject  to maintain 
a constant luminance of 65 cd/m2). The gratings were calibrated by the manufacturer and 
confirmed within the system by moving a tiny pinhole aperture ( -1/2 mm) and photodetector 
(ILT  950, International  Light  Technologies,  Peabody  MA)  across  and very close  to the surface 
of the grating  while  changing  the position  of the wedges.  Optical  baffling  was used throughout 
(not shown in the schematic) to prevent light noise between the  channels.  
 
Subject head position is maintained using a forehead and chin rest assembly (36 inches from 
the grating). Contrast thresholds are calculated based on the Michelson contrast formulation. 
A method of limits is used to obtain threshold (ascending and descending). A method of 
constant stimuli combined with the forced cho ice procedure (canted left or right) is used to 
refine  the threshold  determination  to approximately  75% correct  (based  on 10 determinations).  
 
To measure  CSF,  two ascending  and two descending  thresholds  will be taken  for each grating, 
with grating  order  randomly  assigned  for each participant.  If raw values  vary by more  than 200 
arbitrary units on the wedge display, the forced choice / constant stimuli method will be used 
to arrive at a more exact  threshold.  
 
Glare system  
The glare system is composed of a one -channel optical system with a 1000 -watt xenon light 
source. Light exits the housing and is collimated using an achromatic plano -convex  lens. This 
collimated  light passes  through  a water  baffle  (a clear  tube with optica l flats on either  end) that 
removes heat without altering the light spectrum. The collimated light passes through a series 
of achromatic plano -convex lenses that alternately focus and collimate the light. A color 
correcting  filter  (e.g.,  Daylight  Blue  Filter, Edmunds  Optics)  will be used to achieve  a CCT  of 
at least 6500K. The collimating light will be approximately three inches in diameter. The 
entire  system  is orthogonal  to the CSF device.  At the junction  between  the exit port of the CSF 
device a large thin glass beam -splitter (analogous to a large cover slip) will be used. This 
creates a large perfectly homogeneous glare source between and co -liner with the grating and 
the eye of the subject. See Figure  9. 
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 28 of 160   
 
 
Figure 9: University of Georgia glare system  
 
 
1.1. Name and Descriptions of Investigational  Products  
This study will evaluate two (2) senofilcon A designs with and without a new UV/HEV filter. 
The Test lens is FDA -approved and pending commercial distribution. The Control lens is 
ACUVUE OASYS 1 -Day with HydraLuxe ™ Technology. Further details about the test  
articles are found in section 6 of this protocol.  
 
1.2. Intended Use of Investigational  Products  
The intended use of the investigational products is for correcting myopia (Test and Control) 
and improving visual performance characteristics under applicable cond itions (Test). The 
study articles will be worn contralaterally in a daily wear, daily disposable modality for 1 -2 
hours.  
 
1.3. Summary of Findings from Nonclinical Studies  
Not Applicable - Marketed product only.  
 
1.4. Summary of Known Risks and Benefits to Human  Subjects  
Benefits to the subjects include the correction of their refractive error with the potential of 
improved visual performance in HEV environments. The risks of wearing soft contact lenses 
are well known and are described in the Investigator's Brochu re and Informed Consent. The 
material safety testing/lens release criteria was determined based on the Risk Assessment.  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 29 of 160   
  
For the most comprehensive risk and benefit information regarding Test and Control lenses, 
refer to the latest version of the package insert.  
 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed 
Clinical Study  
The new HEV -filter i n the Test lens has been evaluated in two previous objective -based 
studies:  and . In both studies, psychophysical evaluations were carried out 
on an optical breadboard system using a broadband light source that emulated sunlight in 
spectral content. These studies demonstrate that benefits of a HEV -filter can be seen when 
tested in an HEV -rich environment such as natural  sunlight:  
 
1.  (n=60 cohort): when compared to a similar contact lens without the new 
UV/HEV filter, the Test lens demonstrated statistical s uperiority in the following 
metrics:  
o 2-point light threshold  
o Halo  diameter  
o Starburst  diameter  
o Disability  glare  
o Discomfort  glare  
o Chromatic  contrast  
 
2.  (n=58 cohort): when compared to a similar contact lens without the new 
UV/HEV  filter  (different  control  lens than ), the Test lens demonstrated 
statistical superiority in the following  metrics:  
o 2-point light threshold  
o Halo  diameter  
o Discomfort  glare  
o Chromatic  contrast  
o Photostress  recovery  
 
To further, many of the metrics noted above provide a reason for why the specifi c hypotheses 
of this study are of interest.  Mainly:  
 
1. Improved  contrast  
o In and , disability glare was measured by noting the intensity 
of a broadband light source needed to obscure a central grating target. The results 
from this study demonstrate that s ubjects can see a high contrast central grating 
target under HEV -rich conditions such as sunlight better with an  HEV -filter.  
o In and , heterochromatic contrast was measured by noting the 
intensity of a 460 nm light source needed to obscure a 580 nm central grating 
target. The results demonstrate an improved ability to detect edges while wearing 
an HEV -filter.  
2. Improved low light  vision  
o In and , broadband light that emulated sunlight in spectral 
content was used to generate a point source of light. The halo and  starburst  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 30 of 160   
  
diameters of that light were measured using precision calipers. The results 
demonstrate that positive dysphotop sia, which is most prevalent in dim 
illumination, can be improved with an HEV -filter. 4-6 
 
(n=59) was a method development pilot study intended to test contrast sensitivity 
and resolution acuity under various conditions. The learnings from that study are mentioned 
throughout the introduction of this protocol and incorporated into the current stu dy. 
 
Refer to the Package Insert (Appendix C) for additional information about the study lenses.  
 
2. STUDY OBJECTIVES, ENDPOINTS AND  HYPOTHESES  
 
2.1. Objectives  
The intent of this study is to determine whether or not the Test lens is likely to provide visual 
benef its under conditions for which it was designed. All mentions of broadband glare, or just 
glare, are referring to an ecologically -valid light source that emulates sunlight in spectral 
content.  
 
Primary Objective(s)  
The primary  objective  is to evaluate  the visual  performance  characteristics  of a new UV/HEV 
filter under conditions where an ecologically -valid light source is  present.  
 
2.2. Endpoints  
Primary Endpoint(s)  
• Area under the curve of photopic contrast sensitivity function under bright light 
conditions ( 120 cd/m2) with a broadband glare  source.  
 
Secondary Endpoint(s)  
• Area under the curve of mesopic contrast sensitivity under dim light conditions ( 3 
cd/m2) with a broadband glare  source.  
 
Other Observations:  
• Area under the curve of photopic contrast sensitivity function under bright light 
conditions ( 120 cd/m2) without a broadband glare  source.  
• Area under the curve of mesopic contrast sensitivity under dim light conditions ( 3 
cd/m2) without a broadband glare  source.  
 
2.3. Hypotheses  
Primary Hypothesis  
No primary hypothesis will be tested. The primary endpoint will be descriptively summarized.  
 
Secondary Hypothesis  
No secondary hypothesis will be tested. The secondary endpoint will be descriptively 
summarized.  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 31 of 160   
  
 
Exploratory Hypotheses  
• The Test lens will provide  greater  photopic  contrast  sensitivity  compared  to the Control 
lens under conditions of a broadband glare  source.  
• The Test lens will provide  greater  mesopic  contrast  sensitivity  compared  to the Control 
lens under conditions of a broadband glare  source.  
 
3. TARGETED STUDY  POPULATION  
 
3.1. General  Characteristics  
Subjects must be habitual wearers of silicone hydrogel contact lenses worn on a daily wear 
basis. Subjects can be of any gender, race, and ethnicity that meet the eligibility criteria.  
 
3.2. Inclusion  Criteria  
Potential subjects must satisfy all  of the following criteria to be enrolled in the study: 
Inclusion Criteria following Screening  
The subject must:  
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the  form.  
2. Appear able and willing to adhere t o the instructions set forth in this clinical  protocol.  
3. Be between 18 and 65 (inclusive) years of age at the time of  screening.  
4. By self -report, habitually wear spherical silicone hydrogel soft contact lenses in both 
eyes in a daily reusable or daily dispos able wear modality (i.e. not extended wear 
modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a 
minimum of 5 days per week during the past 30  days.  
5. Possess a wearable pair of spectacles that provide correction for distance  vision. 
Inclusion Criteria at Baseline  Evaluation  
6. The spherical equivalent of the subject's vertex corrected distance refraction must be 
between -1.00 D and -6.00 D (inclusive) in each  eye. 
7. The magnitude of the cylindrical component of the subject's vertex -corrected distance 
refraction must be between 0.0 0 D and 1.00 D (inclusive) in each  eye. 
8. The best corrected, monocular, distance visual acuity must be 20/25 or better in each 
eye. 
 
3.3. Exclusion  Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study:  
Exclusion Criteria following Screening 
The subject must not:  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 32 of 160   
  
1. Be currently pregnant or  lactating.  
2. Be currently using any ocular medica tions or have any ocular infection of any  type.  
3. By self -report, have any ocular or systemic disease, allergies, infection, or use of 
medication  the investigator  believes  might  contraindicate  or interfere  with contact  lens 
wear, or otherwise compromise study endpoints, including infectious disease (e.g., 
hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human 
Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, 
Sjogren's synd rome), or history of serious mental illness or seizures. See section 9.1 
for additional details regarding excluded systemic  medications.  
4. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or 
hybrid lenses (e.g. SynergEyes, SoftP erm) within the past 6  months.  
5. Be currently wearing monovision or multifocal contact  lenses.  
6. Be currently wearing lenses in an extended wear  modality.  
7. Have participated in a contact lens or lens care product clinical trial within 30 days 
prior to study  enrollment.  
8. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family 
member of an employee (including partner, child, parent, gran dparent, grandchild or 
sibling of the employee or their spouse) of the clinical  site. 
Exclusion Criteria at Baseline Evaluation 
The subject must not:  
9. Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp 
findings (e.g., corneal  edema, neovascularization or staining, tarsal abnormalities or 
bulbar  injection)  or other  corneal  or ocular  disease  or abnormalities  that the investigator 
believes might contraindicate contact lens wear or may otherwise compromise study 
endpoints (includi ng entropion, ectropion, chalazia, recurrent styes, glaucoma, history 
of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic 
keratitis).  
10. Have a history of strabismus or  amblyopia.  
11. Have fluctuations in vision due to clinically significant dry eye or other ocular 
conditions.  
12. Have had any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, 
iridotomy, retinal laser photocoagulation,  etc.).  
13. Have signs of a contact lens -related corneal inflammatory event (e.g., past peripheral 
ulcer or round peripheral  scar).  
14. Have a history of eyelid injury, surgery or procedure that resulted in abnormal eyelid 
position or movement.  
 
3.4. Enrollment  Strategy  
Study subjects will be recruited from the Institution/clinical site's subject database and/or 
utilizing Independent Ethics Com mittee (IEC) or Institutional Review Board (IRB) approved 
materials.  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 33 of 160   
  
4. STUDY DESIGN AND  RATIONALE  
 
4.1. Description of Study  Design  
This is a split -plot design with two parallel arms consisting of randomized photopic and 
mesopic  conditions  where  subjects  are also randomized  contralaterally  to the Test and Control 
lenses  within  each arm. This study  will be non-dispensing,  controlled,  and double -masked.  The 
study  lenses  will be worn  in a daily  wear  modality  for 1-2 hours.  Subjects  will not have access 
to the study lenses at the conclusion of their  visit.  
 
4.2. Study Design Rationale  
This is a split -plot design with two parallel arms consisting of randomized photopic and 
mesopic  conditions  where  subjects  are also randomized  contralaterally  to the Test and Control 
lenses  within  each arm. The photopic  and mesopic  conditions  will be the two-parallel  arms  so 
that these two conditions can be assessed separately. There are several benefits to the choice 
of the contralateral design within each condition arm. First, a contralateral design will allow 
us to compare  performance  within  the same individual,  ostensibly  with the same  baseline  light 
sensitivity  by eye. Second,  other  subject  factors  that can influence  visual  performance,  such as 
iris color and absorption of test lights via macular pigment, are better controlled using this 
design. Third, in psychophysical testing, which is the gold standard for many of the visual 
functions  being  tested,  participants  make  judgments  about  some  event threshold,  such as when 
an image disappears. Participants may have different criteria for threshold events that are 
internally consistent within subjects but can vary between subjects. A contralateral design 
allows the investigational lens to be compare d within subjects, with consistent criteria for 
threshold  events.  
 
4.3. Enrollment Target and Study  Duration  
This study  will have  an enrollment  target  of 44 subjects,  with a target  of at least 40 to complete 
(approximately 20 subjects [10 subjects from the 18 -40 years of age range; 10 subjects from 
the 41 -65 years of age range] in each arm). The study will be conducted at a single clinical 
site. A subject will be considered enrolled upon signing of th e informed consent  form.  
 
There will be 1 visit total per subject; total study duration including the enrollment period is 
expected to be approximately 2 months. If subjects discontinue prior to the final evaluation, 
then additional subjects may be enrolle d at the discretion of the study sponsor to maintain the 
sample size plan. The investigation will end at the time that the study data is hard locked.  
 
5. TEST ARTICLE ALLOCATION AND  MASKING  
 
5.1. Test Article  Allocation  
Use of the test articles will be randomized using a lens fitting schedule supplied by the study 
biostatistician. The randomization scheme will be generated by the unmasked biostatistician 
using  the PROC  PLAN  procedure  from  Statistical  Analysis  System  (SAS)  Software  Version  
9.4 or higher (SAS Institute, Cary, NC).7 The clinical site will follow the lens fitting  schedule  
Clinical Study Protocol  
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 34 of 160   
  
provided and will complete enrollment according to the randomization list and will not pre - 
select or pre -assign subjects.  
 
Randomly -permuted block randomization will be used to avoid bias in the assignment of 
subjects to treatment and to enhance the valid ity of statistical comparisons across treatment 
groups.  Randomization  will be stratified  into two age groups  (18-39 years  old and 40-65 years 
old) using  a 1:1 allocation  ratio.  Subjects  will be first assigned  randomly  to the photopic  or the 
mesopic condition arm. The order of the light sources within each condition arm is 
predetermined: visual performance will be assessed under the no broadband light source 
(without  glare)  condition  first and then assessed  under  the broadband  light source  (with  glare) 
condition.  Within  each condition  arm, subjects  will be randomized  to either  wear  the Test lens 
in the left eye and the Control lens in the right eye or the Control lens in the left eye and the 
Test lens in the right  eye. There  will be only one lens assignment  for the two light sources  (i.e., 
without  glare  and with glare)  per subject.  Under  each light source  condition,  the right  eye will 
always be tested first. Once a participant's lens assignment has been randomized, the order of 
test stimuli will also be randomly assigned. Five spatial frequencies for contrast sensitivity 
testing (1.6, 3.2, 8, 16, and 24 cycles per degree) will be tested in the no -glare condition, and 
in the glare condition. Spatial frequency order will be randomized for both the no -glare 
condition and the glare condition for each subject  eye. 
 
Randomization will be performed at  visit 1. The following must have occurred prior to 
randomization:  
 
• Informed consent must have been  obtained.  
• The subject must have met all eligibility  criteria.  
• The subject's screening and baseline information must have been  collected.  
 
When dispensing test articles, the following steps should be followed to maintain 
randomization codes:  
1. Investigator or designee (documented on the Delegation Log) will consult the lens 
fitting  schedule  to obtain  the test article  assignment  for that subject  prior  to dispensing.  
2. Investigator or designee will record the subject's number on the appropriate line of the 
lens fitting  schedule.  
3. Investigator or designee will pull the appropr iate test articles from the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed 
outside the clinical site) or not, must be recorded on the Test Article Accountability 
Log in the "Dispensed"  section.  
 
5.2. Masking  
This is a double -masked trial. Masking will be used to reduce potential bias. Subjects will be 
unaware of the identity of the investigational product assigned in the left eye and right eye. 
Investigators involved in the clinical assessment and data collect ion will be masked as to the 
identity of the investigational product. However, the clinician fitting the lenses may be aware 
of the identity of the investigational product due to the slight color difference between the  
Clinical Stud y Protocol 
John son & John son Vision Care, Ine. 
Page 35 of 160  
 
Test 
Name 
Man ufacturer  - AOMAX  Control 
AOlD  
JNC  
Lens Mate1i al senofilco n A C3  senofilcon A C3  - JNC   
study lenses , and the clinician won't be involved in any clinical assessment or data collection 
of the study. 
5.3. Procedures for Maintainin g and Breaking the Masking 
Eve1y  attempt  will be made to keep  the clinical  trial personnel involved in the study  (e.g. data 
manageme nt, biostatistician and clinical operati ons) unaw are of the identity of the assigned 
study lenses. The identi ty of the study lenses will be masked by having the blister packs 
labeled with the study number , lot number , sphere power, expiration date and the 
randomization codes . Only the urun asked biostat istician generat ing the lens fitting schedule 
will have  access  to the decode  infonn ation  that allows matching  of the randomization  codes  to 
the test aiiicles . The medi cal monitor will also have access to the decode info1mation in case 
breaking the mask is necessa1y for the urgent medica l treatment of a subject. 
 
Under no1ma l circumstances, the mask should not be broken until all subjec ts have completed 
the study and the database is finalized . Othe1wi se, the mask shou ld be broken only if specific 
emergency  treatment /course  of action would  be dictated  by knowing  the treatment  status of the 
subject. In such cases , the invest igator may, in an emergency, contact the medical monitor. In 
the event  the mask  is broken,  the sponsor  must  be info1med  as soon  as possible.  The date, time, 
and reason for the unmasking must be docume nted in the subject record. The investigator is 
also advised not to reveal the study treatment ass ignment to the clinical site or sponsor 
personnel.  
 
If subjects  discontinue  prior  to the final  evaluation , then additional subjects  may be emolled  at 
the discret ion of the study  sponsor  to maintain  the sainple size plan.  
 
6. STUDY INTERVEN TION 
 
6.1. Identi ty of Test Articl es 
The following contact lenses will be used in this study: 
Table 1: Test Atiicles  
 
 
 
 
 
 
 
 8.5 8.5 
   Nomi na1 Diameter  14.3 14.3 
Nomi nal Di stance Powers  -1.00 throu h -6.00 -1.00 throuo  -6.00 
Water Content (O tional  38 38 
Center Thickness  0.085 0.085  
Ox oen Pe1meabilit  Dk 103 103 
 
 
Clinical Stud y Protocol 
John son & John son Vision Care, Ine. 
Page 36 of 160  
 CR-6501, v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Stud y Protocol 
John son & John son Vision Care, Ine. 
Page 37 of 160  
  
 Test  Control 
Wear Schedule in Cunent Study  Daily Daily 
Replacement Frequency  Daily Daily 
Packaging Fonn (vial, blister , etc.) Bhster Bhster 
New UV/HEV -blocker  Yes No 
AOMAX = ACUVUE® OASY S MAX 1 -Day, AOID = ACUVUE® OASYS 1 -Day 
 
Approximately  11 lenses  per stock  keeping unit  (SKU)  will be prov ided based  on 44 subjects, 
I-period , contralateral , non-dispensing design , US population n01mahzed far peak  SKUs.  
 
6.2. Ancillary Suppli es/Product s 
The fa llowing solutions will be used in this study:  
 
Table 2: Anc illaiy Supphes  
 
 Solut ions 
 
Solution 
Name/Desc ription  Acuvue ™ RevitaLens 
Mult ipurp ose Solution  Single use 
Eye-Cept® 
Rewetting  
Drops  LacriPure 
Sahne 
Solution  ScleralFil 
Preservative 
Free Sahne  
Solution  
Manufacturer  Johnson & Johnson 
Vision  Optics 
Laborato1y  Menicon  Bausch & 
Lomb 
 
Preservative  alexidine 
dihydrochloride 
0.00016% and 
polyquatemium -1 
0.0003%  None  None  None  
Lens cases and fluorescein strips (either 0.6 mg o r 1.0 mg) will be supp lied far use as needed . 
 
6.3. Admini stration of Test Articles 
Test aiticles will be dispensed to subjec ts meeting all eligibihty requirements , including any 
dispensing requirements set fa1th in this clinical protocol. Subjects will be dispensed an 
adequate supply of test aiticles to complete the study. Lost or damaged test aiticles may be 
replaced at the discretion of the invest igator and/or the sponsor.  
6.4_ Pa  c k aging and Labeling 
The study  aiticles  will be packaged  in blisters  as the primaiy  packaging.  The study  aiticle  will 
be over -labeled to mask the subject and investigators to the identity of the lens. The study 
aiticles will be in plastic bags as the seconda 1y packaging fo1m. The samp le study label is 
shown below (Figure  10). 
 
 
 
 
 
 
 
Clinical Stud y Protocol 
John son & John son Vision Care, Ine. 
Page 38 of 160  
 CR-6501, v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol  
Page 39 of 160   
 Johnson & Johnson Vision Care, Inc.  
 
Figure 10: Packaging Labels  
 
 
Secondary Packaging  
Primary Packaging  
 
 
6.5. Storage Conditions  
Test articles will be maintained at ambient temperatures at the clinical site. Test articles must 
be kept under secure conditions.  
 
6.6. Collection and Storage of  Samples  
No samples will be collected as part of the study procedures.  
 
When possible, any lens or test article associated with an Adverse Event and/or a Product 
Quality Complaint must be retained and stored in a glass vial with moderate solution pending 
directions from the sponsor for potential return to JJVC.  
 
6.7. Accountability  of Test  Articles  
JJVC will provide the Investigator with sufficient quantities of study articles and supplies to 
complete  the investigation.  The Investigator  is asked  to retain  all lens shipment  documentation 
for the test article accountability  records.  
 
Test articles must be kept in a locked storage cabinet, accessible only to those assigned by the 
Investigator  for dispensing.  The Investigator  may delegate  this activity  to authorized  study  site 
personnel  listed  on the Site Delegation  Log. All test articles  must  be accounted.  This includes:  
 
1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between  visits.  
2. What was returned to the Investigator unused, including expired or malfunctioning 
product.  
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 40 of 160   
  
3. The number and reason for  unplanned replacements.  
 
The Invest igator  will collect  all unused test aiticles  from  the subject s at the end of the subject's 
paiticipation. Subject retumed unused test aiticles must be sepai·ated from the clinical study 
invent01y of un -dispensed test aiticles and must be labeled with the subject numbe r and date 
of retum. Following final reconciliation of test ait icles by the mon itor, the Investigator or 
monitor  will retum  all unused  test articles to JJVC.  
 
If there is a disc repancy between the shipment documents and the contents, contact the study 
monitor immedi ately. 
 
 
7. STUDYEVALUATIONS  
 
7.1. Time and Event  Schedule  
 
Table 3: Time and Events  
 
 
 
Visit Information  Visit 1 
Screen ing, Baseline, Fitting / 
Assessme nt 
Final Evaluation  
Time Point  DayO  
Estimated Visit Dmation  3.0 hom s 
Statement of Infonned Consent  X 
Demographic s X 
Medica! Hist01y /Concomitan t Medicat ions X 
Habitual Contact Lens Info1mation  X 
Eligibilitv Following Screening  X 
Entrance Visual Acuity  X 
Subjective Sphero -Cylindr ical Refract ion and best- 
co1Tected VA  X 
Eve Doininanc v X 
Slit Lamo Bioinicroscoov  X 
Eligibility Following Baseline Evaluat ion X 
Lens Selection  X 
Lens Inse1t ion & Settling  X 
Visual Acuity and Over Refraction  X 
Lens Power Modification (if applicable)  X 
Subiect Repo1ied Ocular Symptoms X 
Visual Acuitv  X 
General Fit Assessment  X 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 41 of 160   
 
 
 
 
Visit Informat ion Visit 1 
Screen ing, Baseline, Fitti ng / 
Assessme nt 
Final Evaluation  
Time Point  DavO  
Estimated Visit Duratio n 3.0 hours  
Vision Assessments: photopic an d mesopic contras t 
sensitivitv  X 
Exit Snellen Distance Visual Acuity  X 
Studv Completion  X 
 
 
7.2. Detailed Study Proc edures 
 
VISIT 1  
The subjects must present to Visit 1 wearing spectacles , not having wom contact lenses on the 
day of the visit.  
 
Visit 1: Screen in  
Step  Procedure  Deta ils 
1.1 Statement of 
Infonned Consent  Each subject must read, understand , and sign 
the Statement of Infonned Consent before 
being emolled in to the study. The Principal 
Investigator or his/her designee conducting 
the info1med consent discussion mus t also 
sign the consent f01m.  
 
Note: The subject  must  be provided  a signed 
co of this document.   
1.2 Demographics  Record the subject's year of bi1th , age, 
oender , race and ethnicit .   
1.3 Medical Histo1y and 
Concomitant 
Medications  Record the subject's medical histo 1y and 
concom itant medic.a tions .  
1.4 Habitual Lenses  Record the subjecfs habitual lens type, 
parameters , lens care solution, wear modality , 
dmation of lens wear , and approximate  
rescri tion date .  
 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 42 of 160   
  
 
 
 
Visit 1: Baseline   
 Step Procedure  Details  
1.6 Entrance Visual 
Acuity  Record the distance Sne11en visual acuity 
(OD, OS, and OU) to the nearest letter with 
their habitual spectacle. Subjects must read 
the sma11est line until at least 50% of the  
letter s are read incon ec tl .  
 
 
 
 1.7 Subjective Sphero­ 
cylindrical 
Refraction  Complete subjec tive spherocy lindrical 
refraction and record the resultant distance 
visual acuity (OD, OS, and OU) to the neare st 
letter.  
1.8 Eye Dominancy  The investigator wi11 detennine eye 
dominancy of the subject by first using the 
+1.00 blur test. If this fails to detennine  
dominancy , then the sight ing test wi11  be 
used.   
 
 
 
 
 
 1.9 Slit Lamp 
Biomicro scopy  FDA  Slit Lamp  Classification  Scale  wi11  be 
used to grade the findings.  
 
If any of these slit lamp findings a re grade 3 
or higher , the subject may not continue at this 
time, but may retum up to one additional time 
to detennine eligibility. If  discontinued a 
final examination must be  completed.  
 
If the clearance of the fluorescein need s to be 
expedited , preservat ive-free rewetting drops  
or saline ma be insti1led . 
Visit 1: Screen in 
Details  
 
AH responses to Screen ing Inclusion Criteria 
questions must be answered "yes" and al1 
responses to Exclusion Criteria must be 
answered "no" for the subject to be 
considered eligible.  
 
If subject is deemed to be ineligible after 
screening, proceed to Fina! Evaluation and 
complete Subject Disposition. Refraction and 
Biomicroscopy forms do not need to be 
com leted as art o Fina! Evaluation.  Eligib ility after 
Screening  1.5 Procedure  Step 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 43 of 160   
 
 
 
 
 
 
Visit 1: Treatment 1 Lens Fittin   
Step Procedure  Detail s 
1.11 Lens Selection  Assign the study lens based on the 
randomization scheme provided by the 
biostatistician . 
Select the contact lens power based on 
ve1texe d spherical equivalent from the  
refraction.   
1.12 Lens Inse1tio11 The Investigator  or the subject  inse1ts  the 
study lenses. Record the time of lens 
inse1t io11.  
Check for lens damage under the slit lamp 
before proceeding with lens settling.  
Re  lace dama  ed lenses  if a licable.   
1.13 Lens Settling  Allow the study lenses to settle for a 
minimum of 5 minutes.   
1.14 Subjective Best 
Sphere Over 
Refraction  Perfo1m subjective best sphe re refraction 
over the study lenses (adopt the maximum 
plus to maximum visual acuity (MPMV A) 
a roach.  
1.15 Lens Power 
Modification (if 
applicable)  Adjust the lens power if the subject's best 
sphere over -refractionis not plano.  
For each power modification , select the 
adjusted fitting lens power as appropriate and 
repeat steps 1.12 through 1.14 . 
 
Up to two power modificat ions are allowed 
ere e. 
Visit 1: Baseline 
Detail s 
 
AH re sponses  to Inclusion  Criteria questions 
must be answered "yes" and al1responses to 
Exclusion Criter ia questions must be 
answered "no" for the subject to be 
considered  eligible.  
 
If subject is deemed to be ineligible after 
baseline, proceed to Fina! Evaluation and 
complete Subject Disposition. Refraction and 
Biomicroscopy forms do not need to be 
com leted as art o Fina! Evaluation.  Eligib  i lity afte r 
B ase l ine 1.1O Procedure  Step 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 44 of 160   
 
 
 
Visit I: Treatment I Lens Fittin  
Step Proced ure Details 
1.16 Subject Reported 
Ocular S m  toms  Subjects will res pond to a verbal o pen-ended  
s m toms uestio nnaire. 
1.17 Visual Ac uity Record the best conected Snelle n distance  
visual acuity to the nearest letter (OD, OS 
and OU). Subjec ts must read the smalles t 
line until  at least 50%  of the letters are read 
incon ec tly. Visua l acuity with the study 
contact lenses must be 20/30 or better OD 
and OS.   
 
 
 
 
 
 
 
 1.18 General Lens F it 
Assessment  Evalua te lens cen tration, mo vement on b link, 
a.ud push -up tes t for each eye.  
 
An unacceptable fit is deemed by one of the 
following  criteria: 
• limba! exposure at pr ima1ygaze  or 
with extreme eye  moveme nt. 
• edge  lift. 
• excessive movement in pr imaiy and 
up gaze . 
• insuffic ient moveme nt in all three of 
the following cond itions: primaiy 
gaze, up gaze,  and push -up test. 
 
Note: if lens fit is unacceptable for eithe r eye, 
the subjec t will be discon tinued from the 
stud . 
1.19 Cont inuance  For the subject  to continue  in the study , they 
must meet all three  of the following  criteria:  
1. Visua l acuity is 20 /30 or better OD 
andOS.  
2. The lens fit is acceptable OD and OS. 
3. Investigator  approval.  
If the Investigato r does not approve the study  
lens, then the study is termina ted for that 
subject.   

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 45 of 160   
 
Visit I: Photo 
Details  
Contrast sensit ivity testing will be perfo1med 
using the University of Georgia syste m OD 
and OS in the following order. The eye not 
being tested will be patched. The following 
spatia l frequencies will be randomized: 1.6 , 
3.2, 8, 16 and 24 cpd.  
 
Photopic contrast sensit ivity without glare  
1. Participant is seated in front of the 
optical device with their chin in the 
chin rest assembly and asked to  patch 
OS. 
2. To practice , the paiticipant is shown  the 
0.5 cycles per mm grating (which 
yields a threshold at 8 cycles per  degree 
of visual angle ). The procedure is 
demonstrated , and the paiticipant 
confinns that they can view the grating  
easil  . Photopic Contrast 
Sensitivity Testing 
Without Gla re 1.21 Procedure  Step   
 
Visit I : Treatment I Lens Fittin   
Step  Procedure  Details  
1.20  Lenses Wom in 
Clinic  The lenses will be relea sed for approximately 
two hours.  
1. The subjects must wear both study  
lenses the entire  time.  
2. The lenses will be wom as daily  wear  
only.  
3. Rewetting  drops   are   pennitted  if 
needed.  
Note: In the event a lens is lost or damaged , it 
will be replaced immedia tely. 
A clinic -only -wear Patient Instmction 
Guide will be provided.   
 
 
Based on the randomization scheme , subjects are either in the photop ic testing group or the 
mesopic testing group. Proceed to the co ITect test:  
 
 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 46 of 160   
 
 
Visit 1: Photo 
Step Proced me Deta ils 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.22  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Photopic Contrast 
Sensitivity Testing 
With Glai·e 3. The paiiicipant rests for a period of two 
minutes while the researcher replaces 
the 0.5 cycles pe r mm filte r with the 
first spatial frequency grating d ictated 
by the randomiza tion scheme . Three 
ascend ing and three descending 
thresholds are obtained for the first  
spatial frequency dictated by the 
randomizatio n scheme . EDC to record 
contrast sensitivity to 2 decimal places 
(range 0.01 - 10,000).  
4. The paiiicipant rests for two minutes  
while the researcher changes the spatial 
frequency  grating. 
5. The procedure is repeated until all 5 
spatial frequencies have been tested, 
with two-minute breaks betwee n trials. 
EDC to record contrast sensitivity to 2 
decimal places (range 0.01 - 10,000). 
Area tmder the contrast sensitivity 
curve will be computed (range 5.00 - 
20,000) and  entered.  
6. The participant will then be g iven a  5- 
minute break and asked to change the 
patch to OD, in order to test OS.  
7. The procedure above will be repeated  
OS. 
Contrast sensit ivity testing wi ll be pe rfo1med 
using the University of Geo rgia system OD 
and OS in t he follow ing order. T he eye not 
being tested will be patched. T he follow ing 
spatia l frequencies will be randomized: 1.6 , 
3.2, 8, 16 and 24 cpd.  
 
1. The paiiicipant will be given a 5 
minute b reak to change the patch back 
to OS while the researche r confinns 
alignment with the glare  stimulus. 
2. The paiiicipai1t will be instrncted to 
keep eyes closed , and to position their 
chin in the chin rest assembl  . 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 47 of 160   
 
 
Visit 1: Photo 
Step Procedure  Deta ils 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.23  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lens Removal  3. With the glare  stimulus  on, paiiicipants 
will complete three ascending and three 
descending trials for the first spatial 
frequency dictated by the 
rai1domizat ion scheme for the glare 
condition. Note that the first  spatia l 
frequency tested in the glai·e condit ion 
will likely be different from the first 
spatial frequency tested in the  110-gl 
are condit ion. EDC to record 
contrast sensitivity  to  2  decimal 
places (range 0.01 - 10,000) . 
4. The paiiicipant will be given a four  
minute b reak and will be instrncted  to 
keep eyes closed during the  break . 
5. The procedure is repeated until all 5 
spatia l frequencies have been tested , 
with four -minute breaks between 
trials. EDC to record contrast 
sensitivity to 2 decimal places  (range  
0.01 - 10,000 ). Area under the 
contrast sensitivity curve will be 
computed (range 5.00 - 20,000) and 
entered . 
6. The paiiicipant will  then be given  a 5- 
minute break and asked to change the 
patch to OD , in orde r to test OS . 
7. The procedure above will be  repeated  
OS. 
The wom study lenses will be removed and 
discarded. Proceed to the Final Evaluation.  
 
 
Visit 1: Meso 
Detai ls 
1.24  Mesopic Contrast 
Sensitivity Testing 
Without  Glare  Mesopic contrast sensitivity testing will be 
perfo1med using the University of Georgia 
system OD and OS in the following order. 
The eye not being tested will be patched. The 
following spatial frequencie s will be 
randomized: 1.6 , 3.2, 8, 16 and 24 cpd.  Procedure  Step 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Visit 1: Meso  
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 48 of 160  
 
Step Procedme  Deta ils 
 
Mesopic contras t sensitivi ty without glare  
1. Prior to seating the participant , the 
resea1·che r confams that the wedge 
controlling the background  luminance 
is dimmed to the appropria te position 
for mesopic testing. 
2. Paiticipant i s sea ted in fron t of the 
optical device wi th their chin in the 
chin rest assembly and asked to patch 
OS. 
3. To practice, the participa11t is shown  
the 0.5 cycles per mm grating (which 
yields a threshold at 8 cycles per 
degree of visual angle ). The procedure 
is demons trnted, and the pa1t icipant 
confums that they can view the 
grating easily.  
4. The pait icipa nt rests fora  periodof 
two minutes while the reseai·cher 
replaces the 0.5 cycles per mm filter 
with the first spatial frequency gra ting 
dicta ted by the randomization scheme . 
Three ascending and three descending 
thresholds are ob tained for the first 
spatia l frequenc y dictated by the 
randomization scheme.  EDC to 
recor d contrast sensitivity to 2 
decima l places (r ange 0. 01 - 10,00 0). 
5. The pait icipant  rests for two minu tes 
while the reseai·c her changes the 
spatia l frequenc y grating. 
6. The procedure is repeated un til all 5 
spatia l frequencies ha ve been tested , 
with two-minute breaks between trials 
EDC to record contrast sensitivity to 2  
decima l places (range 0.01 - 10,000). 
Area under the contrast se nsitivity 
cmve will be co mputed ( range 5.00 - 
20,000) and  entered.  
7. The participant will then be given a 5- 
minute break and asked to change the 
atch to OD , in orde r to test OS. 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Visit 1: Meso  
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 49 of 160  
 
Step 
 
 
 
1.25 Procedure  
 
 
 
Mesopic Contrast 
Sensitivity Testing 
With  Glai-e Deta ils 
 
The procedure above will be repeated 
OS. 
Mesopic contrast sensitivity testing will be 
perfo1med using the University of Georgia 
system OD and OS in the following order. 
The eye not being tested will be patched. The 
following spatial frequencies will be 
randomized : 1.6, 3.2, 8, 16 and 24 cpd.  
 
Mesopic contrast sensitivity with glare  
1. Prior to seating the pariicip ant, the 
researcher confirms that the wedge 
controlling the background lumina nce 
is dimmed to the appropriate position 
for mesopic  testing. 
2. The pariicipant will be given a 5 
minute break to change the patch  back  
to OS while the researcher confinns  
alignment with the glare  stimulus.  
3. The pariicipant will be instmcted to 
keep eyes closed , and to position their 
chin in the chin rest  assembly.  
4. With the glar·e stimulu s on, 
pariicipants will complete three 
ascend ing and three descend ing trials 
for the first spatial frequency dictated 
by the randomization scheme for the 
glare conditio n. Note that the first 
spatia l frequenc y tested in the glare 
condit ion will likely be differen t from 
the first spatia l frequen cy tested in the 
no-glare condition. EDC to record 
contrast sensitivity to 2 deci mal 
places (range 0.01 - 10,000) . 
5. The pariicipant will be given a four 
minute b reak and will be instrncted to 
keep eyes closed during the break . 
6. The procedure is repeated until all 5  
spatia l frequencie s have been tested, 
with four-minute breaks between  
trials. EDC to record co ntrast 
sensitivity to 2 dec imal laces  range  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Visit 1: Meso  
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 50 of 160  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FINAL EV ALUATIO N 
The final evaluation will ordinarily take place immediately following the last scheduled 
follow -up visit per the study protocol. It may also take place at any point the subject 
discon tinues the study o r is tennin ated from the study.  
 
Final Evaluatio n  
 Ste Procedure  Detail s 
F.1 Final Exam Fo1m  fudic ate if the subject completed the study  
succe ssfully. If subject discon tinued from  the 
stud indic ate the reason.  
F.2 Exit Slit Lamp 
Bioinicro scopy  FDA Slit Lamp Classification Sca le will be 
used to grade the findings.  
 
If the clearance of the fluorescein need s to be 
expedited , preservative -free rewetting drops 
or saline may be ins tilled. This step is no t 
necessa1y if the subject was exi ted due to 
screen failure .  
 
 
 
 
 
 
 
 F.3 Exit Visual Acu ity Record the distance Snellen visual acuity 
(OD, OS, and OU) to the nearest letter with 
their habitual co n ection in place. Subjects 
must read the smallest line until at least 50%  
of the letters are rea d inconectl . 
 
7.3. Unscheduled Visits  
If , during the investigation , a subject requires an unscheduled visit to the clinical site, the 
following info1mation will be collected , as appropriate:  
Deta ils 
The wom study lenses will be removed  and 
discarded. Proceed to the Final  Evaluation.  Lens Removal  1.26 0.01 - 10,000). Area under the 
contrast sensitivity curve will be 
computed (range 5.00 - 20,000) and 
entered . 
7. The participant will then be given a 5- 
minute break and asked to change the 
patch to OD , in orde r to test OS.  
8. The procedure above will be  repea ted 
OS. Procedure  Step 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 51 of 160   
  
• Chief comp laint prom pting the visit. If the re ason is an adverse event, t he applicable 
eCRF for t he adverse even t must be completed and subject record completed as 
appropriate.  
• Date  and time of the visit and all procedures  completed  at the unscheduled  visit. 
• Review  of adverse  event and concomitant medications. 
• Documentat ion of any test aiticle  dispensed  or collected  from  the subject , if applicable.  
• Slit lamp findings  (using  the Slit Lamp  Classification Scale) . 
 
If the Investigator  withdraws  a subject from the study,  the final study  visit case report  fo1ms 
must  be completed  indicating the reason(s)  why the subject  was withdrawn.The  subject  record 
must be comple ted docume nting the date and primaiy reason for withdrawal and the study 
CRA  notified.  
 
Any ocula r and non-ocular Adverse  Events that ai-e ongo  ing at th e time of the study  visit will 
be followed by the Investigator, within licens ure, until they have resolved , returned to pre ­ 
treatme nt stat us, stabilized, or been satisfactorily explained. If fmther treatment i .e., beyond 
licensure is requ ired, the subject  will be refened  to the appropr iate health cai·e  provide  r. 
 
The fo llowing info1m ation will be collec ted dming an unscheduled visit.  
 
Unscheduled Visit   
Ste Procedme Details  
U.I Reason for 
unscheduled visit Indicate if the only reaso n for the visit is that 
the s ubject requires additional test ait icles.If 
the reason is other t han resupply of  
previously  dispensed lenses,  specify the 
reason  for the visit.    
U.2 Chief Co mplaints (if  
a lic.able  Record the subject's chief comp laints for 
reasons for the unsched uled visit.  
U.3 Adverse Eve nts and 
Concomitant 
Medicat ions Review  
if a licable  Review any changes to the s ubject's medica! 
histo1y or concomitant medications from the 
previous study visi t. Record a ny cha nges, and 
an adverse events .  
U.4 Entra nce VA (if  
a licable  Record t he entrance distance vis ual acuity 
OD, OS, and OU to t he nearest letter.  
U.5 Subjective Sphero ­ 
cylindrical 
Refract ion (if 
applicable)  Perfo1m bare-eye subject ive spherocylindr ical 
refrac tion w ith a phoropte r (adopt the 
maximum plus to maximum vis ual acuity 
(MPMVA) approach and use t he duo -chrome 
test for binocular balanc ing) and record the 
best conected dista nce visual acuity to the 
nearest let ter OD OS, and O 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 52 of 160   
  
 
Unscheduled Visit   
 Ste Procedure  Details 
U.6 Slit Lamp 
Biomicroscopy ( if 
applic.able) FDA Slit Lamp Classifica tion Scale will be 
used  to grade  the findin gs. If the clearance  of 
the fluorescein needs to be expedited , 
preservative -free rewe tting drops  may be 
instille d.  
U.7 Dispensing (if 
applicable)  If the subject requires additional lenses to 
comp lete the wear period and is eligible to do 
so, previde additional lenses per the 
dispensing ins tmctions given in the detai led 
stud rocedures.   
 
 
 
 
 
 U.8 Exit Visual Acui ty 
if a licable  Record the subject's exit dis tance visual 
acm OD, OS, and O to the nearest  letter.  
 
NOTE : If the only reason for the unscheduled visit is that the subject requir es additio nal test 
aiticles , only the dispensing infonnation needs to be recorded.  
 
7.4. Laboratory  Procedure s 
None  
 
8. SUBJECTS  COMPLETION/WITHDRAW AL 
 
8.1. Completion  Criteria  
Subjects are considered to bave completed the study if they: 
 
• provide d info1med  consent. 
• they ai·e eligible  . 
• Complete d a ll sc hedu led tests 
 
8.2. Withdrawal/Discontinuation from the  Study  
A subject  will be withdrawn  from  the sh1dy  for any of the following  reasons : 
 
• Subject withdrawal of  consen t. 
• Subject not compliant to protocol (e.g., subject does no t complete all scheduled  tests).  
• Subject develops signi ficant or serious adverse even ts necessitat ing discontinuat ion of 
study lens wear.  
• Subjects who have experienced a Comeal Infiltrative Event (CIE).  
• Investigator's clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment).  
• Subject not successfully released wit h lenses due to lack of efficacy and safety  
including  poor vision,  poor  comfo1t or unaccepta ble fit. 

Clinical Study Protocol  
Page 53 of 160   
 Johnson & Johnson Vision Care, Inc.  
 
For discontinued subjects, the Investigator will:  
 
• Complete the current visit (scheduled or  unscheduled).  
• Complete the Final Evaluation, indicating the reason that the subject was  discontinued 
from the  study.  
• Record the spherocylindrical refraction with best corrected distance visual  acuity.  
• Collect used t est article(s) from the subject and discard them, unless otherwise stated 
in section  7.2. 
• Collect all unused test article(s) from the  subject.  
• Make arrangements for subject care, if needed, due to their study participation 
Additional  subjects  will be enrolled  if a subject  discontinues  from  the study  prematurely.  
In cases  where  a subject  is lost to follow -up, every  possible  effort  must  be made  to contact  the 
subject  and determine  the reason  for discontinuation/withdrawal.  The measures  taken  to follow 
up must  be documented  including  two written  attempts  and a certified  letter  (or equivalent)  as 
the final  attempt.  
 
9. PRE -STUDY AND CONCOMITANT  INTERVENTION/MEDICATION  
Concomitant medications will be documented during screening and updated during the study. 
Disallowed medications for this study include: any ocular medications.  
Concomitant therapies that are disallowed inc lude: see section 9.1.  
 
9.1. Systemic  Medications  
Certain systemic medications are known to have a higher likelihood to interfere with contact 
lens wear, chiefly by disrupting the tear film.  
 
A summary of disallowed systemic medications is shown in Table 4. Sub jects with a history 
of taking these medications will be allowed to enroll only if:  
 
• The medications have been taken on a continual, routine basis for at least 6 months, 
and 
• The subject has demonstrated successful contact lens wear during this  time.  
Or:  
• The subject was taking the medication on a temporary basis and ceased taking that 
medication at least 2 weeks prior to signing the informed consent (this is considered 
sufficient time for the medication to have left the body prior to  enrollment).  
 
Subjects with a history of taking medications listed in Table 4 on a long -term, routine basis 
for less than 6 months will not be allowed to participate in the study.  
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Stud y Protocol 
John son & John son Vision Care, Ine. 
Page 54 of 160  
  
Table 4: Disallowed systemic medications  
 
Class of Drug Commo n Indicatio n(s) Commo n Examples  
Estrogens (not 
including  Menopause, osteoporosis , vaginitis Vagifem , Estrace , Climara, 
Vivelle -Dot, Premarin , Minivelle,  
contrnceptive 
medication)   etc. 
Anticholinergics  IITitable bowel syndrome , 
Parkinson 's disease , peptic ulcer , 
cystitis , nasal congestion, cold 
symptoms , overactive bladder , 
COPD  Bentyl , Spiriva , Atrovent, 
Hyosyne , Levsin, Symax Fastab , 
Symax SL , Homax SL, Cogentin, 
Transdenn Scop , etc. 
Beta -blockers  Hypertension , angina, heait attack , 
migraine , atrial fibrillation , adrenal 
cancer, essential tumor , glaucoma  Toprol X L, Lopressor , Tenonnin, 
Propranolol , Timoptic , Trandate , 
Indera l LA, etc. 
Psychotropics  Antipsychotic (schizophrenia , 
mania),  antidepression , 
antiob sessive, antianxiety , mood 
stabilizer , stimu lants (ADHD)  Zoloft , Celexa , Prozac , Lexapro , 
Effexor ,  Cymbalta ,  Ativan, 
Xanax, Desy rel, Wellbutrin , etc. 
Vitamin A 
analogs  Cystic acne  Isotretinoin  
 
Examples of disallowed systemic antihistamines are given in Table 5. Subjects with a histo1y 
of taking systemic antihistam ines will be allowed to emoll only if: 
 
 
 
Or: • They  have  taken  antihistamines  continuously  for at least  2 weeks,  and 
• They  have  demonstrnted  successful  weai·  while  taking  the medication  
 
• They  stopped  taking  the medication  for at least  2 weeks  prior  to emollment.  
 
Table 5: Disallowed systemic antihistamines  
 
Class of Drug Common Indicat ion(s)  Common Examples  
Antihistamines  Allergic rh initis, sedation, hives, 
allergic  conjm1ctivitis,  skin allergy, 
itching , motion  sickness  Hydroxyz ine,  Promethagan, 
Phenadoz , Vistaril , Claritin,  
Zyitec , Astepro, Astelin , Optivar , 
Allegra , Benadiyl , etc. 
 
10. DEVIA TIONS FRO M THE PROTO COL 
Investigator will notify study sponsor upon identification of a protocol deviat ion. Protocol 
deviations must be reported to the sponsor within 24 hours after discove1y of the protocol 
deviation. The Investigator will report deviations per IRB /IEC requirements. All deviations 
will be tracked, and corrective actions implemented as appropriate.  
 
Clinical Stud y Protocol 
John son & John son Vision Care, Ine. 
Page 55 of 160  
 CR-6501, v 4.0 -  
 
 
 
JJVC CONFIDE NTIAL  
Clinical Stud y Protocol 
John son & John son Vision Care, Ine.  
 -  
 
If it becomes  necessaiy  for the Investigator to implement  a deviation  in order  to eliminate  an 
immediate hazard to the trial subject, the Investigator may implement the deviation 
immediately without notification to the sponsor. Within 24 hours after the implemented 
deviation,  the Invest igatormust  notify  and provide the rationale  to the Sponsor  and as required , 
the IEC/IRB . 
 
If the deviat ion potentially  impacts  the safety of patient  or changes  the technical  integrity  of 
the study, then it must be reported  to IEC/IRB. This is a "Major  Deviation". Deviations 
that contradict the info1mation contained in the Info1med Consen /tAssent fo1m s will be 
considered Major Devia tions. 
 
Minor deviations have no substantive effect on patient safety or technical integrity of the 
study. They ai·e often logistical in nature.  
 
Protoc ol waivers a re prohibited.  
 
Table 6 lists examples of deviations that will constitute major and minor protocol deviations 
for this study . 
Table 6: Examples of major and minor protocol deviations  
 
Deviation category Major de viation  Minor d eviation  
Incomplete tests  Subject  does not complete  all 
scheduled psychophysical 
tests. NA 
 
1n the case of a major  protocol  deviation,  the decision  of whether  or not the subject  will be 
excluded  from  the Per-Protocol analysis  population  will be made  at the time of coho1t  review. 
 
11. STUDY TERMINATION 
The occunence of one or more Unanticipated Serious Adverse Device  Effec t  (USA DE),  or 
any SAE where the relationship to study agent cannot be mled out, may result in stopping 
fmther dispensing of test a1t icle. 1n the event of a USADE or SAE, the Sponsor may unmask 
the treatme nt regimen for the subject(s) and will discuss this with the Investigator before any 
fmther subjects are enrolled.  
 
The Sponsor  will detennine  when  a study  will be stopped.  The Principal  Investigator  always 
has the discretion to initiate stopp ing the study based on patient safety or if info1mation 
indica  tes the study 's results  are compromised . 
 
JJVC  reserves  the right  to te1minate  the study  at any time for any reason. Additionally , the 
IEC/IRB reserves  the right  to te1minate  the study if an unrea sonable  risk is dete1mined.  The 
study can be te1mi nated by the Principal Investigator at the individua! clinical site due to 
 
 
 
 
CR-6501, v 4.0 
Page SO of 1 6 0  
J JVC CO NFIDE NTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 51 of 160   
  
 
specific  clinical  observations,  if in their opinion,  after a discussion  with JJVC,  it is determined 
that it would be unwise to continue at the clinical  site. 
 
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unreasonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible.  
 
Should the study be terminated (either prematurely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by local regulatory require ments.  
 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY  COMPLAINTS  
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety, 
effectiveness  or performance  of test articles  after they have  been  released  for clinical  trial use. 
 
Potential  complaints  may come  from  a variety  of sources  including  but not limited  to subjects, 
clinical research associates (CRA), clinical operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality  complaints:  
 
• Subject satisfaction inquiries reported via "Subjective Questionnaire s" and "Patient 
Reported Outcomes  (PRO)."  
• Clinical test articles that are stored improperly or damaged after receipt at the 
investigational  site. 
• Lens replacements that occur due to  drops/fall -outs.  
• Damage deemed by clinicians or clinical staff to be caused by handling by the user, 
and not indicative  of a quality  deficiency  (i.e. tears,  rips, etc.),  only in situations  where 
there is no deficiency alleged by the  subject.  
 
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be 
recorded in the EDC system, which will trigger an automatic email notification to the 
appropriate  COM/CRA  and Clinical  QA representative.  In cases  where  the EDC  system  in use 
is not configured to send automatic notifications or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has  occurred.  
 
Upon receipt o f the EDC notification, the COM/CRA will contact the study site to collect 
additional information which will include:  
 
• Date the complaint was received/recorded in the EDC System (Date of Sponsor 
Awareness).  
• Who received the  complaint.  
• Study  number.  
• Clinical site information (contact name, site ID, telephone  number).  
• Lot number(s).  
• Unique Subject Identifier(s).  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 52 of 160   
  
• Indication of who first observed complaint (site personnel or  subject).  
• OD/OS indication, along with whether the lens was  inserted.  
• Any related AE number if  applicable.  
• Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms,  etc.).  
• Eye Care Provider objective (slit lamp) findings if  applicable.  
• Confirmation  of product  availability  for return  (and tracking  information,  if available), 
or rationale  if product  is not available  for return  
 
Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel 
to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow se ction 13 of this 
protocol.  If the AE/SAE  was potentially  the result  of a product  quality  related  deficiency,  these 
procedures also apply and will be executed in  parallel.  
 
In some cases, a PQC form may be generated in EDC by the site in error. In this even t, the 
PQC forms will be marked "Intentionally Left Blank" or "ILB". Justification for ILB must be 
documented.  
 
13. ADVERSE  EVENTS  
 
13.1. Definitions and  Classifications  
Adverse Event (AE) - An AE is "any untoward medical occurrence, unintended disease or 
injury, or  untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investigational medical device and whether 
anticipated or unanticipated."  
Note : This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. For users or other persons, this definition is 
restricted to events related to investigational medical devices.1 
 
An AE includes any condition (including a pre -existing condition) that:  
 
1. Was not present prior to the study, but appeared or reappeared following initiation of 
the study.  
2. Was present prior to the study but worsened during the study. This would include any 
condition resulting from concomitant illnesses, reactions to concomitant medications, 
or progression of disease  states.  
 
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immediately upon  learning of the event.  
 
Serious Adverse Event (SAE) - An SAE is any adverse event that led to any of the following:  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 53 of 160   
  
• Death  
• Serious deterioration in the health of the subject that resulted in any of the  following:  
• Life-threatening illness or  injury  
• Permanent or persistent impairment of a body structure or a body  function  
• Hospitalization or prolongation of patient  hospitalization  
• Medical or surgical intervention to prevent life -threatening illness or injury or 
permanent impairment to a body str ucture or a body  function.  
• Chronic  disease  
• Foetal distress, foetal death or a congenital physical or mental impairment of birth 
defect.  
 
Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not 
limited to:  
 
• Microbial Keratitis  (MK)  
• Iritis (including cells in the anterior chamber)  
• Permanent  decrease  in best spectacle  corrected  visual  acuity  equivalent  to 2 acuity  lines 
or greater  
• Central Corneal  Opacity  
• Central Corneal  Neovascularization  
• Uveitis  
• Endophthalmitis  
• Hypopyon  
• Hyphemia  
• Penetration of Bowman's Membrane  
• Persistent Epithelial  Defect  
• Limbal cell Damage leading to  Conjunctivalization  
 
Significant Adverse Events - are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact lens wear  
 
Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but 
not limited to the following:  
 
• Contact Len s Induced Peripheral Ulcer  (CLPU)  
• Significant Infiltrative Events (SIE)  
• Superior Epithelial Arcuate Lesions  (SEALs)  
• Any Temporary Loss of > 2 Lines of  BSCVA  
• Other grade 3 or higher corneal findings, such as abrasions or  edema  
• Non-contact lens related corne al events - e.g. Epidemic Keratoconjunctivitis  (EKC)  
• Asymptomatic Corneal  Scar 
• Any corneal event which necessitates temporary lens discontinuation > 2  weeks  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 54 of 160   
  
Non-Significant Adverse Events - are defined as those events that are usually asympt omatic 
and usually do not warrant discontinuation of contact lens wear but may cause a reduction in 
wear time. However, the Investigator may choose to prescribe treatment as a precautionary 
measure.  
 
Diagnoses  and conditions  that are considered  Ocular  Non-Significant  Adverse  Events  include, 
but not limited to the  following:  
 
• Non-significant Infiltrative Event (NSIE)  
• Contact Lens Papillary Conjunctivitis  (CLPC)  
• Superficial Punctate Keratitis  (SPK)  
• Conjunctivitis: Bacterial, Viral,  Allergic  
• Blepharitis  
• Meibomianitis  
• Contact  Dermatitis  
• Localized Allergic  Reactions  
• Any corneal event not explicitly defined as serious or significant adverse event,  which 
necessitates temporary lens discontinuation < 2  weeks 
 
Adverse Device Effect (ADE) - An ADE is an "adverse event related to the use of an 
investigational medical device."  
 
NOTE 1: This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantatio n, installation, or operation, or any malfunction 
of the investigational medical device.  
 
NOTE  2: This definition  includes  any event  resulting  from  use error  or from  intentional  misuse 
of the investigational medical  device.1 
 
Unanticipated Adverse Device Effect (UADE) - A UADE is any serious adverse effect on 
health  or safety  or any life-threatening  problem  or death  caused  by, or associated  with,  the test 
article, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational plan, Investigator's Brochure or protocol, or any 
other unanticipated serious problem associated with the test article that relates to the rights, 
safety and welfare of  subjects.  
 
13.2. Assessing Adverse  Events  
In conjunction  with the medical  monitor,  the Investigator  will evaluate  adverse  events  to ensure 
the events are categorized correctly. Elements of categorization will  include:  
 
• Seriousness/Classifications (see definition in section  13.1).  
• Causality  or Relatedness  - i.e. the relationship  between  the test article,  study  treatment 
or study procedures and the adverse event (not related, unlikely related, possibly 
related, or related - see definition in section  13.2.1).  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 55 of 160   
  
• Adverse Event Severity - Adverse event severity is used to assess the degree of 
intensity o f the adverse event (mild, moderate,  or  severe  -  see  definition  in  
section  13.2.2).  
• Outcome - not recovered or not resolved, recovering or resolving, recovered or 
resolved with sequelae, recovered or resolved, death related to adverse event, or 
unkn own.  
• Actions  Taken  - none,  temporarily  discontinued,  permanently  discontinued,  or other.  
13.2.1.  Causality  Assessment  
Causality  Assessment  - A determination  of the relationship  between  an adverse  event  and the 
test article. The test article relationship for each adverse event should be determined by the 
investigator using these explanations:  
 
• Not Related - An adverse event that is not related to the use of the test article, study 
treatment or study  procedures . 
• Unlikely Related - An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not  likely.  
• Possibly Related - An adverse event that might be due t o the use of the test article, or 
to the study  treatment  or study  procedures.  An alternative  explanation,  e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is 
reasonable. Therefore, the causal relationship cannot  be excluded.  
• Related  - An adverse  event  that is listed  as a possible  adverse  effect  (device)  or adverse 
reaction (drug) and cannot be reasonably explained by an alternative explanation, e.g. 
concomitant treatment of concomitant disease(s). The relationship in time is very 
suggestive, e.g. it is confirmed by de -challenge and  re-challenge.  
 
13.2.2.  Severity  Assessment  
Severity  Assessment  - A qualitative  assessment  of the degree  of intensity  of an adverse  event 
as determined by the Investigator or reported to him/her by the subject. The assessment of 
severity is made irrespective of test article, study treatment  or study procedure relationship or 
seriousness of the event and should be evaluated according to the following  scale:  
 
• Mild - Event is noticeable to the subject but is easily tolerated and does not interfere 
with the subject's daily activities.  
• Moderate - Event is bothersome, possible requiring additional therapy, and may 
interfere with the subject's daily  activities.  
• Severe - Event is intolerable, necessitates additional therapy or alteration of therapy 
and interferes with the subject's daily  activities.  
 
13.3. Documentation and Follow -Up of Adverse  Events  
The recording and documenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure. Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 56 of 160   
  
recorded as medical history. However, if the condition deteriorates at any time during the 
study, it will be recorded and reported as an AE. Untoward medical events reported after the 
subject's exit from the study will be recorded as adverse events at the discretion of the 
Investigator.  
 
Upon finding an adverse event, the Principal Investigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.  
 
Complete descriptions of a ll adverse events must be available in the subject record. All 
Adverse Events including local and systemic reactions not meeting the criteria for "serious 
adverse  events"  shall  be captured  on the appropriate  case report  form  or electronic  data system. 
All adverse events occurring while the subject is enrolled in the study must be documented 
appropriately regardless of  relationship.  
 
It is the Investigator's  responsibility  to maintain  documentation  of each reported  adverse  event. 
All adverse  even ts will be followed  in accordance  with applicable  licensing  requirements.  Such 
documentation will include the  following:  
 
• Adverse event (diagnosis not symptom).  
• Drawings or photographs (where appropriate) that detail the finding (e.g., size, 
location, and depth,  etc.).  
• Date the clinical site was  notified.  
• Date and time of  onset.  
• Date and time of  resolution.  
• Adverse event classification, severity, and relationship to test articles, as  applicable.  
• Treatment regimen instituted (where appropriate), including concomitant medications 
prescribed, in accordance with applicable licensing  requirements.  
• Any referral to another health care provider if  needed.  
• Outcome, ocular damage (if  any).  
• Likely etiology.  
• Best corrected visual acuity at the discovery of the event and upon conclusion of the 
event, if the AE is related to the visual  system.  
 
Upon discovery of an AE that  is deemed 'possibly related' or 'related' to the test article or 
study procedures (whether related to the visual system or not), an AE review form  
must be completed. Additional dated and initialed entries should be made at follow -up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral.  
 
In addition,  if an infiltrate(s)  is present,  he/she  will complete  the Corneal  Infiltrate  Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be  recorded.  
 
Changes in the se verity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 57 of 160   
  
intermittent require documentation of the onset and duration of each episode. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.  
 
Subjects who present with an adverse event shall be followed by the Investigator,  within 
licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or 
been satisfactorily resolved. If further treatment beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The  Investigator will use his/her clinical 
judgment  as to whether  a subject  reporting  with an adverse  event  will continue  in the study.  If 
a subject is discontinued from the study, it will be the responsibility of the Investigator to 
record the reason for dis continuation. The Investigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse 
events  related  to the test article,  study  treatment  or study  procedures,  as of the final study  visit 
date, should be followed to resolution of the adverse event or until referral to an appropriate 
health care provider, as recommended by the Investigator. Non -ocular adverse events that are 
not related to the test article, study treatment, or study pr ocedures may be recorded as 
"ongoing" without further  follow -up. 
 
13.4. Reporting Adverse  Events  
The Investigator  will notify  the Sponsor  of an adverse  event  by e-mail,  facsimile,  or telephone 
as soon as possible and no later than 24 hours from discovery for any  serious /significant 
adverse events, and 2 days from discovery for any non -significant adverse event. In addition, 
a written report will be submitted by the Principal Investigator to the IEC/IRB according to 
their requirements (section 13.4.2). The report  will comment whether the adverse event was 
considered to be related to the test article, study treatment or study  procedures.  
13.4.1.  Reporting Adverse Events to Sponsor 
Serious/Significant Adverse  Events  
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e -mail or telephone, but no later than 24 hours 
following discovery of the event. The Investigator is obligated to p ursue and obtain 
information  requested  by the Sponsor  in addition  to that information  reported  on the eCRF.  All 
subjects  experiencing  a serious/significant  adverse  event  must  be followed  up and all outcomes 
must be  reported.  
 
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.  
 
In the event of a seri ous/significant adverse event, the Investigator must:  
 
• Notify the Sponsor  immediately.  
• Obtain and maintain in the subject's records all pertinent medical information and 
medical judgment for colleagues who assisted in the treatment and follow -up of the 
subject.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 58 of 160   
  
• Provide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test  article.  
• Notify the IEC/IRB as required by the IEC/IRB reporting procedure according to 
national  regulations.  
 
Unanticipated (Serious) Adverse Device Effect (UADE)  
In the event  of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit  a report  of the UADE  to the Sponsor  and IEC/IRB  as soon  as possible,  but no later 
than 24 hours after the Investigator first learns of the effect. This report is in a ddition to the 
immediate notification mentioned  above.  
 
The Sponsor must conduct an evaluation of the UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after 
the Sponsor first receives notification of the effect.  
 
Non-Serious Adverse Ev ents 
All non -serious adverse events, including non -serious adverse device effects, will be reported 
to the sponsor by the Investigator no later than 2 days from discovery.  
 
13.4.2.  Reporting Adverse Events to the Responsible IEC/IRB and Health  Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB's  written  guidelines.  Each  clinical  site will refer  to and follow  any guidelines  set forth 
by their Approving  IEC/IRB.  Each  clinical  site will refer  to and follow  any guidelines  set forth 
by their local governing Health  Authorities.  
 
The Sponsor will report applicable Adverse Events to the local health authorities according to 
the written guidelines, including reporting timelines.  
 
13.5. Event of Special  Interest  
None . 
 
13.6. Reporting of  Pregnancy  
Subjects reporting pregnancy (by self -report) dur ing the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact lens or  solution related studies for safety concerns, but due to 
general  concerns  relating  to pregnancy  and contact  lens use. Specifically,  pregnant  women  are 
discontinued  due to fluctuations  in refractive  error  and/or  visual  acuity  that occur  secondary  to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or  fetus.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 59 of 160   
  
14. STATISTICAL METHODS  
 
14.1. General  Considerations  
Statistical  Analysis  will be undertaken  by the sponsor  or under  the authority  of the sponsor.  A 
general  description  of the statistical  methods  to be implemented  in this clinical  trial is outlined 
below.  
 
All data summaries and statistical analyses will be performed using the SAS software Version  
9.4 or higher (SAS Institute, Cary, NC).7 Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis. 
Unscheduled visits will be summarized separately and will be excluded from the statistical 
analysis.  
 
Summary  tables  (descriptive  statistics  and/or  frequency  tables)  will be provided  for all baseline 
variables, efficacy variables and safety variables as appropriate. Continuous variables will be 
summarized with descriptive statistics (n, mean, standard deviation (SD), median, minimum  
and maximum).  Frequency  count  and percentage  of subjects  or eyes within  each category  will 
be provided for categorical  data.  
 
14.2. Sample Size  Justification  
The plan is to enroll  approximately  44 subjects  with approximately  40 subjects  to compete  the 
study.  Given  that no historical  data is available  for the primary  and secondary  endpoints  using 
the same  glare  system,  the sample  size was not determined  based  on any empirical  sample  size 
calculation. Targeting 40 subjects to complete the study (20 subjects for each condition arm) 
is considered appropriate to assess descriptive summaries of the primary and secondary 
endpoints. The data collected for this study may be used to design fut ure clinical  trials.  
 
14.3. Analysis  Populations  
The following analysis populations will be defined and used in the analysis and presentation 
of the data.  
All Enrolled:  
All Enrolled Population includes all subjects with recorded data in the electronic Case Report 
Form (eCRF) database.  
Safety Population:  
All subjects who are administered any test article excluding subjects who drop out prior to 
administering any test article. At least one observation should be recorded. Subjects will be 
analyzed as per treatment received.  
 
Per-Protocol Population:  
All subj ects who successfully complete all visits and do not substantially deviate from the 
protocol as determined by the trial cohort review committee prior to database hard lock.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 60 of 160   
  
Justification for the exclusion of subjects with protocol deviations  from the per -protocol 
population set will be documented in a memo to file.  
 
Intent -to-Treat (ITT) Population:  
All randomized subjects regardless of actual treatment and subsequent withdrawal from the 
study or deviation from the protocol. At least one obse rvation should be recorded. Subjects 
will be analyzed as per randomized treatment.  
 
14.4. Level of Statistical  Significance  
No primary  or secondary  hypothesis  will be tested.  Each  exploratory  hypothesis  will be tested 
at the 2 -sided Type I error rate of  0.05.  
 
14.5. Primary Analysis  
No primary  hypothesis  will be tested.  The primary  endpoint  will be summarized  descriptively, 
as discussed in  14.1.  
 
14.6. Secondary  Analyses  
No secondary hypothesis will be tested. The secondary endpoint will be summarized 
descriptively, as discussed in 14.1.  
 
14.7. Other Exploratory Analysis  
Exploratory  analyses  of the primary  and secondary  endpoints  will be conducted  using  the ITT 
population. With a broadband glare source, the AUC of the photopic and mesopic contrast 
sensitivity function will be analyzed separately using a linear mixed effects model. Lens type, 
dominant eye, and the interaction of lens type by dominant eye will be included in the mo del 
as fixed effects adjusting for age and gender. The covariance of residuals of within -subject 
repeated measurements (R -side) will be modeled using Unstructured (UN) covariance 
structure. If the model does not converge, then a compound Symmetry (CS) cova riance 
structure  will be considered.  The Kenward  and Roger  method  will be used for the denominator 
degrees of  freedom.8 
 
Hypothesis Testing  
The null and alternative hypotheses for testing superiority of the Test Lens compared to the 
Control lens from the previously described model are presented below:  
 
HO    µT - µC � O 
HA  µT - µC > O  
 
Where,  µT and µc represent  the mean  AUC  of photopic  or mesopic  contrast  sensitivity  function 
with a glare source for the Test lens and the Control lens, respectively. Statistical superiority 
will be declared if the lower bound of the 2 -sided 95% confidence interval of the mean 
difference (Test - Control) is larger than 0. A model -based point estimate of the mean 
difference being 0.06 log or more (2'0.06 log) will be considered clinically  meaningful.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 61 of 160   
  
 
If the proposed mixed effect model fails to converge, the hypothesis will be tested using a 
paired sample t-test or equivalent non -parametric method.  
 
Other  study  endpoints  and observations  will be summarized  descriptively.  Further  exploratory 
and/or  post-hoc analyses  may be conducted  at the discretion  of the study  responsible  clinician.  
 
14.8. Interim  Analysis  
Not applicable.  
 
14.9. Procedure for Handling Missing Data and  Drop -Outs  
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings.  
 
14.10.  Procedure for Reporting Deviations from Statistical  Plan  
The analysis will be conducted according to that specified in above s ections. There are no 
known  reasons  for which  it is planned  to deviate  from  these  analysis  methods.  If for any reason 
a change  is made,  the change  will be documented  in the study  report  along  with a justification 
for the  change.  
 
15. DATA HANDLING AND RECORD  KEEPING/ARCHIVING  
 
15.1. Electronic Case Report Form/Data  Collection  
The vision  assessments  (photopic  and mesopic  contrast  sensitivity  with and without  glare)  will 
be collected using the previously validated optical device described above. The data from the 
device  will be recorded  on a paper  case report  form  (CRF)  stored  at the study  site. Paper  forms 
will be used to record  the raw values  that are used to comput e the final sensitivity  values,  which 
are then entered into electronic case report forms (eCRFs) using the Bioclinica EDC system. 
An authorized  data originator  will enter  study  data into the eCRFs  using  the EDC  system.  Data 
collected on equipment that is not captured in EDC will be formatted to the specification of 
the JJVC database manager and sent to JJVC for  analysis.  
 
The clinical  data will be recorded  on dedicated  eCRFs  specifically  designed  to match  the study 
proce dures for each visit. Only specifically delegated staff can enter data on a CRF. Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by the 
Investigator. The sponsor or sponsor's representatives will be authorized to gain ac cess to the 
subject recordation for the purposes of monitoring and auditing the  study.  
 
Edit checks,  electronic  queries,  and audit  trails  are built into the system  to ensure  accurate  and 
complete data collection. Data will be transmitted from the clinical site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
confidentiality.  After  the final database  lock,  the Investigator  will be provided  with Individual 
Patient  Profiles  (IPP)  including  the full audit  trail on electronic  media  in PDF format  for all of 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 62 of 160   
  
the study  data.  The IPP must  be retained  in the study  files as a certified  copy  of the source  data 
for the  study.  
 
The content and structure of the eCRFs are compliant with ISO14155:2020.1 
15.2. Subject  Record  
At a minimum, subject record should be available for the following:  
 
• subject  identification  
• eligibility  
• study  identification  
• study discussion  
• provision of and date of informed  consent  
• visit dates  
• results of safety and efficacy parameters as required by the  protocol  
• a record of all adverse  events  
• follow -up of adverse  events  
• medical history and concomitant  medication  
• test article receipt/dispensing/return  records  
• date of study  completion  
• reason for early discontinuation of test article or withdrawal from the study, if 
applicable  
 
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.  
 
Adverse event notes must be reviewed and initialed by the  Investigator . 
 
15.3. Trial Registration on  ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by the Sponsor.  
 
16. DATA  MANAGEMENT  
 
16.1. Access to Source  Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an IEC/IRB or regulatory autho rity, JJVC must be 
contacted and notified in writing within 24 hours.  
 
16.2. Confidentiality of  Information  
Information  concerning  the investigational  product  and patent  application  processes,  scientific 
data or other pertinent information is confidential and re mains the property of JJVC. The 
Investigator  may use this information  for the purposes  of the study  only.  It is understood  by 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 63 of 160   
  
the Investigator that JJVC will use information developed in this clinical study in connection 
with the development  of the investigational product and therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study, the Investigator understands that he/she ha s an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor.  
 
16.3. Data Quality  Assurance  
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must  ensure that all Sub - 
Investigators and clinical site personnel are familiar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article.  
 
Training on case report form completion will be provided to clinical site  personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, 
as appropriate.  
 
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during  the study  and to access  compliance  with applicable  regulations  pertaining  to the conduct 
of cli nical trials. The clinical sites will provide direct access to study -related source 
data/documents and reports for the purpose of monitoring and auditing by JJVC and for 
inspection by local and regulatory  authorities.  
 
16.4. Data Monitoring Committee  (DMC)  
Not applicable  
 
17. CLINICAL  MONITORING  
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator's designated clinical site personnel. The monitor's responsibilities will include:  
 
• Ensu ring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulatory requirements are  maintained.  
• Ensuring the rights and wellbeing of subjects are  protected.  
• Ensuring adequate resources, including facilities, laboratories, equipment, and 
qualified clinical site  personnel.  
• Ensuring that protocol deviations are documented with corrective action plans, as 
applicable.  
• Ensuring that the clinical site has sufficient test article and  supplies.  
• Clarifying questions regarding the  study.  
• Resolving study issues or problems that may  arise.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 64 of 160   
  
• Reviewing of study records and source documentation verification in accordance with 
the monitoring plan.  
 
18. ETHICAL AND REGULATORY  ASPECTS  
 
18.1. Study -Specific Design  Considerations  
Potential  subjects  will be fully  informed  of the risks  and requirements  of the study,  and, during 
the study,  subjects  will be given  any new information  that may affect  their decision  to continue 
participation.  Subjects  will be told that their consent  to participate  in the study  is voluntary  and 
may be withdrawn at any time with no reason given and without penalty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully 
able to understand the risks, benefits, and potential adverse ev ents of the study and provide 
their consent  voluntarily.  
 
18.2. Investigator  Responsibility  
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance  with the signed  agreement,  the investigational  plan,  according  to ISO 14155:2020,1 
and applicable regulatory requirements. GCP is an international ethical and scientific quality 
standard for designing, conducting, recording, and reporting studies that involve the 
participation  of human  subjects.  Compliance  with this standard  provides  public  assurance  that 
the rights,  safety,  and well-being  of study  subjects  are protected,  consistent  with the principles 
of the Declaration of Helsinki 64th WMA General Assembly 20132 and that the clinical study 
data are credible. The Investigator must maintain clinical study files in accordance applicable 
regulatory  requirements.  
 
18.3. Independent Ethics Committee or Institutional Review Board  (IEC/IRB)  
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the 
IEC/IRB with current and complete copies of the following documents (where applicable):  
 
• Final  protocol.  
• Sponsor -approved informed consent form (and any other written materials to be 
provided to the  subjects)  
• Investigator's Brochure (or equivalent  information).  
• Sponsor -approved subject recruitment  materials.  
• Information on compensation for study -related injur ies or payment to subjects for 
participation in the  study.  
• Investigator's curriculum vitae, clinical licenses, or equivalent information (unless not 
required, as documented by IEC/IRB).  
• Information regarding funding, name of the Sponsor, institutional affi liations, other 
potential conflicts of interest, and incentives for  subjects.  
• Any other documents that the IEC/IRB requests to fulfill its  obligation.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 65 of 160   
  
This study  will be undertaken  only after IEC/IRB  has given  full approval  of the final protocol, 
the informed consent form, applicable recruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of this approval. This approval letter must be 
dated and must clearly identify the documents being  approved.  
 
During the study, the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:  
 
• Protocol  revisions  
• Revision(s)  to informed  consent  form  and any other  written  materials  to be provided  to 
subjects  
• If applicable, new or revised subject recruitment materials approved by the  Sponsor  
• Revisions to compensation for study -related injuries or payment to subjects for 
participation in the  study  
• Investigator's Brochure  revisions  
• Summaries of the status of the study (at least annually or at intervals stipulated in 
guidelines of the  IEC/IRB)  
• Reports of adverse events that are serious, unanticipated, and associated with the test 
articles, according to the IRB's  requirements  
• New  information that may adversely affect the safety of the subjects or the conduct of 
the study  
• Major protocol deviations as required by the  IEC/IRB  
• Report of deaths of subjects under the Investigator's  care 
• Notification if a new Investigator is responsible for the study at the clinical  site 
• Any other requirements of the  IEC/IRB  
 
For protocol  revisions  that increase  subject  risk, the revisions  and applicable  informed  consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before 
implementation of the  change(s).  
 
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in  writing.  
 
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about  the study  completion.  Documentation  of this notification  must  be retained  at the clinical 
site and a copy provided to the CRO or Sponsor as  applicable.  
 
18.4. Informed  Consent  
Each  subject  or their representative,  must  give written  consent  according  to local  requirements 
after the nature  of the study  has been  fully  explained.  The consent  form  must  be signed  before 
performance of any study -related activity. The consent form that is used must be approved by 
both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with 
principles that originated in the Decl aration of Helsinki,2 and ISO 14155:20201 guidelines, 
applicable regulatory requirements, and Sponsor  Policy.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 66 of 160   
  
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel  must  explain  to potential  subject the aims,  methods,  reasonably  anticipated  benefits, 
and potential  hazards  of the study,  and any discomfort  it may entail.  Subjects  will be informed 
that their participation is voluntary and that they may withdraw consent to participate at any 
time.  
 
The subject  will be given  sufficient  time to read the informed  consent  form  and the opportunity 
to ask questions. After this explanation and befo re entry into the study, consent should be 
appropriately recorded by means of the subject's dated signature. After having obtained the 
consent, a copy of the informed consent form must be given to the  subject.  
 
18.5. Privacy of Personal  Data  
The collection, proc essing and disclosure of personal data and medical information related to 
the Study Subject, and personal data related to Principal Investigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portability and Accountability Act (HIPAA) in the 
United  States  and other  applicable  personal  data protection  and security  laws and regulations.9 
Appropriate  measures  will be employed  to safeguard  these  data,  to maintain  the confidentiality 
of the person's related health and medical information, to properly inform the concerned 
persons about the collection and processing of their personal data, to grant them reasonable 
access to their personal data and to prevent access by unauthorized  persons.  
 
All information  obtained  during  the course  of the investigation  will be regarded  as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by Investigators, 
monitors, Sponsor's personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subject concerned , with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their 
investigation related activities that, as part of the investigation will have access to the CRFs 
and subject  records.  
 
The collection  and processing of personal data from subjects enrolled in this study will be 
limited  to those  data that are necessary  to investigate  the efficacy,  safety,  quality,  and utility  of 
the investigational product(s) used in this  study.  
 
These  data must  be colle cted and processed  with adequate  precautions  to ensure  confidentiality 
and compliance with applicable data privacy protection laws and  regulations.  
The Sponsor ensures that the personal data will be:  
 
• processed fairly and  lawfully.  
• collected for specified, explicit, and legitimate purposes and not further processed in a 
way incompatible with these  purposes.  
• adequate, relevant, and not excessive in relation to said  purposes.  
• accurate and, where necessary, kept  current.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 67 of 160   
  
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also address the transfer of the data to 
other entities and to other countries.  
 
The subject  has the right  to request  through  the Investigator  access  to his personal  data and the 
right to request rectification of any data that are not correct or complete. Reasonable steps 
should  be taken  to respond  to such a request,  taking  into consideration  the nature  of the request, 
the conditions of the study, and the applicable laws and  regulations.  
 
Appropriate technical and organizational measures to protect the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor personnel whose respon sibilities require access to 
personal data agree to keep the identity of study subjects confidential.  
 
19. STUDY RECORD RETENTION  
In compliance with the ISO 14155:2020,1 the Investigator/Institution will maintain all CRFs 
and all subject records that support t he data collected from each subject, as well as all study 
documents as specified in ISO 14155:20201 and all study documents as specified by the 
applicable  regulatory  requirement(s).  The Investigator/Institution  will take measures  to prevent 
accidental or premature destruction of these  documents.  
 
Essential documents must be retained until at least two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical development of the investigational product. These 
documents will be retained for a longer period if required by the applicable regulator y 
requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained.  
 
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name and address of 
the new custodian. Under no circumstance shall th e Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.  
 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Inv estigator must permit access to such reports.  
If the Investigator has a question regarding retention of study records, he/she should contact 
JJVC.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 68 of 160   
  
20. FINANCIAL  CONSIDERATIONS  
Remuneration  for study  services  and expenses  will be set forth  in detail  in the Clinical  Research 
Agreement. The Research Agreement will be signed by the Principal Investigator and a JJVC 
management representative prior to study  initiation.  
 
JJVC  reserves  the right  to withhold  remuneration  for costs  associated  with protocol  violations 
such as: 
 
• Continuing an ineligible subject in the  study.  
• Scheduling a study visit outside the subject's acceptable visit  range.  
 
JJVC reserves the right to withhold final remuneration until all study related activities have 
been complet ed, such as:  
 
• Query  resolution.  
• Case Report Form  signature.  
• Completion of any follow -up action  items.  
 
21. PUBLICATION  
This is a single site study. The participating institution and Principal Investigators for this 
study agree that, should the study results be published, the first publication of the results of 
this study  shall  be made  in conjunction  with the presentation  of a joint publication  of the study 
results with the investigators contributing data, analyses and  comments.  
 
22. REFERENCES  
 
1. ISO 14155:2020:  Clinical  investigation  of medical  devices  for human  subjects  - Good 
clinical practice, Available  at: 
https://www.iso.org/standard/71690.html  
2. Declaration  of Helsinki  - Ethical  principles  for Medical  Research  Involving  Human 
Subjects, Available at: https://www.wma .net/polic ies-post/wma -declaration -of- 
helsinki -ethical -principles -for-medical -research -involving -human -subjects/  
3. United States (US) Code of Federal Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectio nCode=CF R 
4. Buch J. The Effects of Contact Lenses With HEV -Blocker on Visual FunctionAugust 
21, 2019.  
5. Buch  J. The Effects  of Contact  Lenses  With  UV/HEV -Blocker  on Visual  FunctionJune 
22, 2021.  
6. Kojima T HA, Hara S, et al. Quantitative evaluation of night vision and correlation of 
refractive and topographical parameters with glare after orthokeratology. Graefe's 
Archive for Clinical and Experimental Ophthalmology.  2011;249(10):1519 -1526.  
7. SAS/STAT® 14.3 User's Guide. . Cary, NC: SAS Institute Inc;  2016.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 69 of 160   
  
8. Kenward  MG, Roger  JH. An Improved  Approximation  to the Precision  of Fixed  Effects 
from Restricted Maximum Likelihood. Computational Statistics and Data Analysis. 
2009(53):2583 -2595.  
9. Health Information Portability and Accountability Act (HIPAA), Available at: 
https://www.hhs.gov/hip aa/for -professionals/privacy/index.html  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 70 of 160   
  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
Not Applicable for this study.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 71 of 160   
  
APPENDIX B: PATIENT INSTRUCTION GUIDE  
Not Applicable for this study.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 72 of 160   
  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 73 of 160   
  
IMPORTANT: Please read carefully and keep this information for future use.  
 
This Package Insert and Fitting Guide is intended for the Eye Care Professional, but should be 
made available to patients upon request.  
 
The Eye Care Professional should provide the patient with the appropriate instructions that 
pertain to the patient's pr escribed lenses. Copies are available for download at www.acuvue.com .  
 
 
PACKAGE INSERT & FITTING INSTRUCTION  GUIDE  
 
 
 
 
ACUVUE® OASYS MAX 1 -Day Contact Lenses 
ACUVUE® OASYS MAX 1 -Day MULTIFOCAL Contact  Lenses  
senofilcon A Soft (hydrophilic) Contact Lenses 
for Daily Disposable Wear  
 
 
 
 
 
 
 
 
 
 
CAUTION: U.S. Federal law restricts this device to sale by or 
on the order of a licensed practitioner.  

Clinical  Study  Protocol  
Page 74 of 160   
 Johnson & Johnson Vision Care, Ine.  
 
SYMBOLS KEY  
The fo ll ow ing symbols may appear on the la be l or carton:  
 
 
.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SYMBOL  DESCRIPTION  
&CDJ Caution, Consult lnst ructio ns for Use  
d Date of Manufacture  
 Manufacturer  
 Use-By Date (expiration date)  
 Batch Code  
'IIJILII 11 o Sterilized Using Steam Heat  
 lndicates a Single Sterile Barrier System  
DIA Diameter  
BC Base Curve  
D Diopter (lens power)  
CE: 2191 CE Mark and lde nti fication number of Notified  
Body  
UV BLOCKIN G UV Blocking  
e) Fee Paid for Waste Management  
 I Oriy I CAUT ION: US Federal law restricts this device to  
sale by or on the order of a licensed practitioner  
 Lens Orientation Correct  
 
X Lens Orientation lnco rrect 
(Lens lnside Out)  
I EC j R EP I Authorized Representative in the European 
Community  
 Contains Hazardous Substances  
® Do Not Re -Use (Single  
Use)  
 
Do Not Use if Package is Damaged  
 Medical Device Symbol  
.. / Package Opening lcon (Blister)  
G Package Opening lcon (Carton)  
L "Low" near ADD  
M "Medium" near ADD  
H "High" near ADD  
MAXADD  Near ADD  
 
Clinical  Study  Protocol  
Page 75 of 160   
 CR-6501,  v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 76 of 160   
  
LOW  "Low" near ADD  
MID  "Medium" near ADD  
HGH  "High" near ADD  
Visit www.acuvue.com/guides for additional information about symbols.  
 
 
 
 
 
 
 
  DESCRIPTION   
ACUVUE® OASYS MAX 1 -Day Contact Lenses are soft (hydrophilic) contact lenses available as s pherical 
and multifocal lenses.  
 
These lenses are made of a silicone hydrogel material (senofilcon A) containing an internal wetting agent 
and are tinted using Reactive Blue Dye #247 to make lenses more visible for handling.  
 
A benzotriazole ultraviolet (U V) absorbing monomer is used to block UV radiation (280 nm - 380 nm) in 
combination with a novel fused tricyclic chromophore that also blocks UV radiation and partially filters 
high energy visible radiation (HEV)* in the range of 380 nm to 450 nm. The light transmittance 
characteristics for these lenses are less tha n 1% in the UVB range of 280 nm to 315 nm and 10% in the 
UVA range of 315 nm to 380 nm. The thinnest lenses transmit � 45% of the radiation in the range from 
380 nm to 450 nm. Please see HEV filtering NOTE in the ACTIONS section below.  
 
Lens Properties:  
The physical/optical properties of the lens are:  
 
• Specific  Gravity  (calculated):  0.98 - 1.12  
• Refractive  Index:  1.42  
• Visible  Light  Transmittance:  ;?78%  
• HEV Light  Transmittance*:  � 45%  
• Surface  Character:  Hydrophilic  
• Water  Content:  38%  
• Oxygen Permeability  (Dk):  
VALUE  METHOD  
103 x 10-11 (cm2/sec)  
(ml O 2/mL x mm Hg) @ 35°C  Fatt (boundary corrected, edge 
corrected)  
 
Lens Parameter Ranges:  
• Diameter  (DIA):  12.0 mm to 15.0  mm 
• Center  Thickness:  varies with  power  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 77 of 160   
  
• Base  Curve (BC):  7.85 mm to 10.00  mm 
• Spherical  Power  (D): -20.00D to  +20.00D  
• Multifocal  ADD  Power:  +0.25D to  +4.00D  
Each lens is supplied in a foil -sealed plastic package containing borate buffered saline solution with 
methyl ether cellulose.  
 
 
 
 
 
 
 
  AVAILABLE LENS  PARAMETERS   
 
The ACUVUE® OASYS MAX 1 -Day Contact Lenses (senofilcon A) are hemispherical shells of the 
following dimensions:  
Diameter  (DIA):  14.3  mm 
Center  Thickness:  0.085 mm to 0.221 mm (varies with  power)  
Base  Curve  (BC):  8.5 mm, 9.0  mm 
Powers  (D): -12.00D to  +8.00D  
 
 
The ACUVUE® OASYS MAX 1 -Day MULTIFOCAL Contact Lenses (senofilcon A) are hemispherical 
shells of the following dimensions:  
Diameter  (DIA):  14.3  mm 
Center  Thickness:  0.070 mm to 0.191 mm (varies with  power)  
Base  Curve  (BC):  8.4 mm 
Powers  (D): -9.00D to  +6.0 0D 
ADD Powers  (D): +1.25D (LOW), +1.75D (MID), +2.50D  (HGH)  
 
 
  TRANSMITTANCE  CURVE   
ACUVUE® OASYS MAX 1 -Day Contact Lenses (senofilcon A) vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens.  
Clinical  Study  Protocol  
Page 78 of 160   
 
V) Johnson & Johnson Vision Care, Ine.  
 
 
 
 
100 
 
90 
 
80 uv --------...  , ,---------- 
 
z 70 o 
vi 
V) 
� 
z so 
o:: 
I- 40 
 
30 
 
20 
 
10 
 
o  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
200 300  
 
 
 
 
 
 
 
I 
I 
I 
I 
I 
I 
 
 
 
 
 
 
 
 
400  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
500 
WAVELENGTH 
(NANOMETERS)   
 
 
- 24 Yr Old Human  Cornea1 
 
- - - 25 Yr Old Crystalline  Lens2 
 
----•-0.500 ACUVUE® OASYS MAX 1 - 
Day3  
- Crystalline lens with -0.50D  
ACUVUE®  OASYS  MAX  1-Day 3 
 
 
 
600 700 800 
 
1 Le r man, S., Rad ia nt Energy and the Eye , MacMillan, Ne w York, 1980, p . 58, figure 2 -21 
2Waxler, M. Hitchins, V.M., Opt ica l Radiation and Vis ua l Health, CRC Press, Boca Raton, F lo r ida, 1986, p. 19, figure  
s 
3The  data  wasobtained from  measurements taken through  the  centra I 6  mm  portion  for  the  thinne st  sing le   vision 
le ns (-0.500 lens, 0.085mm center thickness ) . 
 
ACTIONS  
 
ln its hydrated  state,  the contact  lens,  when  placed  on the cornea,  acts as a refracting  medium  to focus 
light rays on the  retina.  
 
These  len ses cont ain UV and HEV*  light absorbing  monomers  to help protect  against  transmission  of 
harmful UV radiation to the cornea and into the eye and reduce transmittance of HEV* light. The light 
transmittance  characteristics  for these  lenses  are less than 1% in the UVB  range  of 280 nm to 315 nm 
and less than 10% in the UVA range of 315 nm to 380 nm for the entire power range. The thinnest 
lenses transmit  $ 45%  of the radiation  across  the high energy  visible*  light wavelength  in the range  from 
380 nm to 450 nm. The visib le light transmittance  in the range  from  380 nm to 780 nm is greater  than or 
equal to 78% depending on the lens thickness.  
 
WARNING: UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear, 
such as UV absorbing goggles or sunglasses because they do not completely cover the eye and 
surrounding area. You shou ld continue to use UV absorbing eyewear as directed.  
 
NOTE: long -term exposure to UV radiation is one of the risk factors associated with cataracts. 
Exposure  is based  on a number  of factors  such  as environmental  conditions  (altitude,  geography,  
 60 
Clinical  Study  Protocol  
Page 79 of 160   
 CR-6501,  v 4.0 -  
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 80 of 160   
  
cloud cover) and personal factors (extent and nature of outdoor activities). UV Blocking contact lenses 
help provide protection against harmful UV radiation. However, clinical studies have not been done to 
demonstrate that wearing UV Blocking contact lense s reduces the risk of developing cataracts or 
other eye disorders. The Eye Care Professional should be consulted for more  information.  
 
*NOTE: Filtering of HEV light by contact lenses has not been demonstrated to confer any health 
benefit to the user, incl uding but not limited to retinal protection, protection from cataract 
progression, reduced eye strain, improved contrast, improved acuity, reduced glare, improved low 
light vision, or improved circadian rhythm/sleep cycle. The Eye Care Professional should be consulted 
for more information.  
 
  INDICATIONS  (USES)   
ACUVUE® OASYS MAX 1 -Day Contact Lenses (senofilcon A) are indicated for daily disposable wear for the 
correction of vision in people with non -diseased eyes who are nearsighted (myopic) or farsighted  
(hyperopic) and may have 1.00D or less of astigmatism that does not interfere with visual acuity.  
ACUVUE® OASYS MAX 1 -Day MULTIFOCAL Contact Lenses (senofilcon A) are indicated for daily 
disposable wear for the correction of vision in people with non -diseased eyes who are presbyopic and 
may be nearsighted (myopic) or farsighted (hyperopic) and may have 0.75D or less of astigmatism that 
does not interfere with visual acuity.  
The lenses are to be prescribed for daily disposable wear. Therefore, no cleaning or disinfection is 
required. Lenses should be discarded upon removal.  
 
 
  CONTRAINDICATIONS (REASONS NOT TO  USE)   
DO NOT USE these lenses when any of the following conditions exist:  
 
• Acute or subacute inflammation or infection of the anterior chamber of the  eye 
• Any eye disease, injury or abnormality that affects the cornea, conj unctiva, or  eyelids  
• Severe insufficiency of lacrimal secretion (dry  eye)  
• Corneal hypoesthesia (reduced corneal  sensitivity)  
• Any systemic disease that may affect the eye or be exaggerated by wearing contact  lenses  
• Ocular irritation due to allergic reactions which may be caused by use of contact lens 
solutions (i.e. rewetting drops) that contain chemicals or preservatives (such a s mercury or 
Thimerosal, etc.) to which some people may develop an allergic  response  
• Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by 
wearing contact  lenses  
• Any active corneal infection (bacterial, fungal, protozoal, or  viral)  
• If eyes become red or  irritated  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 81 of 160   
  
  WARNINGS   
Patients should be advised of the following warnings pertaining to contact lens wear:  
 
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP RAPIDLY AND LEAD TO LOSS OF 
VISION. IF THE PATIENT EXPERIENCES:  
 
• Eye Discomfort,  
• Excessive  Tearing,  
• Vision  Changes,  
• Loss of Vision,  
• Eye Redness, or  
• Other Eye  Problems,  
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY REMOVE THE LENSES, AND PROMPTLY 
CONTACT THE EYE CARE PROFESSIONAL.  
 
• Patients should be instructed not to wear their lenses while sleeping. Clinical  studies have 
shown that the risk of serious adverse reactions is increased when lenses are worn 
overnight, and that the risk of ulcerative keratitis is greater for extended wear contact lens 
users than for daily wear  users.4 
• Studies have shown that contac t lens wearers who are smokers have a higher incidence of 
adverse reactions than  nonsmokers.  
• Problems with contact lenses or lens care products could result in serious injury to the eye. 
Patients should be cautioned that proper use and care of contact lens es and lens care 
products are essential for the safe use of these  products.  
• The overall risk of ulcerative keratitis may be reduced by carefully following directions for 
lens care.  
4New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773 -783 
 
Specific Instructions for Use and Warnings:  
• Water Activity  
lnstruction for Use  
Do not expose contact lenses to water while wearing them.  
WARNING:  
 
Water can harbor microorganisms that can lead to severe infection, vision loss, or 
blindness. If lenses have been submersed in water when participating in water sports or 
swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard 
them and replace them with a new pair. The Eye Care Professional should be consulted for 
recommendation s regarding wearing lenses during any activity involving water.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 82 of 160   
  
  PRECAUTIONS   
 
Special Precautions for Eye Care Professionals:  
• Due to the small number of patients enrolled in clinical investigation of lenses, all refractive 
powers, design configurations, or lens parameters available in the lens material are not 
evaluated in significant numbers. Consequently, when selecting an appr opriate lens design 
and parameters, the Eye Care Professional should consider all characteristics of the lens that 
can affect lens performance and ocular health, including oxygen permeability, wettability, 
central and peripheral thickness, and optic zone  diameter.  
The potential impact of these factors on the patient's ocular health should be carefully 
weighed against the patient's need for refractive correction; therefore, the continuing 
ocular health of the patient and lens performance on the eye should b e carefully monitored 
by the prescribing Eye Care Professional.  
• Patients who wear these lenses to correct presbyopia using monovision or multifocal 
correction may not achieve the best corrected visual acuity for either far or near vision. 
Visual requiremen ts vary with the individual and should be considered when selecting the 
most appropriate type of lens for each  patient.  
• Fluorescein, a yellow dye, should not be used while the lenses are on the eyes unless 
otherwise indicated. The lenses absorb this dye an d become discolored. Whenever 
fluorescein is used in eyes, the eyes should be flushed with a sterile saline solution that is 
recommended for in -eye use. 
• Eye Care Professionals should instruct the patient to remove lenses immediately if the eyes 
become red or irritated.  
Eye Care Professionals should carefully instruct patients about the following care regimen 
and safety precautions:  
 
Handling Precautions:  
• Before leaving the Eye Care Professional's office, the patient should be able to promptly 
remove lenses or should have someone else available who can remove the lenses for him or 
her. 
• DO NOT use if the sterile blister package is opened or  damaged.  
• Always wash, rinse, and dry hands before handling lenses. It is best to put on lenses before 
putting on  makeup.  
• DO NOT touch contact lenses with fingers or hands if the hands are not free of foreign 
materials, as microscopic scratches of the lenses may occ ur, causing distorted vision and/or 
injury to the  eye.  
• Carefully follow the handling, insertion, removal, and wearing instructions in the "Patient 
Instruction Guide" for ACUVUE® OASYS MAX 1 -Day Contact Lenses and those prescribed by 
the Eye Care  Profession al. 
• Always handle lenses carefully and avoid dropping  them.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 83 of 160   
  
• Never use tweezers or other tools to remove lenses from the lens container. Slide the lens 
up the side of the bowl until it is free of the  container.  
 
Lens Wearing Precautions:  
• If the lens sticks (stops moving) on the eye, follow the recommended directions  in "Care for 
a Sticking (Non -Moving) Lens" . The lens should move freely on the eye for the continued 
health of the eye. If non -movement of the lens continues, the patient should be instructed 
to immediately consult his or her Eye Care  Professional.  
• Never wear lenses beyond the period recommended by the Eye Care  Professional.  
• The patient should be advised to never allow anyone else to wear their lenses. Sharing 
lenses greatly increases the chance of eye  infections.  
• If aerosol products, such as hair sp ray, are used while wearing lenses, exercise caution  and 
keep eyes closed until the spray has  settled.  
• Avoid all harmful or irritating vapors and fumes while wearing  lenses.  
• Ask the Eye Care Professional about wearing lenses during sporting  activities.  
• The patient should be advised to never rinse the lenses in water from the tap. Tap water 
contains many impurities that can contaminate or damage the lenses and may lead to  eye 
infection or  injury.  
 
Lens Care Precautions:  
• The patient should be informed that  no cleaning or disinfection is needed when lenses are 
worn for daily disposable wear. Patients should always dispose of lenses when removed and 
have spare lenses or spectacles available.  
 
Other Topics to Discuss with Patients:  
• Always contact the Eye Care Professional before using any medicine in the  eyes.  
• Certain medications, such as antihistamines, decongestants, diuretics, muscle relaxants, 
tranquilizers, and those for motion sickness may cause dryness of the eye, increased le ns 
awareness, or blurred vision. Should such conditions exist, proper remedial measures should 
be prescribed. Depending on the severity, this could include the use of lubricating drops that 
are indicated for use with soft contact lenses or the temporary di scontinuance of contact 
lens wear while such medication is being  used.  
• Oral contraceptive users could develop visual changes or changes in lens tolerance when 
using contact lenses. Patients should be cautioned  accordingly.  
• Do not change lens type (e.g. bra nd name, etc.) or parameters (e.g. diameter, base curve, 
lens power, etc.) without consulting the Eye Care  Professional.  
• Instruct patients to always confirm the lens parameters printed on the multi -pack and on 
the individual lens package match their prescr iption. If there is a mismatch the patient 
should not use the  product.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 84 of 160   
  
• As with  any contact  lens,  follow -up visits  are necessary  to assure  the continuing  health  of 
the patient's eyes. The patient should be instructed as to a recommended follow -up 
schedule.  
 
Who Should Know That the Patient is Wearing Contact Lenses?  
• Patients should inform all doctors (Health Care Professionals) about being a contact lens 
wearer.  
• Patients should always inform their employer of being a contact lens wearer. Some jobs may 
require use of eye protection equipment or may require that the pat ient not wear contact 
lenses.  
  ADVERSE  REACTIONS   
The patient should be informed that the following problems may occur when wearing contact lenses:  
 
• The eye may burn, sting and/or  itch.  
• There may be less comfort than when the lens was first placed on the  eye.  
• There may be a feeling of something in the eye (foreign body, scratched  area).  
• There may be the potential for some temporary impairment due to peripheral infiltrates, 
peripheral corn eal ulcers, or corneal erosion. There may be the potential for other 
physiological observations, such as local or generalized edema, corneal neovascularization, 
corneal staining, injection, tarsal abnormalities, iritis, and conjunctivitis; some of which ar e 
clinically acceptable in low  amounts.  
• There may be excessive watering, unusual eye secretions or redness of the  eye.  
• Poor visual acuity, blurred vision, rainbows or halos around objects, photophobia, or dry 
eyes may also occur if the lenses are worn continuously or for too long a  time.  
The patient should be instructed to conduct a simple 3 -part self -examination at least once a day. They 
should ask themselves:  
 
• How do the lenses feel on my  eyes?  
• How do my eyes  look?  
• Have I noticed a change in my  vision?  
If the patient reports any problems, he or she should be instructed to IMMEDIATELY REMOVE THE LENS. 
If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the 
eye.  
 
If after inserting the new lens, the problem  continues, the patient should be directed to IMMEDIATELY 
REMOVE THE LENS AND CONTACT HIS OR HER EYE CARE PROFESSIONAL.  
 
The patient should be advised that when any of the above symptoms occur, a serious condition such as 
infection, corneal ulcer, neovascu larization, or iritis may be present. He or she should be instructed to  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 85 of 160   
  
seek immediate professional identification of the problem and prompt treatment to avoid serious eye 
damage.  
 
  GENERAL FITTING  GUIDELINES   
 
A. Patient Selection  
 
Patients selected to wear these lenses should be chosen based on:  
 
• Motivation to wear  lenses  
• Ability to follow instructions regarding lens wear  care  
• General  health  
• Ability to adequately handle and care for the  lenses  
• Ability to understand the risk and benefits of lens  wear  
Patients who do not meet the above criteria shoul d not be provided with contact lenses.  
 
B. Pre-fitting  Examination  
 
Initial evaluation of the patient should begin with a thorough case history to determine if there are any 
contraindications to contact lens wear. During the case history, the patient's visual needs and 
expectations should be determined as well as an assess ment of their overall ocular, physical, and mental 
health.  
 
Preceding the initial selection of trial contact lenses, a comprehensive ocular evaluation should be 
performed that includes, but is not limited to, the measurement of distance and near visual acu ity, 
distance and near refractive prescription (including determining the preferred reading distance for 
presbyopes), keratometry, and biomicroscopic evaluation.  
 
Based on this evaluation, if it is determined that the patient is eligible to wear these lens es, the Eye Care 
Professional should proceed to the appropriate lens fitting instruction outlined below.  
 
C. Initial Power  Determination  
 
A spectacle refraction should be performed to establish the patient's baseline refractive status and to 
guide in the selection of the appropriate lens power. Remember to compensate for vertex distance if 
necessary.  
 
D. Base Curve Selection (Trial Lens  Fitting ) 
 
The following trial lenses should be selected for patients regardless of keratometry readings. However, 
corneal curvature measurements should be performed to establish the patient's baseline ocular status.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 86 of 160   
 Example 2:   
For the Spherical or Multifocal ACUVUE® OASYS MAX 1 -Day Contact Lenses, the initial lens should be 
selected from the currently available base curves.  
 
The trial lens should be placed on each of the patient's eyes and evaluated after the patient has 
adjuste d to the lenses.  
 
1. Criteria of a Properly Fit  Lens  
 
A properly fit lens will center and completely cover the cornea (i.e., no limbal exposure), have 
sufficient movement to provide tear exchange under the contact lens with the blink, and be 
comfortable. The lens should move freely when manipulated digitally with the lower lid, and then 
return to its properly centered position when released.  
 
2. Criteria of a Flat Fitting  Lens  
 
A flat fitting lens may exhibit one or more of the following characteristics: decentra tion, 
incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink, and/or 
edge standoff. If the lens is judged to be flat fitting, it should not be dispensed to the patient.  
 
3. Criteria of a Steep Fitting  Lens  
 
A steep fitting lens may exhibit one or more of the following characteristics: insufficient 
movement with the blink, conjunctival indentation, and resistance when pushing the lens up 
digitally with the lower lid. If the lens is judged to be steep fitting, it should not be dispensed to 
the patient.  
 
If the initial base curve is judged to be flat or steep fitting, the alternate base curve, if available, should 
be trial fit and evaluated after the patient has adjusted to the lens. The lens should move freely w hen 
manipulated digitally with lower lid, and then return to a properly centered position when released. If 
resistance is encountered when pushing the lens up, the lens is fitting tightly and should not be 
dispensed to the patient.  
 
E. Final Lens  Power  
 
A sph erical over -refraction should be performed to determine the final lens power after the lens fit is 
judged acceptable. The spherical over -refraction should be combined with the trial lens power to 
determine the final lens prescription. The patient should ex perience good visual acuity with the correct 
lens power unless there is excessive residual astigmatism.  
 
Example 1:  
Diagnostic lens:  -2.00D  
 Spherical over -refraction:  -0.25D  
 Final lens power:  -2.25D  
 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 87 of 160   
  
Diagnostic lens:  -2.00D  
 Spherical over -refraction:  +0.25D  
 Final lens power:  -1.75D  
If vision is acceptable, perform a slit lamp examination to assess adequate fit (centration and 
movement). If fit is acceptable, dispense the lenses instructing the patient to return in one week for 
reassessment (see dispensing and follow up information in  PATIENT MANAGEMENT ). 
 
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. 
Copies are available for download from www.acuvue.com . 
 
  MULTI FOCAL FITTING  GUIDELINES   
 
A. Presbyopic Needs Assessment & Patient  Education  
Multifocal contact lenses may produce compromise to vision under certain circumstances and the 
patient should understand that they might not find their vision acceptable in specific situations (i.e., 
reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). Therefore, 
caution should be exercised when the patient is wearing the correction for the first time until they 
are familiar with the vision provided in visually challenging environments. Occupational and 
environmental visual  demands should be considered. If the patient requires critical visual acuity and 
stereopsis, it should be determined by trial whether this patient can function adequately with the 
ACUVUE® OASYS MAX 1 -Day Multifocal Contact Lenses. Wear may not be optimal for such activities 
as: 
1. Visually demanding situations such as operating potentially dangerous machinery or performing 
other potentially hazardous activities;  and 
2. Driving automobiles (e.g., driving at night). Patients who cannot pass their state driver's li cense 
requirements with these lenses should be advised to not drive with this correction, OR may 
require that additional over -correction be  prescribed.  
These lenses are not recommended for patients who have -1.00D or greater of refractive cylinder as 
this level of uncorrected cylinder may lead to additional visual compromise.  
These lenses are available in the following ADD powers:  
• Lens "LOW" ="low" near ADD lens (Max +1.25  ADD)  
• Lens "MID" = "medium" near ADD lens (Max +1.75  ADD)  
• Lens "HGH" = "high" near ADD  lens (Max +2.50  ADD)  
 
B. Initial Power  Determination  
A spectacle refraction should be performed to establish the patient's baseline refractive status and 
to guide in the selection of the appropriate lens power. Remember to compensate for vertex 
distance if the refraction is ;? ±4.00D. Determine the spherical  equivalent distance prescription for a 
multifocal patient. Determine the eye dominance using one of the methods below:  
Method 1:  Determine which eye is the "sighting eye." Have the patient point to an object at the 
far end of the room. Cover one eye. If t he patient is still pointing directly at the object, the eye 
being used is the dominant (sighting) eye.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 88 of 160   
  
 
Method 2 (preferred):  Determine which eye will accept the added power with the least 
reduction in vision while both eyes are open. Place  a hand -held trial lens equal to +1.00D in 
front of one eye and then the other while the distance refractive error correction is in place for 
both eyes. Determine whether the patient functions best with the +1.00D lens over the right or 
left eye, which is the non -dominant eye.  
 
C. Select the Initial Trial  Lens  
1. For each eye, select the trial lens distance power that is closest to the patient's distance 
spherical  equivalent.  Remember  to compensate  for vertex  distance  if the refraction  is ;? ±4.00D.  
2. Select the near power of the lens based on the patients ADD range as follows:  
• ADD: +0.75 to +1.25 use a "LOW" near ADD lens on each  eye 
• ADD: +1.50 to +1.75 use a "MID" near ADD lens on each  eye 
• ADD: +2.00 to +2.50 use a "MID" near ADD on the dominant eye and a "HGH" near ADD 
lens on the non -dominant  eye 
3. Allow the lenses to settle for a minimum 10  minutes.  
4. Assess distance and near vision binocularly and  monocularly.  
5. Demonstrate  the vision  under  various  lighting  conditions  (normal  and decreased  illumination) 
and at distance, intermediate and  near.  
6. Make adjustments in power as necessary based on the distance over -refraction. The use of 
hand held trial lenses is recommended. Check the impact o n distance and near  vision.  
7. If vision is still unacceptable, make adjustments in power as necessary (see "Multifocal 
Troubleshooting" below). If distance and near vision are acceptable, perform a slit lamp 
examination to assess adequate fit (centration and  movement). If fit is acceptable, dispense the 
lenses instructing the patient to return in one week for reassessment (see PATIENT 
MANAGEMENT section).  
D. Multifocal Troubleshooting 
Unacceptable Near  Vision:  
If it has been determined that no change is required  based on the over -refraction then add +0.25 D 
to the spherical power of the non -dominant eye.  
 
Unacceptable Distance Vision:  
If it has been determined that no change is required based on the over -refraction then make the 
changes as listed below:  
• If the patient is wearing two "LOW" ADD lenses, change the dominant eye to an 
ACUVUE® OASYS MAX 1 -Day Contact Lens sphere lens with a power equal to the spherical 
equivalent distance  prescription.  
• If the patient is wearing two "MID" ADD lenses, change the ADD power in the dominant eye 
to the "LOW" ADD  power.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 89 of 160   
  
• If the patient i s wearing a "MID" ADD lens in the dominant eye and a "HGH" ADD lens in the 
non-dominant eye, change the non -dominant eye to a "MID" ADD lens and add +0.25D to 
the distance power.  
 
Once the changes have been made for the troubleshooting repeat steps 3 -6 in section C above 
("Select the Initial Trial Lens") to assess if the vision is acceptable.  
 
E. Adaptation  
Visually demanding situations should be avoided during the initial wearing period. A patient may at 
first experience some mild blurred vision, dizziness, headaches and a feeling of slight imbalance. You 
should explain the adaptational symptoms to the patie nt. These symptoms may last for a brief 
minute or for several weeks. The longer these symptoms persist, the poorer the prognosis for 
successful adaptation.  
To help in the adaptation process, the patient can be advised to first use the lenses in a comfortab le 
familiar environment such as in the home.  
Some patients feel that automobile driving performance may not be optimal during the adaptation 
process. This is particularly true when driving at night. Before driving a motor vehicle, it may be 
recommended tha t the patient be a passenger first to make sure that their vision is satisfactory for 
operating an automobile. During the first several weeks of wear (when adaptation is occurring), it 
may be advisable for the patient to only drive during optimal driving c onditions. After adaptation 
and success with these activities, the patient should be able to drive under other conditions with 
caution.  
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. 
Copies are available for download from www.acuvue.com . 
 
  MONOVISION FITTING  GUIDELINES   
 
A. Patient Selection 
Monovision Needs  Assessment  
For a good prognosis the patient should have adequately corrected distance and near visual acuity in 
each eye. The amblyopic patient with significant amounts of uncorrected astigmatism (greater than 
1.00D) in one eye may not be a good candidate for monovis ion correction with these lenses.  
 
Occupational and environmental visual demands should be considered. If the patient requires critical 
vision (visual acuity and stereopsis), it should be determined by trial whether this patient can function 
adequately wit h monovision correction. Monovision contact lens wear may not be optimal for activities 
such as:  
 
(1) visually  demanding  situations  such  as operating  potentially  dangerous  machinery  or 
performing other potentially hazardous activities;  and 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 90 of 160   
  
(2) driving automobiles (e.g., driving at night). Patients who cannot pass their state driver's 
license requirements with monovision correction should be advised to not drive with  this 
correction, OR may require that additional over -correction be  prescribed.  
 
Patient Education  
 
All patients do not function equally well with monovision correction. Patients may not perform as well 
for certain tasks with this correction as they have with spec tacles (multifocal, bifocal, trifocal, readers, 
progressives). Each patient should understand that monovision, as well as other presbyopic alternatives, 
can create a vision compromise that may reduce visual acuity and depth perception for distance and 
near  tasks. Therefore, caution should be exercised. During the fitting process, it is necessary for the 
patient to realize the disadvantages as well as the advantages of clear near vision, and straight ahead 
and upward gaze that monovision contact lenses provi de. 
 
B. Eye Selection  
 
Generally, the non -dominant eye is corrected for near vision. The following two methods for eye 
dominance can be used.  
 
1. Ocular Preference Determination  Methods  
 
Method  1: Determine which eye is the "sighting eye." Have the patient point to an object at 
the far end of the room. Cover one eye. If the patient is still pointing directly at 
the object, the eye being used is the dominant (sighting)  eye.  
 
Method  2: Determine which eye will accept the added power with the least reduction in 
vision. Place a hand -held trial lens equal to the spectacle near ADD in front of 
one eye and then the other while the distance refractive error correction is in 
place for both eyes . Determine whether the patient functions best with the near 
ADD lens over the right or left  eye 
 
Other methods include the "Refractive Error Method" and the "Visual Demands Method."  
 
2. Refractive Error  Method  
 
For anisometropic correction, it is generally b est to fit the more hyperopic (less myopic) eye for 
distance and the more myopic (less hyperopic) eye for near.  
 
3. Visual Demands  Method  
 
Consider the patient's occupation during the eye selection process to determine the critical 
vision requirements. If a p atient's gaze for near tasks is usually in one direction, correct the eye 
on that side for near.  
 
Example:  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 91 of 160   
  
A secretary who places copy to the left side of the desk will function best with the near lens on 
the left eye.  
 
C. Special Fitting  Characteristics  
 
1. Unilateral Vision Correction  Requirement  
 
There are circumstances where only one contact lens is required. As an example, an emmetropic 
patient would only require a near lens whereas a bilateral myope would require corrective 
lenses on both eyes.  
 
Example:  
 
A presbyopic emmetropic patient who requ ires a +1.75D ADD would have a +1.75D lens on the 
near eye and the other eye left without correction.  
 
A presbyopic patient requiring a +1.50D ADD who is -2.50D myopic in the right eye and -1.50D 
myopic in the left eye may have the right eye corrected for distance and the left uncorrected for 
near.  
 
2. Near ADD  Determination  
 
Always prescribe the lens power fo r the near eye that provides optimal near acuity at the 
midpoint of the patient's habitual reading distance. However, when more than one power 
provides optimal reading performance, prescribe the least plus (most minus) of the powers.  
 
3. Trial Lens  Fitting  
 
A trial fitting is performed in the office to allow the patient to experience monovision correction. 
Lenses are fit according to the "General Fitting Guidelines" for base curve selection described in 
this guide.  
 
Case history and standard clinical evaluatio n procedure should be used to determine the 
prognosis. Determine the distance correction and the near correction. Next determine the near 
ADD. With trial lenses of the proper power in place, observe the reaction to this mode of 
correction.  
 
Allow the lense s to settle for about 20 minutes with the correct power lenses in place. Walk 
across the room and have the patient look at you. Assess the patient's reaction to distance 
vision under these circumstances. Then have the patient look at familiar near objects such as a 
watch face or fingernails. Again assess the reaction. As the patient continues to look around the 
room at both near and distance objects, observe the reactions. Only after these vision tests are 
completed should the patient be asked to read print . Evaluate the patient's reaction to large 
print (e.g., typewritten copy) at first and then graduate to news print and finally smaller type 
sizes.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 92 of 160   
  
After the patient's performance under the above conditions is completed, tests of visual acuity 
and reading ability under conditions of moderately dim illumination should be attempted.  
 
An initial unfavorable response in the office, while indicative of a g uarded prognosis, should not 
immediately rule out a more extensive trial under the usual conditions in which a patient 
functions.  
 
4. Adaptation  
 
Visually demanding situations should be avoided during the initial wearing period. A patient may 
at first experie nce some mild blurred vision, dizziness, headaches and a feeling of slight 
imbalance. You should explain the adaptation symptoms to the patient. These symptoms may 
last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the 
prognosis for successful adaptation.  
 
To help in the adaptation process, the patient can be advised to first use the lenses in a 
comfortable familiar environment such as in the home.  
 
Some patients feel that automobile driving performance may not be op timal during the 
adaptation process. This is particularly true when driving at night. Before driving a motor 
vehicle, it may be recommended that the patient be a passenger first to make sure that their 
vision is satisfactory for operating an automobile. Du ring the first several weeks of wear (when 
adaptation is occurring), it may be advisable for the patient to only drive during optimal driving 
conditions. After adaptation and success with these activities, the patient should be able to 
drive under other co nditions with caution.  
 
S. Other Suggestions  
 
The success of the monovision technique may be further improved by having your patient follow 
the suggestions below:  
◼ Have a third contact lens (distance power) to use when critical distance viewing is  needed.  
◼ Have a third contact lens (near power) to use when critical near viewing is  needed.  
◼ Having supplemental spectacles to wear over the monovision contact lenses for specific 
visual  tasks  may  improve  the success  of monovision  correction.  This is particularly  applicable 
for those patients who cannot meet their state driver's license requirements with a 
monovision  correction.  
◼ Make use of proper illumination when carrying out visual tasks. 
Monovision fitting success can be improved with the following  suggestions:  
◼ Reverse the distance and near eyes if a patient is having trouble  adapting.  
◼ Refine  the lens powers  if there  is trouble  with  adaptation.  Accurate  lens power  is critical  for 
presbyopic  patients.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 93 of 160   
  
◼ Emphasize the benefits of clear near vision and straight -ahead and upward gaze with 
monovision.  
The decision to fit a patient with monovision correction is most appropriately left to the Eye Care 
Professional in conjunction with the patient after carefully considering the patient's needs.  
 
All patients should be supplied with a copy of the PATIENT IN STRUCTION GUIDE for these lenses. 
Copies are available for download from www.acuvue.com . 
 
  PATIENT  MANAGEMENT   
 
• Follow the accepted standard of care in fitting and following up with your  patient.  
• Schedule the appropriate follow -up examination.  
• Preferably, at the follow -up visits, lenses should have been wor n for at least six  hours.  
• Provide the patient with a copy of the PATIENT INSTRUCTION GUIDE for these lenses, which 
can be found at  www.acuvue.com . REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO  THAT 
HE OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT 
SCHEDULE (DAILY  DISPOSABLE).  
 
  WEARING  SCHEDULE   
 
The wearing schedule should be determined by the Eye Care Professional. Regular checkups, as 
determined by the Eye Care Professional, are also extremely important.  
 
Patients tend to over wear the lenses initially. The Eye Care Professional should emphasize  the 
importance of adhering to the initial maximum wearing schedule. Maximum wearing time should be 
determined by the Eye Care Professional based upon the patient's physiological eye condition, because 
individual response to contact lenses varies.  
 
The max imum suggested wearing time for these lenses is:  
 
Day Hours  
 
1 6-8 
 
2 8-10 
 
3 10-12 
 
4 12-14 
 
5 and  after  all waking  hours  
 
 
 
  REPLACEMENT  SCHEDULE   
 
These lenses are indicated for daily disposable wear and should be discarded upon removal.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 94 of 160   
  
  LENS CARE  DIRECTIONS   
 
When lenses are dispensed, the Eye Care Professional should provide the patient with appropriate and 
adequate warnings and in structions for daily disposable lens wear.  
 
The Eye Care Professional should review with patients that no cleaning or disinfection is needed with 
disposable lenses. Patients should always dispose of lenses when they are removed and have spare 
lenses or spe ctacles available.  
 
Basic Instructions:  
• Always wash, rinse, and dry hands before handling contact  lenses.  
• Do not use saliva or anything other than the recommended solutions for lubricating or rewetting 
lenses. Do not put lenses in the  mouth.  
• Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to 
wet (lubricate) lenses while they are being worn to make them more  comfortable.  
 
Care for a Sticking (Non -Moving) Lens  
During removal, if the lens sticks to the eye,  the patient should be instructed to apply a few drops of the 
recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to 
move freely on the eye before removing it. If non -movement of the lens continues after a few m inutes, 
the patient should immediately consult the Eye Care Professional.  
 
 
 
 
 
 
 
  EMERGENCIES   
 
The patient should be informed that if chemicals of any kind (household products, gardening solutions, 
laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY 
WITH TAP WATER AND IMMEDIATELY CONTACT THE EYE CARE PROFESSIONAL OR VISIT A HOSPITAL 
EMERGENCY ROOM WITHOUT DELAY.  
 
  REPORTING OF ADVERSE  REACTIONS   
 
All serious adverse experiences and adverse reactions observed in patients wearing these lenses or 
experienced with the lenses should be reported to:  
 
Johnson & Johnson Vision Care, Inc.  
7500 Centurion Parkway  
Jacksonville, FL 32256 
USA 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 95 of 160   
  
Tel: 1 -800-843-2020  
www.acuvue.com  
 
Revision Date: 02/2022 
Revision Number: AO -01-22-03 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 96 of 160   
 Qg ys  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACUVUE8  
H;draluxe ™ 
ACUWE  OASYS• Brand  Contact  lenses 1-Day 
wltllHydraLuxeTM Technology  
ACUWE  OASYS• Brand  Contact  lenses 1-Day 
wlthHydraluxe"'  Teclinology  for ASTIGMATISM  
senofilcon A Soft (hydrophilic) Contact Lenses 
Visibility Tinted withUV Blocker  
for Daily Disposable Wear  
rii':n.i:7 CAUT ION: U.S. Feđeral lawrestricts th is device to 
sale by or on the order of a licensed practitioner.  
IMPORTANT:  Pleas e read carefully  and keep this 
lnformatlon  flN' future  use. 
This Package  Insert  andFrtting  Guide  isintended  for the 
Eye Care  Professlonal,  but should  be made  available  to 
patlents  upon  request . 
The EyeCare Professional should provide the patient 
wittl the appropriate  instructions  thatpertain  tothe 
patient's  prescribed  lenses.  Copies  are available  for 
download at www.acuvu .ecom.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 97 of 160   
  
 
SYMBOLS KEY  
 
The following symbols may appear on the label or carton:  
 
SYMBOL  DEFINITION  
l-liJ Consult lnstructions for Use 
 Manufactured by or in  
d Date of Manufacture  
 Use By Date (expiration date)  
I LOTI Batch Code  
ISTERIL EIiI Sterile Using Steam or Dry Heat  
® Single -Use 
DIA Diameter  
BC Base Curve  
D Diopter (lens power)  
CYL Cylinder  
AXIS  Axis 
CE 
0086 Quality System Certification Symbol  
I!) 
UV Blockin9  UV-Blocking  
(e) Fee Paid for Waste Management  
i lJt0nly I CAUTION: U.S. Federa! law restricts this device  
to sale by or on the order of a licensed practitioner  
'lW e Lens Orientation Correct  
'qD7  
X X Lens Orientation lncorrect (Lens lnside Out)  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 98 of 160   
  
 
DESCRIPTION  
ACUVU E OASYS ® Brand Contac t Lense s 1-Day and ACUVU E OASY S® 
Bran d Contac t Lense s 1-Day for ASTIGMAT IMS are soft (hydrophilic ) 
contact  lense s made  with HydraluxeTM Technolog yT. hey are availabl e as 
spher ical or toric lensesrespective .ly 
These lenses are made of a siliconehydroge l materia l containingan interna! 
wetting  agent,  visibility tint, and UV abso rbingmonomer  and are tinted  blue 
using  Reac tive Blue Dye #4 to make the lensesmore  visiblefor  handling . 
A benzotriazo le UV abso rbing monomer  is used  to block  UV radiation.  The 
transmittance charac teristics for these lensesare lessthan 1% in the UVB 
range  of 280 nm to 315 nm and less than 10% in the UVA range  of 316 nm 
to 380 nm for the entire power range.  
lens Properties:  
The physical/optical properties of the lens  are: 
• Specific  Grav ity (calculated) : 0.98  - 1.12 
• Refractivelndex : 
• Light Transmission:  
• Surface  Charac ter: 
• Water  Content:  
• Oxygen  Permeability : 
 
VALUE  
122 x 10 ·11 (cm2/sec) 
(mi O/ mi x mm Hg) at 35°C 
103 x 10 ·11 (cm2/sec) 
(mi O/ mi x mm Hg) at  35°C 
Lens  Parameters:  
• Diameter  Range:  
• Center  Thickness:  
• Base Curve  Range : 
• Spherical Power  Range:  
• Cylinder Power  Range : 
• Axis Range:  1.42 
85% minimum 
Hydroph ilic 
38% 
 
 
METHOD  
Fatt (boundary corrected, non ­ 
edge corrected)  
Fatt (boundary corrected, edge 
corrected)  
 
 
12.0 mm to 15.0 mm 
varies with power  
7.85 mm to 10.00 mm  
-20.00D to +20 .00D 
-0.25D to -10.00D 
2.5° to 180 ° 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 99 of 160   
  
 
AVAILABLE LENS PARAMETERS  
 
ACUVUE OASYS® Brand 1 -Day w ith Hydraluxe TM Technology are 
hemispherical s hells of the following d imensions:  
Diameter:  14.3 mm 
Center  Thickness:  0.085 mm to 0 .221 mm (varies with  power)  
Base Curve: 
Powers:  8.5 mm, 9.0 mm  
-0.50D to -6.00D (in 0.25D increments)  
-6.50D to -12.00D (in  0.50D increments)  
+0.50D to +6.00D (in 0.25D  increments)  
+6.50D  to +8.00D  (in 0.50D increments)  
 
 
 
ACUVUE OASYS® Brand 1 -Day w ith Hydraluxe TM Technology for 
ASTIGMA TISM are hem itoric shells of the following dimensions : 
Diameter:  14.3 mm 
Center  Thickness:  0.075 mm to 0 .172 mm (varies with  power)  
Base Curve: 
Powers:  8.5 mm  
+0.00D to -6.00D (in 0.25D increments) 
Cylinders : -0.75D, -1.25D, -1.75D, -2.25D*  
Axis: 10° to 180° in 10° increments  
*-2.25Dcylinder is availble in 10°, 20°, 70°, 80°, 90°, 100°, 110°, 
160°, 170°, 180° axes only.  
 
 
+ 0.25D to +4.00D (in 0 .25D increments)  
-6.50D to -9.00D ( in 0.50D increments) 
Cylinders : -0.75D, -1.25D, -1.75D  
Axis: 10°, 20°, 70°, 80°, 90°, 100°, 110° , 160°, 
170°, 180°  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 100 of 160   
 z  
 
TRANSMITTANCE CURVES  
 
ACUVU E OASYS® 1- Day with Hydraluxe TM Technology (senofilcon A) 
Visibility Tint ed with UV Blocke r vs. 24 yr. old human cornea  and 25 yr. old 
huma n crystalline lens. 
 
 
100 
90 z ACUV UE 0ASYS® 
1-Daywith  
Hydraluxe™ 
o 80 
či5 
CI) 70 Technology 
(senofi lconA)*  
CI) 60 
50 24 YR. O LD HUMAN 
I- 40 
30 
20 
10 
0  
 
 
 
 
200  
 
 
 
 
300 400 500 600 
WAVE LENGTH 
(NANOM ETERS)  
 
 
 
 
700 800 COR NEA1 
25 YR. OLD HUMA N 
CRYSTALLINE LENS2 
 
 
* The data was obtaine d from meas ureme nts taken through the centra! 3-5 mm portio n for 
thethinnest marketed lens(-9.00D lens, 0.075mm center  thickness ). 
1Lerm an,S ., Radia nt Energyand the E ye, MacM illan, N ew Yo rk, 1980, p. 58 , figure 2-21 
2Waxler; M ., Hi tchins, V.M ., Optical Radia tion and Visual Health, CRC  Press, Boca Raton, Florida, 
1986,  p. 19, figure5 
 
WARNING: UV absorbing contact lenses are NOT substitutes for 
protective UV absorbing eyewear, such as UV absorbing goggles 
or sunglasses because they do not completely cover the eye and 
surrounding  area.  The patient  should  continue  to use UV absorbing 
eyewear as  directed.  
 
ACTIONS  
ln its hydrated s tate, the co ntact lens, when placed on the cornea , acts as 
a refracting med ium to focus light rays onto the retina.  
The transmittance cha racteristics for these lenses are less than 1% in the 
UVB range of 280 nm to 3 15 nm and less than 10% in the UVA range o f 
316 nm to 380 nm fo r the entire power range.   
 
 
 
 
 
 
 
 
 
 
-  
 
 
 
 
 
 
 
 
 
 
_J_I ---·····----...  
,,. ... . ......  
.. . 
 - - - -- 
 
 
r 
r 
I 
I  
I 
r 
I 
I  
 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 101 of 160   
  
NOTE: Long -term exposure to UV radiation is one of the risk 
factors associated with cataracts . Exposure is based on a number 
of factors such as environmental conditions (altitude, geography , 
cloud cover) and personal factors (extent and nature of outdoor 
activities). UV -Blocking c ontact lenses help provide protection 
against harmful UV radiation. However, clinical studies have not 
been done to demonstrate that wearing UV -Blocking contact 
lenses reduces the risk of developing cataracts or other eye 
disorders.  The Eye Care  Profession al should  be consulted  for more 
information.  
 
INDICATIONS (USES)  
ACUVU E OASY S® Brand Conta ct Lense s 1-Day with HydraluxeTM 
Technology are indicated tor daily disposablewear tor the optica l 
correction ot retrac itveametropia (myopia and hyperop ia)in phakic or 
aphakic  persons  with non-diseasedeyes  who may have  1.00D  or less ot 
astigmatism.  
 
ACUVU E OASY S® Brand Contac t Lense s 1-Day with Hydralux eT M   Tech­ 
nolog y tor ASTIGMATIS Mare indicate d tor daily disposa ble wear tor the 
optical correction  ot refract ive ametropia  (myopia  and hyperopia)in phakic 
or aphaki c person s with non-disease deyes who may have 0.50Dto 3.00D 
ot astigmatism.  
These lenses contain a UV Blocker to help protect aga insttransmission ot 
harm tul UV radiationto the cornea an d into the eye.  
 
CONTRAINDICATIONS  (REASONS NOT TO USE)  
 
DO NOT USE these contact lenses when any of the following 
conditions exist:  
• Acute  or subacuteint lammationor  intectio n ot the anterior chamber  
ot the eye . 
• Any eye diseas e, injury or abnormalit y that affect s the corne a, 
conjunctiva, or  eyelids.  
• Severe  insuffic iencyot lacrimal  secretion  (dry eye).  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 102 of 160   
  
• Corneal  hypoesthesia  (reduced  cornea l sensitivity).  
• Any system ic disease  that may affect  the eye or be exaggerated  by 
wearing contact  lenses . 
• Allergic  reactions  of ocular  surfaces  or adnexa  that may be induced 
or exaggerated by wearingcontact lenses or use of contact lens 
solutions.  
• Ocular irritationdue  to allergic  reactions  which  may be caused  by 
use of contact lenssolutions (i.e., rewet itng drops) that co ntain 
chem icalsor  preservatives  (such  as mercury,  Thimerosal,  etc.) to 
which  some  people  may develop  an allergic  response.  
• Any active  corneal  infection  (bacterial, fungal,  protozoal,  or viral). 
• lf eyes  become  red or irritated.  
 
WARNINGS  
Patients  should  be advised  of the following warnings  pertaining  to 
contact lens  wear:  
EYE PROBLEM$, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPIDLV AND LEAD TO LOSS OF VISION; IF THE PATIENT EXPE­ 
RIENCES:  
• Eye Discomfort,  
• Excessive  Tearing,  
• Vision  Changes,  
• Loss of  Vision,  
• Eye Redness,  
• Or Other Eye  Problems,  
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE­ 
MOVE THE LENSES AND PROMPTLY CONTACT THE EYE CARE 
PROFESSIONAL.  
• When  prescribed  for daily wear,  patien ts should  be instructed  not 
to wear lenses while sleeping . Clinical studies have shown that 
the risk of serious  adverse  reactions  is increased  when  lenses  are 
worn overnight, and that the risk of u lcerativekeratit is is greater for 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine.  
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 103 of 160   
  
extende d wear contact  lens users than for daily wear users3. 
• Studies have  shown  that contact  lens wearers  who are smokers 
have  a higher  incidence  of adverse  reactions  than nonsmokers . 
• Problemswith  contact  lenses  or lens care products  could  result  in 
serious  injury to the eye. Patients  should be cautioned  that proper 
use and care of contact  lenses  and lens care products  are essential 
for the safe use of these  products . 
• The overall  risk of ulcerative keratitismay  be reduced  by carefully 
following  directions  for lens care. 
3 New England Journal of Med icine, September 2 1, 1989; 321 (12), pp. 77 3-783 
 
Specific lnstructions for Use and Warnings:  
• Water Activity 
lnstructions for  Use 
Do not expose contact lenses to water while wear ing them.  
WARNING:  
Wate r can harbo r microorganisms  that can lead to severe  infectio n, 
vision  lossor blindnes s. lf lense s have been submerse din water 
when participatingin water sports or swimming in pools , hot tubs, 
lakes,  or oceans,  the patient  shouldbe  instructed  to discard  them 
and replace  them  with a new pair. The Eye Care  Professional  should 
be consulted  for recommendations  regarding  wearing  lenses  during 
any activity involving  water.  
PRECAUTIONS  
 
Special Precautions for Eye Care Professionals:  
• Due to the small  number  of patients  enrolled  in clinical  investiga ­ 
tionof lenses , ali refractive  powers , desig n configuratio n, sor lens 
parameters  available  in the lens mater ial are not evaluated  in signif­ 
icant numbers . Conseque nlyt, when selec ting an appropriat e lens 
desig n and paramet ers, the Eye Care Professiona l should consid er 
all characteristics  of the lens that can affect  lens performance  and 
ocular health, includingoxygen permeabi lity,wettability, centra! and 
peripheral  thickness,  and optic  zone  diameter.  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 104 of 160   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 105 of 160   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol  
Page 106 of 160   
 Johnson & Johnson Vision Care, Ine. 
 
Other Top ics to Discuss with Patients:  
• Alway s contact  the Eye Care Profession al befor e using any medi­ 
cine in the eyes. 
• Certain medication ,ssuch as antihistamine ,sdecongestants, 
diuret ics, musc le relaxan ts, tranquilizer ,sand those for motion 
sickness  may cause  dryness  of the eye, increased  lens awareness, 
or blurredvision. Should such conditions exist, proper remedial 
measures should be prescr ibed.Depending on the sever ity,this 
could  include  the use of lubricating  drops  that are indicated  for use 
with soft contact  lenses  or the temporary  discontinuance  of contact  
lenswear  while such  medication  is being  used. 
• Oral contrac eptive users could  develo p visual  changes  or changes 
in lens tolerance  when  using  contact  lenses.  Patients  should be 
cautioned  accordingly . 
• As with any contactlens,  follow -up visits are necessary  to assure 
the continuing  health  of the patient'seyes . The patient  shou ld be 
instructe das to a recommended  follow -up schedul e. 
Who Should Know That the Patient is Wearing Contact Lenses?  
• Patient s should inform all doctor s (Healt h Care Profession als)about 
being a contact  lens wearer.  
• Patients should always informt heiremp loyerof  being a contact  
lens wearer.  Some  jobs may require  use of eye protection  equip­ 
ment  or may require  that the patient not wear  contact  lenses . 
 
ADVERSE REACTIONS  
 
The patient should be informed that the following problems may 
occur when wearing contact lenses:  
• The eye may bum, sting,and/or  itch. 
• There  may be lesscomfort  than when  the lens was first placed  on 
the eye. 
• There  may be a feeling  of something  in the eye (foreign  body, 
scratched  area) . 
• There  may be the potential  for some  temporary  impairmen t due to 
 
Clinical Study Protocol  
Page 107 of 160   
 CR-6501 , v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol  
Page 108 of 160   
 Johnson & Johnson Vision Care, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  

Clinical Study Protocol 
Johnson & John son Vision Care, Ine.  
Page 109 of 160   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENERAL FITTING GUIDELINES  
 
A. Patient  Selection 
Patients selected to wear these lenses shou ld be chosen based on: 
• Motivation to wear lenses  
• Ability  to tollow  instructions  regarding  lens wear  care 
• General  health  
• Abiilty to adequately  handle  andcare  for thelenses  
• Ability  to understand  therisk and benefits  of lens wear  
Pa tients who do not meet the above  crtteria shouldnot  beprovidedwith 
oontact  lenses.  
B. Pre-fittin g Examinati on 
lnitial evaluation of thepatientshould begin wlth a thorough casehistory 
to determine lf lhere are anycontraindicat ions to oontactlenswear . Durlng 
the caseh istory, thepatient'sv isual needs andexpec tationsshou ld be 
determinedas well as an assessment of their overall ocular, physical, and 
menta l health.  
Preoedng theinltial selection of trialoontact lenses , a comprehensive 
ooula r evaluation shouldbe performed that includes, but is not limlted to, 
lhemeasurement of distanoe andnear vlsual aculty, distanceand near 
refractive prescription (includng determ ining thepre ferred reacfng distanoe 
tor presbyopes ,)keratometry,and biomicroscopic evaluation . 
Based on this evaluat lon, ff lt isdeterminedthat the patient1s eligible to 
wear  these  lenses,  the Eye CareProfessiona l should prooeed  to thelens 
fitting instructions asoutlned below. 
C. lnltial  Power  Detennlnation  
Aspectacle refraction should be perlormed to establish thepatient's 
basel ine refractive  status  and to guide in the selection  of theappropriate 
lens powe .r Remember  to co m pensa te for vertex  distanoe  therefraction  
is grea terthan :t4.000.  
 
D. Base  Curve  Selection  (Trial  Lens  Fitting ) 
The following triallenses should be selected for patientsregardless of kera• 
tometryreadings. However. oorneal curvatu re measurements shouldbe 
perfor med to estab lish the patient'sbasellne ocular status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
Johnson & John son Vision Care, Ine.  
Page 110 of 160   
 CR-6501 , v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 111 of 160   
  
• ACUVU E OASY S® 1-Day: 8.5 mm/14.3  mm 
• ACUVUE  OASYS®  1-Day tor ASTIGMATISM:  8.5 mm/14.3  mm 
 
The trial lens should  be placed  on each  of the patient's  eyes  and evaluated 
after the patient  has adjusted  to the lenses . 
 
1. Criteria  of a Properly  Fit Lens  
A properly  fit lens will center  and completely  cover  the cornea  (i.e., no 
limbal  exposure),  have  sufficient  movement  to provide  tear exchange 
under  the contact  lens with the blink,  and be comfortable.  The lens 
should  move  freely  when  manipulated  digitally  with the lower  lid, and 
then return  to its properly  centered  position  when  released.  
 
2. Criteria  of a Flat Fitting  Lens  
A flat fitting  lens may exhibit  one or more  of the following  characteris­ 
tics: decentration,  incomplete  corneal  coverage  (i.e., limbal  exposure), 
excessive  movement  with the blink, and/or  edge  standoff.  lf the lens is 
judged  to be flat fitting,  it should  not be dispensed  to the patient.  
3. Criteria  of a Steep  Fitting  Lens  
A steep  fitting  lens may exhibit  one or more  of the following  charac­ 
teristics:  insufficient  movement  with the blink,  conjunctival  indentation , 
and resistance  when  pushing  the lens up digitally  with the lower  lid. 
lf the lens is judged  to be steep  fitting,  it should  not be dispensed  to 
the patient.  
 
lf the initial  trial base  curve  is judged  to be flat or steep  fitting,  the alternate 
base  curve,  if available,  should  be trial fit and evaluated  after the patient 
has adjusted  to the lens.  The lens should  move  freely  when  manipulated 
digitally  with the lower  lid, and then return  to a properly  centered  position 
when  released.  lf resistance  is encountered  when  pushing  the lens up, the 
lens is fitting  tightly  and should  not be dispensed  to the patient.  
 
E. Final  Lens Power (Spherical)  
A spherical  over-refraction  should  be performed  to determine  the final lens 
power  after the lens fit is judged  acceptable.  The spherical  over-refraction 
should  be comb inedwith  the trial lens power  to determine  the final lens 
prescription.  The patient  should  experience  good  visual  acuity  with the 
correct  lens power  unless  there  is excessive  residual  astigmatism.  
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 112 of 160   
  
 
Exampl e 1 
Diagnostic lens:  -2.00D  
Spherical over -refraction : -0.250 
Fina! lens power:  -2.25D 
 
Examp le 2 
Diagnostic lens:  -2.00D  
Spherica l over-refract ion: +0.25D 
Final lens power:  -1.750  
 
lf vision is acceptable, perform a s lit lamp examination to assess adequate 
fit (centration and movement). lf the fit is acceptable, dispense the lenses 
and instruct the patient to return in one week for reassessment (see 
dispensing and follow up information in PATIENT M ANAGEMEN T). 
AII patie nts should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Cop ies are available for 
download at www.acuvue.com . 
 
TORIC FITTING GUIDELINES  
 
Although  most  aspects  of the fitting  procedure  are identical  for all types 
of soft contact  lenses,  including  toric lenses,  there  are some  additional 
steps  and/or  rules  to follow  to assure  the proper  fit of toric lenses . 
The on ly new steps you must fo llow in prescribing ACUVUE OASYS ® 
1-Day for AS TIGMAT ISM are that you must determine t he stability,  
repeatab  ility, and drift angle  of the lens axis so that you can prescribe  the 
correct lens axis for the  patient.  
A. How to Determine Lens Cyl inder and Axis Orientation  
1. Locate the Orientation Marks  
To he lp determine the proper orie ntation of the tor ic lens, you'II 
find two primary marks approximately 1 mm trom the lens edge 
representing the vertical pos ition on opposite ends of the lens at 
6 and 12 o'c lock (Fig. 1). Because of the lens ' ballasting system, 
either mark can represent the vertical pos ition - there is no "top" 
and "bottom" as ina pr ism-ballastedle ns. You do n't need to view 
both marks to assess or ientation; simply look for the 6 o 'clock 
mark as you wou ld with a prism -ballasted lens. 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 113 of 160   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 114 of 160   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-650 1, v 4.0 JJVC CONFIDENTIAL  
Page 115 of 160   
  
Example 2  
Manifest (spectacle) refraction:  
O.O. -3.00D I -1.00D x 90° 20/20 
O.S. -4.75D I -2 .00D x 90° 20/20  
Choose diagnostic lenses of -3.00D / -0.75D x 90° for the right 
eye and -4.50D / -1.75D  x 90° for the left eye, the nearest  lenses 
available  to the spherical  power,  cylinder  power,  and axis needed. 
For the left eye, since the manifest refraction called for -4.75D, 
compensating  for vertex  distance  the sphere  is reduced  by 0.25D 
to -4.50D. The cylinder power will be -1.75D. Place the lens on 
each eye and allow a minimum of 3 minutes for it to equilibrate, 
based on the patient's initial response to the lens. lf the lens has 
not yet stabilized,  recheck  until stable . 
 
Right Eye  
The orientation  mark on  the right lens rotates  left from the 6 
o'clock position by 10° and remains stable in this position . 
Compensa tion for this rotation should be done as  follows : 
Compensate the 10° axis d rift by adding it to the man ifest 
refraction axis.  
Here is the Rx Prescribed : 
O.O. -3.00D I -0.75D x 100°  
 
Left Eye  
The orientatio n mark on t he left lens rotates right from the 6 
o'clock position by 10° and remains stable in this posit ion. 
Compensate for the 10° axis drift by subtracting it from the 
manifest refraction axis.  
Here is the Rx Prescribed:  
O.S. -4.50D I -1.75D x 80°  
lf vision  is acceptable,  perform  a slit lamp  examination  to assess 
adequate fit (centration and movement). lf fit is acceptab le, 
dispense  the lenses  instructing  the patient  to return  in one week 
for reassessment (see d ispensing and follow -up information in 
PATIE NT MANAGEMENT).  
 
AII patients should be supplied with a copy of the PATIENT 
INSTRUCTION  GUIDE  for these  lenses.  Copies  are available  for 
download at  www.acuvue.com.  
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-650 1, v 4.0 JJVC CONFIDENTIAL  
Page 116 of 160   
  
 
MONOVISION FITTING GUIDELINES  
A. Patient  Selection  
1. Monovision Needs  Assessment  
For a good prognosis, the patient should have adequately 
corrected distance and near visua l acuity in each eye. The 
amblyopic patient or the patient with significant astigmatism 
(greater than 1.000) in one eye may not be a good candidate for 
monovision correction with these lenses.  
Occupational and environmental visual demands should be 
considered.  lf the patient  requires  critical  vision  (visua l acuity  and 
stereopsis), it should be determined by tria l whether this patient 
can function  adequately  with monovision  correction.  Monovision 
contact  lens wear  may not be optimal  for activities  such  as: 
• visually demanding situations such as operating potentially  
dangerous  machinery  or performing  other  potentially  hazardous 
activities;  and 
• driving  automobiles  (e.g., driving  at night).  Patients  who cannot 
meet state driver's licensing requirements with monovision 
correction should be advised to not drive with this correction, 
OR may require  that additiona l over-correction  be prescribed.  
2. Patient  Education  
Ali patients do not function equally well with monovision correc­ 
tion. Patients may not perform as well for certain tasks with this 
correction  as they have  with spectacles  (multifocal,  bifocal,  trifocal, 
readers, progressives). Each patient should understand that 
monovision,  as well as other  presbyopic  alternatives,  can create  
a vision compromise that may reduce visual acuity and depth 
perception for distance and near tasks. Therefore , caution sh ould 
be exercised  when  the patient is wearing  the correction  for the first 
time until they are familiar  with the vision  provided  in visually  chal­ 
lenging environments (e.g., reading a menu ina dim restaurant, 
driving at night in ra iny/foggy conditions, etc.). During the fitting 
process,  it is necessary  tor the patient  to realize  the disadvantages 
as well as the advantages of clear near vision and straight ahead 
and upward  gaze  that monovision  contact  lenses  provide.  
Clinical Study Proto col 
John son & John son Vision Care, Ine. 
- CR-650 1, v 4.0 JJVC CONFIDENTIAL  
Page 117 of 160   
  
B. Eye Selection  
1. Ocular Preference Determination  Methods  
Genera lly,the  non-dominant  eye is corrected  for near vision . The 
following  two methods for eye dominance  can be used. 
Method 1 : Determine which eye is the "sighting eye." Havethe 
patientpoi nt to an object at the far end of the room . 
Cover  one eye. lf the patient  is still pointing  directly  at the 
object,  the eye being used  is the dominant  (sighting)eye . 
Method  2: Determine  which  eye will accept  the added  power  with 
the leastreduction  in vision. Place  a hand -held trial lens 
equal to the spectacle near ADD in front of one eye 
and then the other  while  the distance  refractive  error  
correc itonis in place  for both eyes.  Determine  whether 
the patient functions  best with the near ADD  lens over 
the right or left eye. 
 
2. Other Eye Selection  Methods  
Other methods include the "RefractiveError Method" and the 
"Visual Demands Method."  
Refractive Error Method  
For anisometrop ic correc iton,it is generally  best to fit the more 
hyperopic  (less  myopic)  eye for distance  and the more  myopic 
(less  hyperop  ic) eye for near.  
 
Visual Demands Me thod 
Consid er the patient' s occupatio ndurin g the eye selection  process 
to determine  the critical vision  requirements.  lf a patient's  gaze  for 
near tasks  is usually  in one direction,  correct  the eye on that side 
for near.  
Example : A secretary  who places  copy  to the left side of the desk 
will function  best with the near lens on the left eye. 
 
C. Special  Fitting  Characteristics  
 
1. Unilateral Vision  Correction  
Thereare  circumstances  where  only one contact  lens is required. 
As an example,  an emmetropic  patient  would  only require a near 
lens,  whereas  a bilateralmyope  would  require  correc itve lenses  on 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 118 of 160   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 119 of 160   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol  
Page 120 of 160   
 Johnson & John son Vision Care, Ine. 
 
Monovision  fitting  success  can be improved  by the following 
suggestions:  
• Reverse  the distance  and near eyes  if a patient  is having  trouble 
adapting . 
• Reftne  the lens powers  if there  is trouble  with adaptation. 
Accurate  lens power  is critical  for presbyopic  patients.  
• Emphasize  the benefits  of clearnear  vision  and straight  ahead 
and upward  gaze  with monovision.  
The decision to fit a pat ient with monov ision correction is most 
appropr iatelyleft to the Eye Care  Professional  in conjunction  with the 
patient  after carefully  conside irng the patient's  needs.  
Ali patients should be supplied with a copy ot the PATIENT 
INSTRUCTION  GUIDE  tor these  lenses.  Copies  are available  tor 
download at  www.acuvue.com.  
 
PATIENT MANAGEMENT  
Dispensing Visit  
Each  sterile  lensis  supp lied in a foil-sealed  plastic  package  containing 
buffered  saline  solution  with methyl  ether  cellulose.  To remove  the lens 
from the container,  peel back  the foil seal, place  a finger  on the lens,and 
slide the lens up the side of the bowl of the lens package  until it is free of 
the container . 
• Evaluate  the physical  fit and visual acuity  of the lens on each  eye. 
• Teach  the patient  how to apply  and remove  his or her lenses.  
• Explain  daily disposable  lens wear  and schedule  a follow -up 
examination.  
• Previde the patient with a copy ot the PATIENT 
INSTRUCTION  GUIDE  for these  lenses.  Copies  are available 
for download at  www.acuvue.com.  
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE 
OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING 
AND REPLACEMENT SCHEDULES.  
Follow -Up Examinations  
Follow -up care (necessary  to ensure  continued  successful  contact  lens 
wear)  should include  routine  period ic progress  examinations,  management 
of speciftc problems, if any, and a review with the patient of the wear 
schedule,  daily disposable  modality,  and proper  lens hand ling procedures.  
 
Clinical Study Protocol  
Page 121 of 160   
 CR -650 1 , v 4 .0 -  
 
 
 
JJV C CONFIDENTIAL  
Clinical Study Protocol  
Page 122 of 160   
 
Johnson & Johnson Vision Care, Inc.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  

Clinical Study Protocol 
Johnson & John son Vision Care, Ine.  
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 123 of 160  
  
 
the criteria for successful fit are not satisfied during any follow -up 
examinations , repeat the patient's trial fitting procedure and refit 
the patient.  
 
WEARING SCHEDULE  
The wearing  schedule  should  be determined  by the Eye Care  Professional. 
Regular  checkups,  as determined  by the Eye Care  Professional,  are also 
extremely  important.  
Patients  tend to overwear  the lenses  initially.  The Eye Care  Professional 
should  emphasize  the importance  of adhering  to the initial  maximum  wear­ 
ing schedu le. Maximum wearing time should be determined by the Eye 
Care Profession labased upon the patient's physiological eye condition, 
because  individua!  response  to contact  lenses  varies.  
 
The maximum suggested wearing time for these lenses is: 
Day Hours  
1 6-8 
2 8-10 
3 10-12 
4 12-14 
5 and after all waking hours  
 
 
REPLACEMENTSCHEDULE  
These  lenses  are indicated  for daily disposab le wear  and should  be 
discarded upon  removal.  
 
LENS CARE DIRECTIONS  
When  lenses  are prescr ibedfor  daily disposable  wear,  the Eye Care 
Professional  should  provide  the patient with appropriate  and adequate 
warnings  and instructions  for daily disposable lens wear  at the time they 
are dispense d. 
Clinical Study Protocol 
Johnson & John son Vision Care, Ine.  
- CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 124 of 160  
  
The Eye Care  Professional  should  review  with patients  that no cleaning 
or disinfection  is needed  with daily disposab le lenses.  Patients  should  
always  dispose  of lenses  when  they are removed  and have  spare  lenses  or 
spectacles  available.  
Bas ic lnstruct ions 
• Always  wash,  rinse,  and dry hands  before  handling  contact  lenses.  
• Do not use saliva  or anything  other  than the recommended  solutions 
tor lubricating  or rewetting  lenses.  Do not put lensesin  the mouth.  
• Eye Care Professionals may recommend a lubricating/rewetting 
solution  which  can be used  to wet (lubricate)  lenses  while  they are 
being  worn  to make  them  more  comfortable.  
Care for a S ticking (Non -Moving) Lens  
lf the lens sticks  (stops  moving),  the patient  should  be instructed  to apply 
a few drops  of the recommended  lubricating  or rewetting  solution  directly 
to the eye and wait until the lens begins  to move  freely  on the eye before  
removing  it. lf non-movement  of the lens continues  after a few minutes,  the 
patient  should  immediately  consu lt the Eye Care  Professional.  
 
EMERGENCIES  
 
The patient  should  be informed  that if chemicals  of any kind (household 
products, gardening solutions, laboratory chemicals, etc.) are splashed 
into the eyes,  the patient  should : FLUSH  EYES  IMMEDIATELY  WITH  TAP 
WATER  AND IMMEDIATELY CONTACT  THE EYE CARE  PROFESSIONAL 
OR VISIT  A HOSPITAL  EMERGENCY  ROOM  WITHOUT  DELAY.  
 
HOW SUPPLIED  
 
Each  UV-blocking  sterile lens is supplied  in a foil-sealed  plastic  package 
containing  buffered  saline  solution  with methyl  ether  cellulose.  The plastic 
package  is marked  with the following : 
• ACUVUE  OASYS®  1 -Day:base  curve,  power,  diameter,  lot number, 
and expiration  date 
• ACUVU E OASYS ® 1 -Dayfor ASTIGMATIS M: base curve,  power, 
diameter,  cylinder,  axis, lot number,  and expira itonda te 
Clinical Study Protocol 
Johnson & John son Vision Care, Ine.  
Page 125 of 160   
  
 
REPORTING OF ADVERSE REACTIONS  
 
Ali serious adverse experiences and adversereact ionsobserved in 
patients wearing theselenses or experiencedwith these lensesshou ld be 
reported to: 
 
 
Johnson & Johnson Vision Ca re, Ine. 
7500 CenturionParkway  
Jacksonville, FL 32256  
USA 
Tel: 1-800 -843-2020  
www .acuv ue.com 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol 
Johnson & John son Vision Care, Ine.  
Page 126 of 160   
 CR-6501 , v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 127 of 160   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 128 of 160   
  
APPENDIX D:  
• LENS FITTING  CHARACTERISTICS  
• SUBJECT REPORTED OCULAR  SYMPTOMS/PROBLEMS  
•  DETERMINATION OF DISTANCE  SPHEROCYLINDRICAL 
REFRACTIVE  ERROR  
• BIOMICROSCOPY  SCALE  
• DISTANCE AND NEAR SNELLEN VISUAL ACUITY  EVALUATION  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
CR-6501, v 4.0  JJVC CONFIDENTIAL  
Page 129 of 160   
  
LENS FITTING CHARACTERISTICS  
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
Lens Fitting  Chara cteristics   
   
Revision Number: 6 Title: 
Document  T 
- CR-6501, v 4.0 JJVC  CONFIDENTIAL  
Page 130 of160   
  
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
Lens Fitting  Chara cteristics   Title: 
Document  T 
Revision Number: 6 
- CR-6501, v 4.0 JJVC  CONFIDENTIAL  
Page 131 of160   
  
 
 
 
 

Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
Lens Fitting  Chara cteristics   
   
Revision Number: 6 Title: 
Document  T 
- CR-6501, v 4.0 JJVC  CONFIDENTIAL  
Page 132 of160   
  
 
 
■ 
 

Clinical Study Protocol  
Page  133 of 160  
 Johnson & Johnson Vision Care, Inc.  
Title:  Lens Fitting  Characteristics  
Document Type:      
Document Number:   Revision Number:  6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Study Protocol  
Page  134 of 160  
 
Johnson  & Johnson  Vision  Care,  Ine. 
 Title:  Lens Fitting  Characteristi cs 
Document T   
 
Revision Numb er: 6  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Study Protocol  
Page  135 of 160  
 CR-6501,  v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Page 136 of160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
SUBJECT REPORTED OCULAR SYMPTOMS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Page 137 of160   
 
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
Title  ------------------  Subject Reported Ocular  Symptoms /Problems  
Document T   
 
 
Revision Number: 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Page 138 of160   
 CR-6501 , v 4.0 -  
 
 
 
JJVC CONFIDENTIAL  
Page 139 of 160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
DETERMINATION  OF DISTANCE  SPHEROCYLINDRICAL 
REFRACTIONS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Page 140 of160   
 
Title  -------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T  
Revision Number: 5  
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
 
 
 
 
 
 
I 
 
 
 
 
 
·-I 
I 

Page 141 of160   
 CR-6501 , v  4.0 -  
 
 
JJVC CONFIDENTIAL  

Page 142 of 160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
Title:  Determination of Distance Spherocylindrical Refractive  Error  
Document Type:      
Document  Number:   Revision Number:  5 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 143 of160   
 
Title  -------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T   
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 144 of160   
  
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title  -------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T  
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 145 of160   
  
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
 
I 
 
I 
Title  -------------------  Determination  of Distance  Spheroc ylindrical  Refractive  Enor  Document T  

Page 146 of 160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
BIOMICROSCOPY SCALE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Study Protocol 
Johnson  & Johnson  Vision  Care,  Ine. 
 Title:   
DocumentT  
Revision Number: 10 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 147 of 160  
 -  
 
 
 
 
 
 
 
Page 1 of5 

Clinical Study Protocol 
Johnson  & Johnson  Vision  Care,  Ine. 
 Title:   
DocumentT  
Revision Number: 10 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 148 of 160  
 -  
 
 
 
 
 
 
 
Page 2 of5 

Clinical Study Protocol 
Johnson  & Johnson  Vision  Care,  Ine. 
 Title:   
DocumentT  
Revision Number: 10 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 149 of 160  
 -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 3 of5 

Clinical Study Protocol 
Johnson  & Johnson  Vision  Care,  Ine. 
 Title:   
DocumentT  
Revision Number: 10 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 150 of 160  
 -  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 4 of5  

Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 151 of 160  
 -  
 
 
 
 
 
 
 
 
 
I  
I  
 
 
 
 
 
 
 
 
Page S ofS 
 Title:  
Document T 

Page 152 of160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
DISTANCE AND NEAR SNELLEN VISUAL ACUITY EVALUATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Page 153 of160   
 
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
Title  ------------------  Distance  and Near  Snellen  Visual Acuity  Evaluation  
Document T  
 
 
 
 
·­I 
I  
 
 
Revision Number: 5  
·I ­ 
 
 
 
I  
I 
I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Page 154 of160   
 CR-6501 , v 4.0 -  
 
 
JJVC CONFIDENTIAL  
Page 155 of 160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
Title:  Distance and Near Snellen Visual Acuity  Evaluation  
Document Type:      
Document Number:   Revision Number:  5 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 156 of160   
 
 
 
I  
I 
 
 
I 
I 
I 
I  
I 
 
I 
 
Title  ------------------  Distance  and Near  Snellen  Visual Acuity  Evaluation  Document T  

Clinical Stud y Prntocol  
John son & John son Vision Care , Ine. 
- CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 157 of160   
 
Title  ------------------  Distance  and Near  Snellen  Visual Acuity  Evaluation  
Document T  
Revision Number: 5  
Page 158 of 160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
APPENDIX  E: GUIDELINES FOR COVID -19 RISK  MITIGATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 159 of160   
 
Document T y e: 
- -T-it-le  ------------------------------  Guid elines for COVID -19Risk Mitigation  
   Document  Number :    Revision Number:  5  
 
 
1.0 PURPO SE 
 
The purpo se of this documen t is to provide guidelines  for the re-opening  or initia tion of clinical  study sites 
participa ting in Johnson & Johnson Vision C are, Ine. (JJVCI) clinical studie s during the COVID -19 
pandemic . 
 
2.0 SCOPE  
 
This document  provides guideline s for John son & John son Vision Care  (JJVCI) to addre ss the potential  risks 
from  COVID -19 to study subject s, investigators , study site staff, and monito rs at study sites. The guidance 
provided in this document  is in effec t from  the date of appro val through  the date of retirement  of this Work 
Instruction . At a minimum , this Work In struction will be re viewed and updated on a quarterly ba sis, as 
appropri ate. 
 
NOTE: Re -opening of sites outside of the US will be evaluated  on a  countr y by countr y basis subject 
to local health authority  guidan ce. 
 
3.0 DEFINITIO NS 
 
American  Acad emy of Optometr y (AAO ): The American  Academy  of Optometiy  is an organization  of 
optometri sts based in Orlando , Florida. Its goal isto maintain and enhance excellence in op tometric 
practice , by both promoting re search and the dissemina tion of kno wledge . The AAO holds an annual 
meeting , publi shes a monthly  scientific  joumal , gives creden tials to optometi·is ts through  the fello wship 
proces s and publi shes position  statemen ts. 
 
American  Optometric  Association  (AOA ): The American  OptometI'ic  Association, found ed in 1898 , is 
the leading authority  on quality  care and an advocate for our nation 's health , representing more  than 44,000 
Doctor s ofOptometry (O.D.), optometric profe ssional s, and op tometiy student s. Doctor ofOptometry take 
a leading  role in patient  care with respect to eye and visi011care  , as w ell as general  health  and well-being . 
As primary health care providers , Doctor of Op tometiy have extensive, ongoing training to examine , 
diagnose , treat and manage  ocular  disorder s, disea ses and injurie s and systemic  diseases that manife st in the 
eye. The American  Optometric  Association isa fe.deration  of state, student , and anned  forces  optometi·ic 
associations. Through the se affiliation s, the AOA serves membe rs consisting of optometi'i sts, studen ts of 
optometry , paraop tometi·ica ssistants  and technician s. The AOA  and its affiliate s work to provide the public 
with quality  visi011and  eye care. 
Centers fo1· Disease Control  and Preventio n (CDC): The Center s for Disease Contro l and Preventio n is a 
national public heal th institute in the United State s. It is a Unite d States federa! agency , under the 
Departm ent ofHealth and Human Ser vices, and is headquartered in Atlanta , Georgia . 
COVID -19: CtuTent outbreak  of respiratory  disease caused by a nove! corona virus. The virus has been 
named  "S ARS -CoV -2" and the disease it causes has been  named  " Corona virus Disease 2019 " (COVID - 
19). 
Clinical  Study: Volw1taiyre search  studie s conducted  in people  and design ed to answer specific  questions 
about the safety or effecti veness of drugs, vaccine s, other therapie s, or ne w ways of using exi sting 
ti·eatinen st. May also be calle.d clinical trial s, studie s, reseai·ch , ti·iasl, or protocol s. 
Clinical  Study Site: Location  where a clinic a l study is conduc ted, such as a docto r's office , university, or 
labora tory. Clinical studie s are conduct ed by Investigators who are indi vidual (s) responsible for the 
conduc t of the clinical study at a study site. If a study is conducted by a team of individual s, the 
Investigator  is the responsible leader  of the team  and may be called  the Principal  Investigator. 
Clinical  Operation s Manager  (COM ): The John son & John son Vision  Care (JJVCI ) individua! 
respon sible for the overall manag ement  of a clinic al trial.  
 
 
Page 1 of 11 
 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Page 2 of ll 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 160 of 160   
 
Document Ty e: -T-itl-e -------------------------------  Guideline s for COVID -19 Risk Mitigation  
   Document  Number:     Revision Number:  5  
 
Monitor: An individua! designated to oversee the progress of a clinicaI study and ensure that it is 
conducted, recorded, and repo1ted in accordance with the protocol, Standard Operating Procedures (SOPs) , 
Good Clinical Practice (GCP) , and applicable regulat01y requirements.  
 
Medical  Safety  Office1·  (MSO):  Physician  who has prima1y  accountability  in their  product  po1tfolio  for 
product  health  and safety,  and who serves  as an independent medica!  voice  for patient  safety.  
 
Safety Management Team (SMT): A cross -functional , collaborative team responsible for review , 
assessment and evaiuation of medica! safety data arising from any source throughout the product life cycle . 
 
4.0 GUIDANCE FOR STUDY  DOCUMENTS  
 
In alignment with recent health authority guidance, JNCI is providing recommendations for study -related 
management in the event of dismption to the conduct of the clinical study. This guidance does not supersede 
any locaI  or govemment  requirements  or the clinical  judgement  of the investigator to  protect  the health,  safety 
and well -being of pa1ticipants and site staff. If , at any time, a pa1ticipant' s safety is considered to be at risk , 
study intervention will be discontinued , and study follow -up will be conducted as outlined in the  protocol.  
 
During  the COVID -19 pandemic , the additional  risks  listed  below  need  to be considered  for study  pa1ticipants 
and study  personnel:  
 
4. I AdditionaI Risks Related to the COVID -19 Pandemic:  
• The possible transmission of the Coronavims infection and consequent complications , beyond the 
risk of adverse  events  due to the investigational  device  and/or  procedures.  
• The risk may be higher in an optometric clinical study because of the close contact the subject will 
have with heaith care professionals dw·ing the procedures and assessments (since the investigator 
must make the measw·ements close to the subject's face) and , in ad dition the need for multiple 
follow -up visits /exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the vims , even if they do not have  symptoms.  
• Potential dismptions to the study may be necessa1y due  to cun -ent or future pandemic -related  
emergency restrictions , which may lead to delays in scheduled follow -up visits.  
• Subjects experiencing an adverse event related to contact lens wear may receive delayed treatment 
due to COVID -19 restrictions.  1n this event , all assessments  that can be conducted  virtuaUy  will be 
completed by the investigator  to detennine  the best course oftreatment for the subject , including  
an unscheduled visit , up to discontinuation from the study, as  appropriate.  
 
If a study subject is found to have contracted COVID -19 during pa1ticipation ina study , he/she will be 
discontinued from the study and followed until COVID -19 Adverse Event (AE) resolution . 
 
To help minimize the above potential risks, JNCI r ecommend reviewing/complying with locaI, state, 
and govemmental guidance for COVID -19 risks.  
 
JNCI will provide the following studyspecific documents with language pe1taining to COVID -19 risks:  
 
4.1.1 Info1med  Consent:  
 
Will include  info1mation  conceming  the study -associated  risks  related  to the COVID -19 pandemic 
in bold font and/or  boxed  on the first page  of the Infonned  Consent  document:  
 
 
 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Page 2 of ll 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 161 of 160   
 - 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 3 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 162 of 160   
 
Do cument Ty e: -T-itl-e  -------------------------------- - Guidelin es for COVID -19Risk Mitigation  
   Document  Number :    Revi sion Number:  5  
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS) PANDEMIC  
 
It is important  to note that this study  will be conducted , at least  in pa1i, during  the COVID ·19 pandemic . As such, 
additional  risks  associated  with the infection  with COVID -19 exist  for you. This is pa1ticularly  important  for this 
study  due, in part, to the closeness  of the doctor  during  the study  examinations . 
 
The potential effects of the disease are not fully known , at this time, and may include long -tenn serious health 
consequences . In severe cases , this may result in hospitalization and/or death. Based on c tment knowledge from the 
Centers for Disease Control and Prevention (CDC), those at high-risk for severe ilh1ess from COVID -19 include 
older adults and people with underlying medica! conditions . 
 
During  this study , all appropriate  measures  will be taken  to minimize  risks  including  the use of personal protecti ve 
equipment  such  as masks  and gloves , as well as proper  sanitization . This is in conf01mance  to guidance  from  the 
CDC,  local  health  deprut  ments , and the state and county  in which  the study  doctor 's office  is located.  However , 
these  measures  may not completely  eliminate  the risks  associated  with contracting  COVID -19. 
 
Ifyou ru·e found to have contrncted COVID -19 or feel ill with flu-like symptoms during participation in the study, 
you will not be pe1mitted to continue in -office study follow -up visits , but you will receive instmctions and your 
condition will be monitored by the doctor and/or study staff.  
 
4.1.2 COVID -19 Risk Control Checklist  (Attaclunen -tB): 
 
Will include  COVID -19 risk contrnl  methods  that are required  by a site to conduct  JNCI  clinical 
studies. The risk controls are consistent with CDC , AOA , AAO Guidance . The Principal 
Investigator  will review /sign the study  specific  checklist  prior  to the Site Initiation  Meeting.  
 
 
4.1.3 Protocol Compliance Investigato (rs) Signature  Page : 
 
Will include  a statement  indicating  that the Principal  Investigator  (PI) agrees  to conduct  the study 
in compliance  with all local , state,  and govenunental  guidance ' s for COVID -19 risk mitigation . 
 
I have  read the suggested  guidanceprovided  by JNCI  pertaining  to the COVID -19 risk mitigation , 
(COVID -19Work  Instruction  in the Appendix  of this protocol ). I agree  to conduct  this study  in 
compliance with local , state, govenunental  guidance  for COVID -19 risks. 
 
4.1.4 Study  Site Initiation  Training  Slides : 
 
Will include  suggestions  to help mitigate  potential  transmission  of COVID -19. Suggestions  may 
include  maintaining  social  distancing  in the clinical  site by staggered  scheduling  of study  patients , 
wearing proper PPEs , frequent disinfection , and installing shields on the slit lamp and other 
applicable  equipment.  
 
S.O GUIDANCE FOR REMOTE SUBJE CT VISIT S 
 
Potential  dismptions  to the study  may be necessary  due to cmTent  or future  pandemic -related  emergency 
restrictions . Possible  disruption  of the study  as a result of COVID -19 control  measures  may lead to delays 
in scheduled follow -up visits . 
 
Subjects may be delayed in being seen for study follow up visit(s) , for exrunple due to COVID -19 control 
measures or due to the subject's concems or fears about COVID -19 risk. When appropriate, the remote 
assessment will be conducted to the extent possible . Discussions with the subject during remote assessments 
may include : 
 
 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 3 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 163 of 160   
 - 
Clinical Study Protocol 
Johnson & John son Vision Care, Ine. 
Page 4 of 11 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 164 of 160  
 
Document Ty e: -T-it-le  ------------------------------  Guidelines for COVID-19 Risk Mitigation  
   Document Numb er:    Revision Numb er: 5  
 
 
 
Proce dure Details 
Subject Repo1ted Ocular 
Symptoms  Subjects will respond to a verbal open -ended symptoms questionnaire 
regarding the test article when applicable and feasible . 
Change ofMedical History 
(Adverse Events ) and 
Concomitant Medications / 
Therapies Re view Record  any adverse  events  or medical  history  changes  from  the 
previous  study  visit with the subject/parents . 
Review the subject' s concomitant  medications /therapies  and record 
any changes  from  the previous  study  visit.  
Wearing Time and 
Compliance  Record the a:verage w earing time (including number ofhow -s per day 
during weekdays and weekends , and number of days per week) . 
 
Confinn compliance with the prescribed wear schedu le. 
• Re.cord and discuss the lens wear compliance based on the  
subject's self-repo1t . For example , the subjects will be a.sked  the 
time of the day the subject typically puts on the study lenses in the 
moming and takes off in the ev ening, the number of days per week 
lenses were wom , and the mllllber of consecutive days the subject 
didn' t wear the study lenses, etc. 
 
The discussion with the subject will be documented in E DC under Tele -Visit and a minor protoco l deviation 
will be not ed. If during the telephone c.onsultation , a subject states he/she wishes to discontinue participating 
in the study, instruct the subject to stop wearing the study lenses and schedule the subject to retum to the 
clinic for a Final Evaluation at the at earl iest possible time. Subjects should retum all wmsed lens es to the 
clinic at the la.st visit.  
 
Changes in study visit schedules , miss ed visits , or participant discontinuations may lead to missing data, 
including data r elated to protocol -specified procedures . Case repo1t fonns should  capture  specific 
info1mation regarding the basis of missing data , including the relationship to the COVID -19 pandemic . 
 
6.0 STUDY CONDUC T DURING PANDEM IC 
 
It is recognized  that the Coronavims  Disease  2019  (COVID -19) pandemic  may have  an impact  on the conduct 
of this clinical  study  due to, for example , self-isolation/quarantineby  participants  and study -site personnel ; 
trave! rest1·ictions/lin1ited access to public places , including Optometly Clinics ; and changes in clinic 
procedures  required  to address  the COVI D-19 challenge.  
 
Eve1y effort should be made to adhe re to protocol -specified assessments for study participants , including 
follow -up. Howev er, if scheduled visits cannot be conducted in person at the study site it is suggested that 
assessments be pe1fo 1m ed to the ext ent possible remotely /vit1ually or delayed w1til such time that on -site 
visits can be resumed it1 order to continue pruticipant monito ring in a.ccordat1ce with the protocol where 
possible. At each contact , pru·ticipants will be it1te rviewed to collect safety data. K ey effica.cy endpoit1t 
assessments should be perfo1med if required ru1d as feasibl e . 
 
Modifica.tions  to protocol -required  assessments  may be pennitted  via COVID -19 Appendix after consultation 
with the prut icipant , itiv estigator, and the sponsor . Miss ed assessments /visits will be captured in the clinical 
trial manag ement system for protocol devia.tions. Inten uptions of test ruticle wear or discontinuations of 
study it1terventions and withdrawal from the study should be docum ented with the prefix "COVID -19- 
related " it1 the ca.se report f01m  (CRF).  
 
Clinical Study Protocol 
Johnson & John son Vision Care, Ine. 
Page 4 of 11 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 165 of 160  
 - 
Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Page 5 of ll 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 166 of 160  
 
Document Ty e: 
1111 -T-it-le  -------------------------------  Guideline s for COVID -19 Risk Mitigation  
   Document  Number:     Revision Number:  5  
 
The sponsor will continue to monitor the conduct and progress ofthe clinical study, and any changes will be 
communicated to the sites and to the health authorities according to local guidance . 
 
If a patticipant has tested positive for COVID -19, the investigator should contact the sponsor's responsible 
medical monitor to discuss initial plan s for study intervention and follo w-up. The medical monitor will 
notify the Safety Management Team of any subject(s) that have repo1ted "COVI D-19 ", "Asymptomatic 
COVID -19", or "S uspec ted COVID -19" adverse events within 24 hour s of the notification.  
 
Mod ifications  made  to the study conduct  as a result  of the COVID -19 pandemic  will be summar ized in the 
clinical study  repo1t.  
 
COVID -19 scr eening procedures that may be mandated by local healthcare systems do not need to be 
repo1ted as an amendment to the protocol even if đone during clinical study v isits. 
 
6.1 Monitoring  Visits  
 
When  on-site moni toring by the sponsor is not feasibl e, the sponsor's  site monitor  will contact  the study 
site to schedule remote  visits. 1n such cases,  on-site monito ring visits will resume  when  feasible,  with 
incre ased frequency  to address  the source data verifi cation backlog.  
 
Even  with staffi ng liniitations during  this COVID -19 pandemic,  aU routine  opera tions related  to clinica l 
trials  should be well-documented and at·chived  as part of standard  process. When  conditions  permit , all 
pruties  involved  in this clinical  trial should communicate  relevant  information  in a timely manne r so that 
all relevant  parties  remain suffic iently info1med.  
 
6.1.1 Study Site  Initiation:  
 
During the period that this Work Instmction is in effec t, Site Initiation Meetings and training of 
study site staff will be conducted remotely . The JJVCI study t eam will conduct training via Skype, 
Zoom , Microsoft  Teams  or similar software as well as utilize online  train ing materials , as applicable.  
Study site training will be documented utilizing Site Initiation Repo1t   per Study S ite Initia tion  
On-site visits may be considered when, for example , hands -on training or evaluation of site facilities 
is required. While on site, the Clinical Research Associate (CRA) will follo w aU local, stat e, and 
govemmental policies for COVID -19 Risk Mitigatio n, including social distancing, wearing of PPE, 
etc. as applicable for the location of the study site. 
 
6.1.2 Interim Mo nitoring Visits (if applicable):  
 
During the period that this Work Instmction is in effec t, Interim Monitoring On -site visits will be 
kept to a minimum and include only those tasks that the CRA cannot pe1fo rm remote ly (e.g., source 
document verifica tion, test a1ticle reconci liation, etc.). 
 
To en sur e data integrity during the conduct of ali JJVC studies , clinical study teams will follo w the 
study specific Clinical Monitoring Plan  
While  on site, the CRA  will follo w all local, state, and govemmental  policies for COVID -19 Risk 
Mitigati on, including social distancing , weati·ng of PPE, etc. as applicable for the location of fue 
study site. 
 
 
 
 

Clinical Study Protocol 
Johnson & Johnson Vision Care, Ine. 
Page 5 of ll 
CR-6501, v 4.0 JJVC CONFIDENTIAL  
Page 167 of 160  
 - 
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 6 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 168 of 160   
  
 
 
6.1.3 Study Site  Closure: 
 
During the period that this Work Instn1ction is in effect , the duration of the Study Si te Clo sure Vi sit 
will be limited to tasks that the CRA cannot perfonn remotely (e.g., sow·ce document verification , 
test article fina l reconciliation and  retw1 ,1etc.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title:  
   Docu ment Ty  e: Guid elines for CO_VI_D _r-u_·s_1_9k    M·t·tgi_at_i_o_n   
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
Page 6 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 169 of 160   
 - 
Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
Page 7 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Pag e 170 of 160   
 
Document Ty e: -T-itl-e  -----------------------------  Guid elines for COVID -19Risk Mitigation  
   Document  Number :    Revision Number:  5  
 
 
XXXX xx, 2020 At tachment A : Stud y Site Col'l'e spondence  
 
 
 
Re: COVID -19 Mitigation Plan , <<CR-xxxx/protocol title >> 
 
 
Dear <<Principal In vestigator >> and Study Team , 
 
Corona virns (COVID ·19) has impacted several conununitie s and business activities over the past several month s. 
While we work to ward the succe ssful conduct of clinic al studie s, our conunitment continues to be the safety of 
patients, healthc are profe ssional s, and to om conununities . 
 
Therefore , we would like to share the follo wing revision s/addition s related to the above referenced John son & 
John son Visi011Care  company  sponsored clinical  trial(s) you are ctmently  working  on or considering  pa1ticip ation 
within. 
 
Protocol : 
 
• Guideline s for COVID -19 Risk Mitigation  provided in the Appendix  section . 
 
Protocol Signatur e Page: 
 
• Will include  a sta.tement  indic a ting the Principa.I  Investigator agree s to conduc t the study in compliance  
with all local, state, and govenunental  guideline s for COVID -19 risk mitigation . 
 
Inform ed Consent: 
 
• Will include  infonnation  conceming  the study-associated risks related to the COVID -19 pandemic  in bold 
font and/or  boxed  on the  first page  of the Infonned  consent document.  
 
COVID -19 Ri sk Control Checkli st fot· Clinical Studie s: 
 
• Will include COVID -19 ri sk control mea.sme s that are required to en sme the safety and health of subject s, 
site staff and monitor s during the  pandemic . 
 
We want to encourage  the need  for open  lines of communication  a.bout  poten  tial challenge  s you ma y fore s ee as the 
result of the cun -ent COVID -19 situation . Therefore , we encourage you to regularly connec t with your respective 
Johnson & Johnson clinical study team (Clinical Research Associate (CRA ), Lead CRA or S tudy Manager s). 
 
Thank you fo r your continued eng agement , collaboration , and dedication to your study subjec ts during this 
challenging time . 
 
 
Please file this letter in your site file study con -es pondence . 
 
 
 
 
 
 
 
Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
Page 7 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Pag e 171 of 160   
 - 
Clinical Stud y Protocol 
John son & John son Vision Care , Ine. 
Page 8 o f 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 172 of 160   
 
Document T y e: -T-it-le  ------------------------------  Guid elines for COVID -19Risk Mitigation  
   Document  Number :    Revision Number:  5  
 
 
Atta chment B : COVID -19 Risk Control Checkli st 
 
 
 
Study Number 
Site Numbe r 
Principal In vestigator (PI) Name  
 
 
The follo wi.ng COVID  -19 ri sk co .ntrol methods  ru·e required  to co.nduct  John  so.n & Joh.n so.n Vison  Cru·e  cli.nical 
studies . Plea se review the follo wi.ng requiremen  ts a.nd I.nitial each requiremen t. 
 
PI Initials  Gene ral Site Sa fetv PlannirnzMeasures  
 Si1maize w ith i.n s ite de s cribin iz Ri s k Control method s 
 Social Distanci.niz orac tices th roucrhou t site (waiti.niz room s lobbv, exam room s, etc.) 
 Non-contact thermome ter available to assess temoerature s of staff ru1d oa tient s 
 Trai.niniz on oatient flo w and oh vsical di stanci.niz i.n waiti.niz room  
 Establish lonizer time frame be tween oa tient annoin tments to reduce oer sons i.n the s ite 
 Staff should recei ve job -specific traini.ng on PPE and demon strate compe tency with selec tion a.nd  
proper u se of PPE ru1d w ea r at ali tirne s during i.nterac tion s with subject s (e.g., putting on and 
remo ving without self-contami.nation ) 
 
 
P I Initials Site Sta ff Dailv Sa fetv Measures  
 As part of routine practic .e, si te staff should regularly monitor them selves for fe ver and symptoms  
of COVID -19 i.ncludi.ng temperature check s 
 A.ny staff member (including 11011 s- tudy clinic staff and In vestigator s) showi.ng s igns  ofbei.ng sick 
or testing positive for COVID -19 mu st not be pennitted to work on ac tivity  that may  expose  study 
related staff ru1d subjec t and the Spon sor shall be  i.nformed  
NOTE: Inform JJVC in 24 how·s of an y COVID -19 cases and all potentfal expo sure dw'ing  
the dinical study. 
 Ensure that all staff wear a ma sk 
Gloves should be reauired when working directlv with oa tients ru1d changed between e ach oatient  
 Have staff thoroughly wash hand s for at lea st 20 second s or use ru1 a lcohol -ba s ed hru1d s anitizer 
when thev ruri ve. before and afte r each oatient before eati.ng and aBer u sing the ba throom . 
 Cleru1i.ng ru1d disi.nfection procedure s for exrun room s and instrument s or equipment between 
oatient s with izlo v e s . 
 Cleru1i.ng ru1d disinfection procedure s for collllllonly touched surface s (doors, chair s, computer s, 
phone s, etc...) with glo ves. 
 
 
PI Initials Before a Patient or Study Vis it: 
 Patient s should  be asked prior  to enteri.ng  the site about  fever and respiratory illness and whether 
they or a frunily  membe  r have had conta ct with another  person with confinned  COVID -19 i.n the 
past 14 day s. Patients exhibiting signs ofbei.ng sick should be re scheduled when their symptoms 
resolve. 
 Instmct p atients that companion s should remain out side of the facility ru1d not accompany the  
patient  i.nto the facility  unless they are a parent/guardianof the  patient or if they ru·e a trne 
c ru·egi v er and need  to assist the oatient 
 Request the patient to call or text the office upon all'i val so entrance to and mo vement through  
facility can be coordi.nated by site staff 
 
 
 
 
Clinical Stud y Protocol 
John son & John son Vision Care , Ine. 
Page 8 o f 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 173 of 160   
 - 
Clinical Stud y Protocol  
John son & John son Vision Care , Ine. 
-T-itl-e  -----------------------------  Guid elines for COVID -19Risk Mitigation  
Document Ty e: 
   Document  Number :    Revision Number:  5  
Page 9 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 174 of 160   
  
PI Initials Patients Entering the site:  
 Temper atme checks  utilizing  a non-contac t thennometer  for ali patient s and companion s entering 
the site. 
 Alpi a tien ts and comp anions must wear cloth or di sposable ma sk at ali time s in the site 
 Main tain social  distancing . Waiting rooms  or lobbie s should  be as empty  as possible. Advise 
seated patient s to remain at least 6 feet from  one another . 
 Communal obiect s in (e.g. toys, reading material s, etc.) should be remo ved or cleaned re larl y. 
 
 
 
I certify that I ha ve read and agree to implement ali the li sted COVID -19 Risk Con trol Mea sures required for the 
conduc t of John son & John son Vi si011Care studie s. 
 
 
 
 
 
 
 
Principal In vestigator Signature and Da te 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Stud y Protocol  
John son & John son Vision Care , Ine. 
-T-itl-e  -----------------------------  Guid elines for COVID -19Risk Mitigation  
Document Ty e: 
   Document  Number :    Revision Number:  5  
Page 9 of 11 
CR-6501 , v 4.0 JJVC CONFIDENTIAL  
Page 175 of 160   
 - 
Clinical Stud y Protocol  
John son & John son Vi sion Care , Ine. 
-T-itl-e  -----------------------------  Guid elines for COVID -19Risk Mitigation  
Document Ty e: 
   Document  Number :    Revision Number:  5  
Paeg158 of 160  
 -  
RESOUR CE LINK S 
 
US Resource Lin ks 
 
• OSHA Training  
https://www.osha.gov/S LTC/covid• 19/controlprevention.htm l 
 
Personal Protec tive Equipment (PPE) Training  
CDC: https ://www.c dc.gov/coronavims /2019 -ncov/hcp /using-ppe.html  
 
• I&R Training  
ACUVUE ® Len sA ss ist: http s://www.acuvue .com/lensassist  
 
• Clinic Preparedne ss Guide s 
CDC: https ://www.cdc .gov/coronavinis /2019 -ncov/hcp/clinic -preparedness htm l 
AOA : https ://aoa.uberfli p.com/i/1240437 -aoa-guidance -for-re-openin g-practices -covid·19 /1?m4= 
American  Optometric  Association : https://www .aoa.org/optometzy -practice  -reactivation  -prw aredn ess­ 
imide  
 
• lu-Office  Disinfec tion of Multi-Patient  Use Diagno stic Contac t Lense s 
https://www.gpl i.info/wp -content/uploads/2020/03/2020 -01-15-in-office -disinfecting -of-diagnost ic­ 
lenses.pdf  
 
OUS Resource Link s 
 
• Update s on local regulations in Hong Kong  
https://www.coronavims.go vhk/eng/inde x.html  
 
• Resumption of optical  services in England : Letter from Matt Neligan and Poonam Shanna  
https://www.englan d nhs.uk/coronavims/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical ­ 
services -Ietter -17-june-2020.pdf  
 
• NHS Optical  Letter  
https://www.englandnhs.uk/coronavims/wp -content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april- 
2020.pdf  
 
• The College of Optometri sts primacy eye care COVID -19 guidance: Red  phase 
https: //www.college -optometrists.org/the -college/media -hub/news -listgi/ncoronavims -covid -19-guidance ­ 
for-optometrists .html  
 
• The College of Optometri sts COVID -19: College  updates  
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavims -2019 -advice -for­ 
optometrists .html#CollegeGuidelines  
 
• Infection Control Guide lines. (n.d.). Ret,rieved from Canadian A ssociation Of Optometri sts: 
https://opto.c a/sites/default /files/resource s/document s/infection _control _gnideline s_2016.pdf 
 
• Infection pre vention and contro l for COVID -19: Interim guidance for outpa tient and ambulato1y care  
setting s. (2020 , May 2 3 May ). Retrieved from Govemment of Canada : https://www. canada.c a/en/public ­ 
healt h/services/diseases/2019 -novel -corona vims-infectio n/guidance -documents /interim -guidance­ 
outpatien t-ambulato1 y-care-settings html  
 
 
 
 
 
Page 10 ofll  
 
CR-650,1v4.0 JJVC CONFIDENTIAL  
Clinical Stud y Protocol 
John son & John son Vi sion Care , Ine. 
-T-itl-e  ------------------------------  Guid elines for COVID -19Risk Mitigation  
Document T y e: 
   Document  Number :    Revision Number:  5  
Page 159 of 160   
 -  
• Info1mation for Member s On Corona virus (COVID -19). (n.d.). Retrie ved from Canadian A ssociation Of 
Optometri sts: 
https://opto.c a/sites/default /files/resource s/document s/info1mation _for_member s_on_corona vims.pdf 
 
• Corona virns (COVID -19) resource s for health  profe ssionals , including  aged care providers, pathology 
providers and health car e managers. (2020 , Septembe r 24). Retrie ved from Au stralian Govenunent  
Department of Health : 
https://www heal th.gov.au/resource s/collection s/corona vims-covid-19-resource s-for-health -professional s­ 
including -aged -care-providers -pathology -providers -and-health -care-manage rs 
 
• Environmental Cleaning and Disinfection Principle s for COVID -19. (n.d.). Retrie ved from Au stralian 
Govemment Depa 11ment of Health : 
https://www .health.gov.au/sites/default /files/docum ents/2020 /03/enviromnental -cleaning -and-disinfection ­ 
princ iples-for-covid-19.pdf 
 
• Infection control guidelines and advice. (11.d .). Re trie v ed from Op tometiy Australia : 
https://www.optome tiy.org.au/practic e-professional-suppo 11/coron avims-covid-l 9-what-optometri sts-need­ 
to-know/covid-19-clinica l-advice/infe ct.ion - con  ti·ol-guidelines-and-advice/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 11 ofll  
 
CR-650,1v4.0 JJVC CONFIDENTIAL  
Page 160 of 160   
 Clinical Study Protocol 
Johnson & Johnson Vision Care, Inc.  
 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE  
Protocol Number and Title: CR -6501 Protocol Title: Role of glare and spectral filtering on 
contrast sensitivity: A pilot study  
 
Version and Date: 4.0 02 November 2022  
 
I have read and understand the protocol specified above and agree on its content.  
 
I agr ee to conduct this study according to ISO 14155:2020,1 the Declaration of Helsinki,2 
United States (US) Code of Federal Regulations (CFR),3 and the pertinent individual country 
laws/regulations and to comply with its obligations, subject to ethical and safety 
considerations. The Principal Investigator is responsible for ensuring that all clinical site 
personnel, including Sub -Investigators ad here to all GCP guidelines regarding clinical trials 
during and after study completion.  
 
I will assure  that no deviation  from  or changes  to the protocol  will take place  without  prior 
agreement  from  the Sponsor  and documented  approval  from  the Institutional  Review  Board 
(IRB),  except  where  necessary  to eliminate  an immediate  hazard(s)  to the trial participants.  
All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training.  
I agree to ensure that all clinical site personnel involved in the conduct of this study are 
informed about their obligations in meeting th e above commitments.  
 
I shall not disclose the information contained in this protocol or any results obtained from 
this study without written authorization.  
I have read the suggested guidance provided by JJVCI pertaining to the COVID -19 risk 
mitigation, (C OVID -19 Work Instruction in the Appendix E of this protocol). I agree to 
conduct this study in compliance with local, state, governmental guidance for COVID -19 
risks.  
 
Principal  
Investigator:   
    
   
 Signature  Date  
 Name and Professional Position (Printed)   
 
Institution/Site:     
Institution/Site Name  
 
Institution/Site Address  
 
 
 
 
 
 
CR-6501,  v 4.0 JJVC  CONFIDENTIAL  